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MOLECULAR MECHANISMS UNDERLYING OSTEOCYTE APOPTOSIS AND THE 
ASSOCIATED OSTEOCLASTOGENESIS IN CX43-DEFICIENCY AND AGING 
 
Old age is associated with increased bone fragility and risk of fracture as a result 
of skeletal alterations, including low bone density and cortical thinning. Further, apoptotic 
osteocytes accumulate in old mice and humans. We have previously shown that mice 
lacking osteocytic connexin (Cx) 43 (Cx43ΔOt) exhibit a phenotype similar to that of the 
aging skeleton, with elevated osteocyte apoptosis and an associated increase in 
osteoclastogenesis. These findings suggest that osteocyte apoptosis results in the release 
of factors that recruit osteoclasts to bone surfaces close to areas that contain apoptotic 
osteocytes. However, the specific chemotactic signals, the events mediating their release, 
and the mechanisms of their action remain unknown. Consistent with this notion, we also 
found that HMGB1 released by Cx43-deficient (Cx43def) MLO-Y4 osteocytic cells 
enhances osteoclastogenesis in part by increasing osteocytic RANKL, which promotes 
osteoclastogenesis, and, at the same time, directly stimulating osteoclastogenesis. 
Further, expression of the pro-survival microRNA (miR), miR21, is low in Cx43def cells and 
bones from old female mice, and low miR21 levels increase osteocyte apoptosis. 
However, surprisingly, mice lacking miR21 (miR21ΔOt) have decreased osteoclast number 
and activity even under conditions of elevated osteocyte apoptosis; suggesting that 
osteocytic miR21 may mediate osteoclast precursor recruitment/survival induced by 
apoptotic osteocytes. However, whether HMGB1/miR21 are released by osteocytes, and 
if the HMGB1 receptors, receptor for advanced glycation end products (RAGE) and/or toll-
like receptor (TLR4) are involved in osteoclast recruitment in Cx43ΔOt and old mice is 
unknown. The overall objectives of this series of studies were to elucidate the mechanisms 
vii 
underlying osteocyte apoptosis in Cx43-deficiency and aging and identify the signaling 
molecules that link osteocyte apoptosis and osteoclast recruitment. We hypothesize that 
enhanced extracellular release of the signaling factors HMGB1 and miR21 recruits 
osteoclasts to areas containing apoptotic osteocytes and promotes osteoclast activity, 
leading to targeted bone resorption. Overall, these studies will provide insights into the 
mechanisms governing osteocyte apoptosis and the associated targeted osteoclast 
resorption, allowing for the development of novel therapeutics for preserving the structure 
and strength of the aging skeleton.   
Lilian I. Plotkin, Ph.D., Chair 
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Chapter 1 
Introduction 
 
Aging-related osteoporosis 
Given to the considerable advancements in healthcare in recent decades, people 
are now living longer than ever before. Ironically, this has led us to face a new series of 
clinical challenges, i.e. chronic degenerative diseases, including heart disease, cancer, 
diabetes, and neurodegeneration, which are often associated with the development of 
additional debilitating conditions, including osteoporosis.1-3 For example, the annual 
incidence of osteoporotic fractures, resulting from reduced bone mass and strength, is 
greater than that of heart attacks, strokes, and breast cancer combined [affecting ~1:2 
women of all ages, and ~1:4 men over age 50 and costing the US ~$25.3 billion a year in 
healthcare expenses4, 5], and the incidence is forecasted to continue increasing.6  
 
Figure 1-1. Illustration of the cellular and tissue-level skeletal alterations with aging. 
 
Old age is a key risk factor underlying osteoporosis. Bone remodeling, a 
coordinated process critical for the maintenance of bone quality, occurs throughout life, 
but is significantly altered with advancing skeletal age, as illustrated in Fig. 1-1.7, 8 In 
particular, aging leads to dysregulated bone turnover in which the amount of bone 
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resorbed by the osteoclasts outweighs the amount of new bone formed by the 
osteoblasts.9 These alterations in bone turnover eventually result in the loss of trabecular 
and cortical bone mass, reduced thickness and increased porosity, all of which cause 
significant reductions in bone strength and greatly increase the risk of fractures.10, 11  
In humans, studies have found that losses in bone mass are initially observed in 
the trabecular bone compartment and then later in the cortical bone compartment.12 
Interestingly, while aging in both mice and humans leads to reductions in osteoblast 
number and function in both the trabecular and cortical bone compartments,8, 13-15 the 
effects on osteoclasts appear to be compartment specific, shown in Fig. 1-2. In particular, 
in cortical bone osteoclast activity is elevated with aging, which leads to cortical thinning 
and intracortical porosity; whereas, in trabecular bone osteoclast numbers are reduced 
with aging,16-18 suggesting that aging has divergent effects on bone remodeling in the 
trabecular and cortical bone compartments. 
 
Figure 1-2. Graphic illustration of the bone compartment-specific cellular changes with 
aging.  
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In women, there is a rapid increase in bone loss after menopause, which is 
consistent with the numerous studies demonstrating the beneficial effects of estrogen on 
the skeleton.19, 20 In particular, estrogen has been shown to promote osteoblast and 
osteocyte survival and induce osteoclast apoptosis. Conversely, aging has opposite 
effects, leading to reductions in osteoblast and osteocyte viability and increases in 
osteoclast activity.9, 19  In addition, aging is also associated with defective bone material 
properties,21 as changes in bone mineral matrix and collagen composition, as well as 
accumulation of microdamage further contribute to the increased skeletal fragility.22 
Notably, evidence suggests that the increases in osteocyte apoptosis directly contribute 
to the alterations in bone turnover and reductions in bone strength seen with aging.7, 9, 23, 
24 Thus, given the growing number of osteoporosis patients, there is an essential need to 
better understand the mechanisms leading to osteocyte apoptosis in aging and identify 
the contribution of this event to aging-related losses in bone mass and strength.  
 
Cellular alterations associated with bone loss in aging 
Impaired bone formation is one of the key mechanisms that result in bone loss in 
aging.9 There are several factors thought to contribute to the reductions in bone formation 
observed with aging, including decreases in the number of mesenchymal stem cells, a 
reduced capacity of precursors to proliferation/differentiation into osteogenic lineage cells, 
and an increase in osteoblast apoptosis.19, 25 In addition to the decreases in osteoblast 
function, aging is associated with increases in osteoclast recruitment and activity. In 
particular, the decreases in cortical thickness and increases in cortical porosity in aging 
are thought to primarily result from increases in bone resorption.16-18 The processes of 
osteoblast and osteoclast differentiation and function are regulated by a variety of different 
factors and stimuli that control numerous signaling pathways.9 Further, there are a number 
of factors thought to contribute to the alterations in bone turnover seen with aging, in 
4 
particular, increases in osteocyte apoptosis have been shown to directly stimulate 
osteoclast recruitment and function. For example, several models of increased osteocyte 
death, including ovariectomy, unloading, microdamage, and a transgenic model of 
osteocyte apoptosis induced by diphtheria toxin, exhibited co-localization of apoptotic 
osteocytes and osteoclasts, suggesting that signals released by dying osteocytes induce 
osteoclast recruitment.26-29 
 
Figure 1-3. Schematic illustration of a Cx43 molecule, with one amino (NH2) and carboxy 
(COOH) domains and 4 transmembrane domains. A connexon or hemichannel is made 
up of six Cx43 molecules, and 2 connexons on adjacent cells can align to form a gap 
junction channel.  
 
Osteocytes, which are osteoblastic cells that become embedded in the bone 
mineral matrix, are the most abundant and long-lived type of bone cell, accounting for 
~98% of the cells comprising the skeleton.30, 31 Osteocytes have long dendritic processes 
that facilitate cell-signaling and allow for the exchange of nutrients between cells through 
the canaliculi network in the bone. Osteocytes are mechanosensitive cells embedded in 
the bone matrix and are key targets of bone acting stimuli.26, 32-34 These cells allow for 
intercellular signaling with distant cells both through the extracellular release of molecules 
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and cytokines via hemichannels formed via connexins (Cx) and directly with adjacent cells 
through gap junction channels, formed by connexons present on the surface of 
neighboring cells (Fig. 1-3).35, 36 Cx transmembrane proteins are expressed in osteoblasts, 
osteocytes and osteoclasts, with Cx43 being the most highly expressed connexin in 
bone.37 The critical role of Cx43 in early and mature osteoblasts, as well as in osteocytes 
has been demonstrated in numerous studies (Fig. 1-4).38-40  
 
Figure 1-4. Skeletal effects of Cx43 deletion in osteoblastic lineage cells at different 
differentiation stages (adapted from Basic and Applied Bone Biology41). The Cre 
recombinase was targeted to the indicated cell populations using promoter for the Dermo1 
gene (also known as Twist2); a 2.3kb fragment of the collagen 1a1 promoter 
(col1a12.3kb); the human osteocalcin promoter (OCN); or an 8kb fragment of the dentin 
matrix protein 1 promoter (DMP1). 
 
Mounting evidence suggests that osteocytes play a critical role in regulating 
skeletal homeostasis and orchestrating bone turnover, and consistent with this, osteocytes 
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produce and release numerous factors that directly influence osteoblast and osteoclast 
activity. Consistent with this notion, mechanical loading induces fluid flow within the 
canalicularlacunar network and stimulates the release of antiapoptotic factors that can 
promote osteoblast survival. Additionally, several recent studies suggest that preservation 
of osteocyte viability contributes to maintaining bone strength,32, 40, 42, 43 and that 
accumulation of apoptotic osteocytes results in targeted osteoclast recruitment.26-29 
Further, old age and conditions of increased skeletal fragility are associated with 
reductions in osteocyte viability and increased prevalence of empty lacunae; and 
disruptions in the osteocyte network alters osteocytic regulation of bone remodeling.44 
Moreover, skeletal aging is associated with an accumulation of apoptotic osteocytes, 
reduced osteoblast activity and enhanced osteoclast recruitment in both mice and 
humans.8, 45 Taken together, these pieces of evidence suggest that osteocyte apoptosis 
results in the release of signaling factors that induce the dysregulations in osteoblast and 
osteoclast function in aging.   
Our lab previously showed that removal of Cx43 from osteocytes results in a 
skeletal phenotype that resembles that of aged mice, shown in Fig. 1-5, with increased 
osteocyte apoptosis, marrow cavity widening, cortical thinning and defective bone material 
properties.38, 46 In addition to the accumulation of apoptotic osteocytes and empty lacunae 
observed in aging and in the absence of osteocytic Cx43, osteoclast recruitment is also 
enhanced.8, 45 In particular, osteoclasts localize along endocortical bone surfaces in both 
Cx43ΔOt mice and old wild type (WT) mice.8, 46 In both models, the expression of the anti-
osteoclastogenic cytokine osteoprogerin (OPG) is decreased in cells throughout the bone. 
In addition, osteoclasts only localize close to apoptotic osteocyte-containing regions, not 
those with empty lacunae.8, 46 Further, the RANKL/OPG ratio is significantly increased in 
Cx43-deficient (Cx43def) MLO-Y4 osteocytic cells. Consistently, Cx43 levels are 
significantly decreased in old mice and humans.8, 46 However, the signaling events linking 
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osteocyte apoptosis to the subsequent osteoclast activation in old age and the absence 
of osteocytic Cx43 remain unknown.  
Figure 1-5. Illustration of the skeletal phenotype resulting from osteocytic Cx43 removal. 
 
Interestingly, similar to the bone compartment-specific effects observed with aging, 
removal of osteocytic Cx43 also induces bone compartment specific effects. For example, 
removal of Cx43 from mature osteoblasts and osteocytes or exclusively from osteocytes 
results in cortical bone changes, but does not alter cancellous bone.47 Further, other 
studies have shown that expression of a truncated Cx43 lacking the c-terminus domain 
can negatively affect cancellous bone, whereas heterozygous deletion of Cx43 attenuates 
cancellous bone loss.48, 49 Overall, these findings demonstrate the essential role that Cx43 
plays in maintaining osteocyte viability and bone homeostasis; thus underscoring the 
potential contribution of reduced levels of Cx43 in osteocytes to the decreased bone 
quality/strength in aging. However, the signaling pathway activated by Cx43 deficiency 
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involved in stimulating osteocyte apoptosis and the specific role that osteocytic Cx43 plays 
in controlling bone structure and strength in aging remain unknown.   
In osteocytes and other cells, apoptotic cell death results in the release of the pro-
inflammatory cytokine high-mobility group box-1 (HMGB1), a non-histone nuclear DNA-
binding protein responsible of stabilization of nucleosomal structures facilitating gene 
transcription.50, 51 Previous studies have shown that HMGB1 released from cells activates 
the receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4). 
52  In addition, HMGB1 is chemotactic for osteoclasts,53 and induces osteoclastogenesis 
by activating RAGE,54 and can regulate recruitment and differentiation of osteoclast 
precursors.54, 55 However, whether HMGB1 mediates the increases in osteoclast 
recruitment and differentiation induced by apoptotic osteocytes in aging or in the absence 
of osteocytic Cx43, and whether activation of the HMGB1 receptors RAGE and/or TLR4 
mediate the effects on osteoclasts are not known. Additionally, it is unclear if apoptotic 
osteocyte-derived HMGB1 regulates osteoclastogenesis by autocrine actions in 
osteocytes and/or through paracrine actions in osteoclasts, illustrated in Fig. 1-6.    
 
Figure 1-6. Schematic summary of the possible mechanisms of HMGB1 signaling in 
osteocytes and osteoclasts.  
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Aside from the alterations in bone turnover, osteocyte apoptosis is also thought to 
contribute to defects in bone mechanical properties in aging. For example, studies have 
shown that osteocyte apoptosis in aging leads to BMD-independent reductions in bone 
strength, due to increases in the prevalence of mineralized empty lacunae as well as 
decreases in microcrack repair resulting from disruptions in the canalicular system.22, 56, 57  
Further, studies have also shown that many of the factors that regulate cell function in 
bone remodeling, also regulate osteocyte and osteoblast apoptosis.8 There are a variety 
of factors that may contribute to or be a consequence of the increased osteocyte apoptosis 
observed in aging. In particular, previous work by our lab found that reductions in 
osteocytic Cx43 expression levels alter several apoptosis-associated microRNAs (miRs), 
which are single-stranded non-coding RNAs that negatively regulate gene expression.58 
miRs are involved in cancer cell survival, and in particular, the expression of miR21 is 
upregulated in a variety of cancers, promoting cell survival through the direct inhibition of 
apoptotic genes including phosphatase and tensin homolog (PTEN).59 In bone, miRs play 
an important role in controlling the function and lifespan of both osteoclasts and 
osteoblasts.60 However, the role of miRs on osteocyte apoptosis has not been 
investigated. Thus, additional studies are needed to identify the specific mechanisms 
underlying increased osteocyte apoptosis in aging.   
 
Current Osteoporosis Therapeutic Options 
There a currently a number of osteoporosis treatments on the market including 
antiresorptive agents, monoclonal antibodies, and osteoanabolic agents, which function 
through different mechanisms to prevent bone loss or increase bone mass, and preserve 
bone strength.61 The mostly commonly used class of therapeutics are antiresorptive 
agents, in particular bisphosphonates, which attenuate bone loss by inhibiting osteoclast 
activity.61-63 In osteoporotic patients, bisphosphonate treatment has been shown to 
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increase bone mineral density and lower fracture risk.62 However, despite the beneficial 
effects seen in the majority of patients treated with bisphosphonates, in some patients, 
suppression of osteoclast activity with antiresorptive agents has also been shown to have 
negative effects on bone. For example, the use of these agents has been shown to 
significantly suppress bone turnover, which decreases osteoblast activity and bone 
formation.63 Moreover, in a small percentage of patients, extended treatment with 
bisphosphonates has also been linked to decreases in bone tissue toughness,64, 65 and 
consistent with this, in some studies, bisphosphonate treatment has been found to be 
associated with higher fracture risk in elderly women.63 Further, diminished bone turnover 
with prolonged suppression of osteoclast activity, has been shown to induce further 
microdamage and advanced glycation endproducts (AGEs) accumulation.66-70 Thus, while 
these anti-resorptive agents prevent further bone loss, they also reduce the formation of 
new bone. 
Interestingly, in addition to inhibiting osteoclast activity, bisphosphonates have 
been shown to have an antiapoptotic effects on osteoblasts and osteocytes, which are 
Cx43-dependent.40, 43, 71, 72 For example, work by Plotkin et. al., found that bisphosphonate 
analogs without antiresorptive activity still prevent osteoblast and osteocyte apoptosis in 
vitro.43, 73  Further, a bisphosphonate analog blocked osteoblast and osteocyte apoptosis 
and prevented glucocorticoid-induced loss of bone mass and strength in mice, despite 
having no effects on osteoclast activity.74 Taken together, these osteoclast-independent 
beneficial effects of bisphosphonate treatment further highlight the relationship between 
osteocyte viability and bone mass/strength.   
Thus, understanding the mechanisms underlying the increases in osteocyte 
apoptosis in aging and the absence of osteocytic Cx43, and identifying the events that link 
osteocyte apoptosis to the increases in osteoclast activity, are important steps needed to 
identify new therapeutic targets to prevent bone loss in aging. In particular, preventing 
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osteocyte apoptosis could potentially maintain bone mass and strength, without 
completely suppressing normal bone turnover. Additionally, identifying the molecules by 
which apoptotic osteocytes stimulate osteoclastogenesis could allow for the development 
of new treatment methods to reduce, rather than completely suppressing bone resorption. 
For example, using a small-molecule inhibitor of the signaling molecules that link 
osteocyte apoptosis and osteoclast activation, could allow for more opportunities to test 
different treatment regimens, durations and doses.  
The purpose of the current series of studies, illustrated in Fig. 1-7, was to better 
understand the mechanisms underlying osteocyte apoptosis in aging and to identify the 
apoptotic osteocyte-derived signaling molecules responsible for the subsequent increases 
in osteoclast activation. Future studies will aim to improve the management of the adverse 
skeletal effects of aging by targeting osteocyte apoptosis and resorption. 
 
Figure 1-7. Aims of the current studies. Aim1: elucidate the mechanisms underlying 
osteocyte apoptosis in aging and in the absence of osteocytic Cx43. Aim 2: identify the 
signaling molecules that link osteocyte apoptosis and osteoclastogenesis.    
 
Aging
osteocyte
apoptosis
osteoclastogenesis
Aim 1
Aim 2
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Chapter 2 
Reduced osteocyte apoptosis and preservation of cortical bone quality with 
advanced age in mice with osteocytic Cx43 overexpression 
 
Rationale 
Young, skeletally mature mice lacking Cx43 in osteocytes exhibit increased 
osteocyte apoptosis and decreased bone strength, resembling the phenotype of old mice. 
Further, the expression of Cx43 in bone decreases with age, suggesting a contribution of 
reduced Cx43 levels to the age-related changes in the skeleton. Here we sought to 
investigate whether expression of an osteocyte-targeted Cx43 transgene could preserve 
osteocyte viability and attenuate the skeletal phenotype in aged mice; using mice in which 
the DMP1-8kb promoter targeted Cx43 expression to osteocytes (Cx43OT mice). 
 
Introduction 
Advanced age is associated with skeletal fragility as a result of decreases in bone 
quantity and quality due to changes in the structural and material properties of bone.22, 57 
Bone remodeling, a coordinated process critical for the maintenance of bone quality, 
occurs throughout life, however the rate of bone turnover significantly decreases with 
advancing skeletal age.7, 8 Alterations in bone turnover where resorption outweighs 
formation, eventually result in bone loss in old age. Initial age-induced bone loss is 
observed in trabecular bone due to decreased osteoblast activity; whereas cortical bone 
losses occur later.17, 21 In addition to the alterations in bone structure, bone material is also 
affected in aging,21 as changes in bone mineral matrix and collagen composition, as well 
as accumulation of microdamage further contribute to the increased skeletal fragility with 
aging.22  
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Numerous studies suggest that the extensive osteocyte network within the 
mineralized bone matrix plays an essential role in orchestrating bone remodeling through 
cell-cell communication among neighboring osteocytes and with cells on the bone 
surface.30, 75 Consistent with this notion, old age and conditions of increased skeletal 
fragility are associated with reductions in osteocyte viability and increased prevalence of 
empty lacunae; and disruptions in the osteocyte network alters osteocytic regulation of 
bone remodeling.44 Osteocytes participate in intercellular signaling with distant cells both 
through the extracellular release of small molecules via hemichannels formed via 
connexins (Cx) and directly with adjacent cells through gap junction channels, formed by 
connexons present on the surface of neighboring cells.35, 36 Cx transmembrane proteins 
are expressed in osteoblasts, osteocytes and osteoclasts, with Cx43 being the most highly 
expressed connexin in bone.37  
The critical role of Cx43 in early and mature osteoblasts, as well as in osteocytes 
has been demonstrated in numerous studies.38-40 We previously showed that removal of 
Cx43 from osteocytes results in a skeletal phenotype that resembles that of aged mice 
with increased osteocyte apoptosis, enhanced osteoclast recruitment to bone surfaces, 
and defective bone material properties.38, 46 Further, Cx43 is significantly decreased in old 
mice and humans.8, 46 Overall, these findings demonstrate the essential role that Cx43 
plays in maintaining osteocyte viability and bone homeostasis; thus underscoring the 
potential contribution of reduced levels of Cx43 in osteocytes to the bone weakness in 
aging. However, the specific role that osteocytic Cx43 plays in controlling bone structure 
and strength in aging has not been studied.  
We investigated here whether expression of an osteocyte targeted Cx43 transgene 
could preserve osteocyte viability and attenuate the skeletal phenotype in aged mice; 
using mice in which the DMP1-8kb promoter targeted Cx43 expression to osteocytes 
(Cx43OT mice). Overall, the results of this study demonstrate that increased osteocytic 
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Cx43 expression partially preserves osteocyte viability and maintains cortical bone quality 
in aged mice. Because overexpression of Cx43 in osteocytes does not significantly affect 
cancellous bone, these findings also point to a site specific effect of Cx43 in osteocytes.
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Materials and Methods 
Mice. DMP1-8kb-Cx43/GFP mice (abbreviated as Cx43OT) were generated at the 
Transgenic and KO Mouse Core (IUSM) with the Cx43 transgene, generated by S. and 
M. Harris (UTSHC, San Antonio), using the DMP1-8kb promoter76 and a CMV-
Cx43/GFP77 constructs (Fig. 2-7A). The presence of the transgene was evaluated by PCR 
in genomic DNA extracted from ear notch samples using primer sets for Cx43 and GFP. 
DMP1-GFP mice were used as positive controls for GFP.76 GFP expression in DNA from 
Cx43OT mice was detected by PCR but not by fluorescent microscopy, possibly due to low 
expression resulting from the transgene construct design in which GFP was after IRES. 
Mice lacking osteocytic Cx43, Cx43ΔOt mice, were generated by crossing Cx43fl/fl mice with 
DMP1-8kb-Cre mice, as previously published.46, 78  
 All mice were maintained on a C57BL/6Nhsd background (Envigo, Indianapolis, 
IN) and littermates were used as controls. Mice were fed a regular diet and water ad libitum 
and were maintained on a 12 h light/dark cycle. Mice were born at the expected Mendelian 
frequency, were fertile, and exhibited a similar size and weight to wild type (WT) littermate 
mice at birth. Female skeletally mature 6-month-old and aged 14-month-old mice were 
used. Based on published data our 6-month old mice are equivalent to 20-year old 
humans, whereas the 14-month-old mice correspond to middle aged female humans at 
the end of their reproductive stage of life (˜58-year-old).79 For dynamic histomorphometric 
studies, mice received intraperitoneal injections of calcein (30 mg/kg) and alizarin red 
(50 mg/kg) (Sigma Chemical, St. Louis, MO, USA) 7 and 2 days before sacrificing, as 
published.49 The protocols involving animal procedures were approved by the Institutional 
Animal Care and Use Committee of Indiana University School of Medicine. 
 
Osteoblast and osteocyte isolation. Calvaria cells were isolated from Cx43OT 
mice bred to DMP1-8kb-GFP mice which have GFP-labeled osteocytes.46, 78 Cells were 
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isolated by sequential 20-minute digestions using a trypsin/EDTA/collagenase P mixture 
as previously described.80 The first digestion was discarded, and cells from all other 
digestions were pulled. GFP-expressing cells (osteocyte-enriched) were separated from 
GFP-negative cells (osteoblast-enriched) by sorting the cell suspension using a FACSAria 
flow cytometer (BD Biosciences, Sparks, MD) at the Indiana University Flow Cytometry 
Core Facility, as published.81 
 
RNA extraction and real-time PCR (qPCR). Total RNA was isolated and purified 
using TRIzol (Invitrogen, Grand Island, NY). Reverse transcription was performed using a 
high-capacity cDNA kit (Applied Biosystems, Foster City, CA). qPCR was performed using 
the Gene Expression Assay Mix TaqMan Universal Master Mix containing 80 ng of each 
cDNA template using an ABI 7900HT real-time PCR system. The house-keeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used. Primers and probes 
were commercially available (Applied Biosystems, Foster City, CA) or were designed 
using the Assay Design Center (Roche Applied Science, Indianapolis, IN). Relative 
expression was calculated using the ∆Ct method.46 
 
Immunohistochemistry. Cx43 expression in osteocytes and osteoblasts was 
visualized in paraffin-embedded femora from 2-month-old mice, as described.81, 82 Briefly, 
sections were deparaffinized, treated with 3% H2O2, blocked with rabbit serum, and 
incubated with 1:1000 anti-Cx43 (C6219) (Sigma-Aldrich, Saint Louis, MO, USA). 
Sections were incubated with the corresponding biotinylated secondary antibody followed 
by avidin conjugated peroxidase (Vectastain Elite ABC Kit; Vectora Laboratories). Color 
was developed with a diaminobenzidine substrate chromogen system (Dako Corp). 
Sections were counterstained with 2% methyl green.46 Cells expressing the protein are 
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brown, whereas negative cells are green-blue. Non-immune IgGs were used as negative 
controls.  
 
Western Blot analysis. Whole protein extracts from osteocyte-enriched long 
bones (cortical bone preparations), calvaria bones, and soft tissue samples were prepared 
as published.46, 74 Protein levels were measured by western blot analysis. Membranes 
were probed with primary antibodies, rabbit anti-connexin43 (C6219) and mouse anti-β-
actin (A5316) (Sigma Aldrich, Saint Louis, MO, USA) diluted 1:1000, overnight at 4ºC, 
followed by incubation with corresponding secondary antibodies conjugated with 
horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA) for 4 hours at room 
temperature. Membranes were developed with an enhanced chemiluminescence Western 
blotting substrate kit (Pierce Biotechnology Inc., Rockford, IL, USA). Bands were 
quantified using ImageJ.  
 
Bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA). 
BMD was measured monthly by DXA using a PIXImus densitometer (G.E. Medical 
Systems, Lunar Division, Madison, WI, USA).49 BMD measurements included total BMD 
(excluding the head and tail), entire femur (femoral BMD) and L1–L6 vertebra (spinal 
BMD).81 Calibration was performed before scanning with a standard phantom, as 
recommended by the manufacturer.  
 
Apoptosis. Osteocyte and osteoblast apoptosis was detected in undecalcified 
vertebral bone sections and  paraffin embedded femur sections by TdT-mediated dUTP 
nick-end labeling (TUNEL) using a modified version of a commercial kit (EMD Millipore, 
Billerica, MA) in sections counterstained with 2% methyl green, as published.46 
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Serum biochemistry. Plasma collected 3 h after fasting by cheek bleeding was 
aliquoted and stored at − 80°C.49 N-terminal propeptide of type I procollagen (P1NP) 
(Immunodiagnostic Systems Inc., Fountain Hill, AZ, USA, cat.#AC-33F1) and C-
telopeptide fragments (CTX) (RatLaps, Immunodiagnostic Systems Inc., Fountain Hill, AZ, 
USA, cat.#AC-06F1) were measured as published.46, 83  
 
Micro-computed tomography (μCT) analysis. Femora and L4 vertebrae were 
dissected, wrapped in saline-containing gauze and frozen at − 20°C.83 Trabecular 
morphology of the L4 vertebral body was obtained using the Skyscan 1172 system with a 
60kV source, 0.5mm Al filter, 0.7 degree rotation and two-image averaging with an 
isotropic voxel size of 6μm.84 Femora were scanned using a 55kV source, 0.5mm Al filter, 
0.7 degree rotation and two-image averaging with an isotropic voxel size of 9μm using a 
SkyScan 1176 system (SkyScan, Kontich, Belgium). Scans were reconstructed and 
analyzed using manufacturer software. Two different μCT systems were used due to 
constrained availability and only results within each system were captured. Nomenclature 
is reported in accordance with suggested guidelines for μCT.85 
 
Bone histomorphometry. Femora and vertebrae were dissected, fixed in 10% 
neutral buffered formalin, and embedded in methyl methacrylate, as published.83 Dynamic 
histomorphometric measurements were performed in unstained femoral mid-diaphysis 
and vertebrae sections.83 Static histomorphometric analysis was performed on sequential 
plastic-embedded vertebra sections stained with von Kossa/McNeal for osteoblasts and 
TRAP/Toluidine blue for osteoclasts. Osteoclasts were also quantified on paraffin 
embedded femur sections. Analysis was performed by blinded investigators using the 
OsteoMeasure high-resolution digital video system (OsteoMetrics Inc., Decatur, GA, 
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USA).74, 86 The terminology and units used are those recommended by the 
Histomorphometry Nomenclature Committee of the ASBMR.85  
 
Biomechanical testing. Three-point bending testing of the femoral mid-diaphysis 
was performed following previously published protocols.83 Axial compression of the L4 
vertebrae was performed after removing the vertebral processes and endplates. A rate of 
0.5 mm/min was used to load the vertebral bodies until failure, as previously described.87 
Structural mechanical properties were determined from the load-displacement curves 
using standard definitions, while material-level properties were derived from the load-
displacement curves, cross-sectional moments of inertia, and the distances from the 
centroid to the tensile surface using geometrical data determined by μCT and standard 
beam-bending equations.49  
 
Statistical analysis. Data were analyzed by using SigmaPlot (Systat Software 
Inc., San Jose, CA, USA). Differences were evaluated either by two-way ANOVA, with 
post-hoc analysis using Tukey Method or Student’s t-test, as appropriate. Differences 
were considered significant when p<0.05.  
 
20 
Results 
Effective expression of an osteocyte targeted Cx43 transgene in Cx43OTmice. 
To test the effect of Cx43 levels on osteocyte viability and bone homeostasis in aged mice, 
we generated a transgenic mouse model that expresses a DMP1-8kb-Cx43/GFP 
transgene primarily in osteocytes (Cx43OT mice) (Fig. 2-7A). An amplified fragment of 297 
bp corresponding to the Cx43 allele and of 525 bp to the GFP allele was used to generate 
transgenic Cx43OTmice. Of the eleven potential transgenic founders generated, two mice 
were found to express the exogenous Cx43 and GFP genes. Due to higher Cx43 protein 
levels in the founder mouse #82 (data not shown), offspring generated from this mouse 
were used for the outlined studies. Expression of both exogenous Cx43 and GFP were 
transmitted to half of the offspring when crossed with a WT mouse, as expected (Fig. 2-
7B). To confirm that our DMP1-8kb-Cx43/GFP transgene is primarily expressed in 
osteocytes and not in osteoblasts, Cx43OT mice were crossed with DMP1-8kb-GFP 
mice.46, 78 GFP positive osteocytes (Ot) isolated by FACS expressed high levels of the 
osteocyte markers SOST, DMP1, and FGF23, while the osteoblast marker keratocan was 
low (Fig. 2-1A). GFP negative osteoblasts (Ob) had undetectable levels of SOST and 
DMP1, while keratocan expression was higher, validating the identity of the cell 
populations. Cx43 expression was increased in the GFP positive osteocytes and 
decreased in the GFP negative osteoblasts isolated from Cx43OT compared to WT 
littermate mice, demonstrating osteocyte-specific expression of the transgene. Moreover, 
the percentage of Cx43 positive osteocytes, detected by Cx43 immunostaining, was 
increased 2-fold in Cx43OT mice compared to WT mice, whereas the percentage of Cx43 
positive osteoblasts on the bone surface was similar, although it showed a tendency 
towards decrease (Fig. 2-1B), similar to the Cx43 mRNA levels in osteoblastic cells (Fig. 
2-1A). Cx43 expression at the protein level, measured by western blotting analysis, was 
not increased in marrow-flushed cortical bone preparations or in calvaria lysates (Fig. 2-
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1C), possibly due to the presence of other Cx43 expressing cells, such as osteoblasts.46 
Further, no changes in Cx43 protein were detected in the heart, kidney, brain or skeletal 
muscle of Cx43OT mice compared to WT mice.  
Similar to mice lacking osteocytic Cx43,46 overexpression of osteocytic Cx43 in 
Cx43OT mice did not result in major changes in BMD during growth in female (Fig. 2-1D) 
or male mice (data not shown), demonstrating that Cx43 in osteocytes is not involved in 
bone mass accrual. Total, femoral, and spinal BMD of the Cx43OT and WT mice by DXA 
were similar up to 5.5 months, except for a slight increase in total and femoral BMD in the 
female Cx43OT mice at 2 months of age, which was consistent with reduced BMD at this 
age in mice lacking osteocytic Cx43.46 No decreases in total or femoral BMD were 
observed in either genotype up to 14 months compared to 5.5-month old mice. On the 
other hand, spinal BMD began to decline at 9.5 months in the WT mice and by 12 months 
decreases in spinal BMD were detected in both genotypes.  
 
Increased Cx43 expression reduces osteocyte apoptosis in aged mice. To 
investigate the effects of aging on osteocyte viability, apoptosis was quantified in the 
different bone compartments of the lumbar vertebra and femur. No changes in the 
percentage of apoptotic osteocytes or osteoblasts were detected between the two 
genotypes at 6 months of age (young mice) (Fig. 2-2A). Aged WT mice exhibited a 6- and 
5.5-fold increase in osteocyte apoptosis in the cortical and cancellous vertebral bone, 
respectively, and a 22-fold increase in cancellous osteoblast apoptosis compared to young 
WT mice.7, 88 Cortical and cancellous osteocyte apoptosis was higher in aged compared 
to young animals even in Cx43OT mice; however, osteocyte apoptosis was 40% lower in 
the cortical bone and 24% lower in the cancellous bone of the vertebra in the aged 
transgenic mice compared to WT mice. Similar decreases were detected in the femoral 
cortical bone of aged transgenic mice compared to WT mice (Fig. 2-2B). In contrast, the 
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prevalence of apoptotic cancellous osteoblasts was increased approximately 40% with 
aging in both genotypes and no differences in osteoblast viability were detected between 
the two genotypes at 14 months of age (Fig. 2-2A). Thus, increased expression of Cx43 
in osteocytes partially prevents the increase in osteocyte apoptosis induced by aging.  
 
Endocortical bone formation is maintained in aged Cx43OT mice. Aging led to 
alterations in the bone turnover markers in the WT mice, with a 42% decrease in the 
formation marker P1NP and a 34% increase in the resorption marker CTX in aged 
compared to young WT mice (Fig. 2-3A). On the other hand, P1NP levels were increased 
by 66% and CTX levels were decreased by 24% in aged compared to young Cx43OT mice. 
Moreover, while no changes in P1NP were detected between the two genotypes in young 
mice, aged Cx43OT mice exhibited 135% higher P1NP levels compared to WT mice of the 
same age. Further, at 6 months of age CTX levels were slightly increased in the Cx43OT 
mice, whereas at 14 months CTX levels were 28% lower compared to aged WT mice.  
No changes in periosteal bone formation parameters, mineralizing surface per 
bone surface (MS/BS), mineral apposition rate (MAR), or bone formation rate per bone 
surface (BFR/BS), were detected between the two genotypes at either age in the femoral 
mid-diaphysis (Fig. 2-3B). On the other hand, dynamic histomorphometric analysis 
revealed that all bone formation indexes (MS/BS, MAR, and BFR/BS) were increased on 
the endocortical surface in the Cx43OT versus WT mice at 14 months, but not at 6 months 
(Fig. 2-3B), suggesting that increased osteoblast activity in this compartment contributes 
to the higher production of P1NP detected in the serum of 14-month-old Cx43OT mice. As 
for MS/BS, the surfaces occupied by single and double labels on the periosteum were 
similarly increased by aging independently of the genotype of the mice, whereas Cx43 
overexpression did not alter these parameters (Fig. 2-8A). On the other hand, the percent 
single labeled surface on the endocortex was increased by aging and decreased by the 
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transgene, whereas double labeled-covered surface was decreased in 14-month-old wild 
type mice but increased in Cx43OT mice compared to the corresponding 6-month-old mice 
(Fig. 2-8B).  
Similar to the decreases in CTX observed in the Cx43OT mice at 14 months of age, 
static histomorphometric analysis of the endocortical surface of the femoral mid-diaphysis 
revealed a 2.5-fold reduction in the number of osteoclasts per bone surface (N.Oc/BS), a 
1.9-fold decrease in bone surface occupied by osteoclasts (Oc.S/BS), and a 1.9-fold 
reduction in the eroded bone surface (ES/BS) in the 14-month-old Cx43OT compared to 
WT mice (Fig. 2-3C). Consistently, at the mRNA level RANKL and the RANKL/OPG ratio 
were decreased in cortical bone lysates from 14-month-old Cx43OT compared to WT mice 
at the same age (Fig. 2-9). 
 
Cortical bone mechanical properties are preserved in aged Cx43OT mice. μCT 
analysis revealed that both WT and Cx43OT mice exhibited the expected age-related 
skeletal alterations in cortical bone geometry of the femoral mid-diaphysis, with increased 
marrow cavity area, as well as decreased cortical thickness (Ct.Th) and bone area/tissue 
area (BA/TA) in aged mice (Fig. 2-3D). Further, we did not detect changes in the cortical 
bone geometry of the femur between the genotypes at either age, aside from a slight 
increase in marrow cavity area of the aged Cx43OT mice.  
In contrast, biomechanical studies of the femur by 3-point bending revealed that 
increased osteocytic Cx43 expression enhanced the structural and material bone 
properties in skeletally mature mice and prevented the loss of these properties in aged 
mice (Fig. 2-4). At 6-months of age Cx43OT mice exhibited enhanced femoral structural 
properties with increased yield force, ultimate force, stiffness, and work to yield (Fig. 2-
4A), as well as increases in the material properties yield stress, modulus, and resilience 
(Fig. 2-4B). Moreover, aging in the WT mice resulted in decreases in both the structural 
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and material properties of the femoral bone, with decreases in ultimate force/stress, 
stiffness/modulus, postyield/total work, and toughness. Further, decreases were detected 
in the pre-yield properties with lower yield force/stress of WT bones from aged compared 
to young mice. In contrast, although decreases were detected in ultimate force/stress and 
stiffness/modulus of the femur from 14-month-old Cx43OT mice, displacement/strain to 
yield were significantly increased compared to 6-month-old transgenic mice. Aged Cx43OT 
mice also exhibited increases in the pre-yield properties, yield force/stress, 
displacement/strain to yield, and work to yield/resilience, compared to WT mice at the 
same age. In contrast to the effects of osteocytic Cx43 overexpression on pre-yield 
properties, osteocytic Cx43 deletion results in reductions in the pre-yield properties of the 
cortical bone at both the structural and material level (data not shown). Taken together, 
our data suggest that overexpression of osteocytic Cx43 in aging preserves certain cortical 
bone mechanical properties, maintaining the ability of the bone to absorb energy without 
damaging.  
 
Increased osteocytic Cx43 does not prevent age-induced cancellous bone 
loss. Analysis of cancellous bone microarchitecture by μCT revealed that 6-month-old 
Cx43OT mice exhibited increased trabecular thickness (Tb.Th) in the lumbar vertebra, 
without changes in the other trabecular bone parameters (Fig. 2-5A). Consistent with the 
increases in vertebral cancellous bone detected by μCT, vertebral compression testing 
detected increases in ultimate load/stress in the Cx43OT compared to WT mice at 6 months 
of age (Fig. 2-5B). However, by 14 months of age, differences in cancellous bone between 
the two genotypes were no longer detected. Moreover, while aging led to a loss of 
vertebral cancellous bone BV/TV and Tb.N in both genotypes, decreases in vertebral 
Tb.Th were only detected in the 14-month-old Cx43OT mice (Fig. 2-5A). Further, 
stiffness/modulus of the vertebra were decreased in aged mice from both genotypes, 
25 
whereas decreases in ultimate load/stress were only detected in the 14-month-old Cx43OT 
mice (Fig. 2-5B).  
Consistent with the decreases in vertebral cancellous bone observed with aging in 
both WT and trangenic mice, histomorphometric analysis revealed decreases in MS/BS 
and BFR/BS (Fig. 2-6A) along with reductions in osteoblast number (N.Ob/BS) and 
surface (Ob.S/BS) (Fig. 2-6B) in the aged compared to young mice of both genotypes. 
Further, osteoclast parameters, N.Oc/BS, Oc.S/BS, and ES/BS, were higher in both 
genotypes at 14 months compared to 6-month-old mice. At 6 months of age cancellous 
MAR and BFR/BS were reduced (Fig. 2-6A) and Ob.S/BS was decreased along with a 
tendency towards decrease in N.Ob/BS (Fig. 2-6B) in Cx43OT mice compared to WT mice. 
At 14 months of age, MAR was still decreased in Cx43OT compared to WT mice, while no 
differences in N.Ob/BS or Ob.S/BS were detected. On the other hand, no changes in 
osteoclasts were detected between the genotypes at either age (Fig. 2-6C). Taken 
together, these pieces of evidence suggest that increased osteocytic Cx43 does not 
prevent and may actually enhance cancellous bone loss induced with aging. 
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Discussion 
Previous work from our laboratory demonstrated that Cx43 is critical for osteocyte 
survival and removal of osteocytic Cx43 leads a skeletal phenotype similar to that 
observed in aging with increases in osteocyte apoptosis and enhanced osteoclast 
recruitment, as well deficits in the material properties of the cortical bone.38, 46 In this study, 
we examined the contribution of osteocytic Cx43 to the skeletal phenotype of aged mice, 
using Cx43OT mice expressing a Cx43 transgene targeted to DMP1-8kb-expressing cells. 
We show that the prevalence of apoptotic osteocytes was significantly reduced in the 
cortical and to a lesser extent in the cancellous bone of 14-month-old Cx43OT compared 
to WT mice, further demonstrating the critical role of Cx43 in maintaining osteocyte 
viability.  
In addition, we found that in aged Cx43OT mice reductions in osteocyte apoptosis 
were accompanied by changes in bone remodeling with increased formation and 
decreased resorption along the endocortical bone surface. While this did not alter long 
bone geometrical changes induced with aging, improvements in the cortical mechanical 
properties were observed at the material level. It is possible that the aging process has 
just started in our 14-month-old animals and while changes were detected at the cellular 
levels, we did not allow enough time for these alterations to translate into structural 
changes. Consistent with this possibility, we did not detect increases in bone mass in the 
aged compared to the young Cx43OT mice by BMD or µCT analyses, even though the 
circulating markers suggest higher bone mass in the older animals. The reason for this 
discrepancy is not clear. However, it is possible that since the aging process may have 
just started in our animals and while changes were detected at the cellular levels, we did 
not allow enough time for these alterations to translate into structural changes. 
Furthermore, we cannot rule out the possibility that the moderate expression of the 
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transgene in osteocytes and a potential uneven expression in femoral versus vertebral 
bone may provide some explanation for the weak bone mass phenotype of Cx43OT mice. 
In contrast, despite the increases in cancellous bone at 6 months of age in the 
Cx43OT compared to WT mice and maintenance of spinal BMD at 9.5 months, age-induced 
cancellous bone losses were not prevented in the Cx43OT mice by 14 months of age. 
These findings are consistent with previous reports demonstrating that removal of 
osteocytic Cx43 does not alter cancellous bone.46 Altogether, our data demonstrates that 
Cx43 maintains osteocyte viability in both cortical and cancellous bone, and that 
preservation of osteocyte viability appears to be critical for the maintenance of cortical 
bone quality in aging, although cancellous bone is still lost. Furthermore, increased Cx43 
expression in osteocytes partially ameliorates the age-induced skeletal changes, by 
preserving bone turnover which likely improves cortical bone mechanical properties but 
does not prevent against cancellous bone loss in old age.  
Bone fragility in aging individuals results not only from the loss of bone mass, but 
also from deficits in bone quality.21  The findings of the present study highlight the essential 
role of Cx43 in preserving osteocyte viability and maintaining the bone mechanical 
properties in aging. Age-related declines in bone material properties are accompanied by 
changes in the distribution and architecture of the cortical and trabecular bone.17 We found 
that both aged WT and Cx43OT mice exhibited the expected age-related increases in long 
bone diameter accompanied by decreases in BA/TA and cortical thickness. These 
changes in microarchitecture led to a decrease in the biomechanical properties of the bone 
at both the structural and material level. On the other hand, while decreases in the material 
properties were detected in the aged compared to skeletally mature WT mice, aged 
Cx43OT mice partially maintained these biomechanical properties at both the structural and 
material level, when compared to the 6-month-old mice. Further, pre-yield mechanical 
measurements were all increased in aged Cx43OT compared aged WT mice. Interestingly, 
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the pre-yield properties of the cortical bone in mice lacking osteocytic Cx43 were also 
reduced at both the structural and material level, while deficits in bone post-yield 
properties were only detected at the material level.38 Based on the fact that we did not 
detect differences in cortical bone mass or geometry between the two genotypes at 14 
months of age, it is reasonable to speculate that the increases in the structural and 
material properties in the 14-month-old Cx43OT mice are not due to changes in bone 
architecture, but are likely due to other factors at the level of the collagen/mineral. Thus, 
it is possible that the enhanced capability of the cortical bone of aged Cx43OT mice to resist 
damage is due to changes in bone material as a result of increased osteocyte viability.  
Bone quality depends not only on the geometry and microarchitecture of the bone, 
but also on its material composition.22, 57 Bone material properties include mineral content, 
collagen composition, and micro-damage accumulation.57 Numerous studies have 
demonstrated the critical role that osteocytes play in sensing mechanical stimuli and 
coordinating targeted bone remodeling to repair damaged areas.30, 89 Decreases in 
osteocyte viability have been observed in many conditions underlying bone loss.44 
However, the specific mechanisms by which viable osteocytes prevent bone fragility in 
aging are not known. In the current study we found that maintenance of osteocyte viability 
in the 14-month-old Cx43OT mice is associated with preserved cortical bone elastic 
material properties and an improved resilience.  
Preliminary gene expression measurements showed that increased expression of 
Cx43 in osteocytes results in higher levels of keratocan (a proteoglycan) in osteocytic cells 
(Fig. 2-1A) and, not shown, Chsy1 (a glucosaminoglycan) and Lox (lysil oxidase, an 
enzyme involved in collagen maturation) in bone preparations. Interestingly, deletion of 
Cx43 from osteocytic cells results in decreased levels of Lox,38 suggesting that, as with 
the biomechanical properties, Cx43 deletion and overexpression leads to opposite effects 
on collagen-related genes. Further studies are needed to understand the mechanism for 
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the changes in the material properties of the bone of mice expressing DMP1-Cx43. In 
addition, whether the improved ability of the bone to resist damage is due to prevention of 
microdamage accumulation or direct preservation of the bone material by living osteocytes 
or a combination of both, remains to be determined.  
Findings from numerous studies have consistently shown the differential role of 
osteocytic Cx43 in the cortical and cancellous bone compartments.37 Removal of Cx43 
from mature osteoblasts and osteocytes or exclusively from osteocytes results in cortical 
bone changes, but does not alter cancellous bone.38, 46 Further, other studies have shown 
that expression of a truncated Cx43 lacking the c-terminus domain can negatively affect 
cancellous bone, whereas heterozygous deletion of Cx43 attenuates cancellous bone loss 
during hindlimb unloading.48, 49 Our findings that osteocyte-targeted Cx43 transgene 
expression was sufficient to reduce osteocyte apoptosis in the cortical and to a lesser 
extent in the cancellous bone compartments, whereas changes in bone turnover and 
improvements in the mechanical properties of the bone were only observed in cortical 
bone, further demonstrate the differential actions of Cx43 in the two bone compartments.  
 In summary, the findings from the current study further highlight the critical role 
osteocytes play in the maintenance of cortical bone structure and mechanical properties 
in aging, and demonstrate the requirement of Cx43-mediated actions in osteocytes for the 
preservation of osteocyte viability and cortical bone quality in aging. On the other hand, 
osteocytic Cx43 does not appear to play a critical role in maintaining cancellous bone in 
aged mice. 
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Figure 2-1. Effective osteocyte targeted Cx43 transgene expression in DMP1-8kb-
Cx43/GFP (Cx43OT) mice. (A) mRNA expression in primary osteoblasts and osteocytes 
isolated from DMP1-8kb-GFP mice expressing GFP under the control of the 8kb fragment 
of the DMP1 promoter. Ob: osteoblastic cells; Ot: osteocytic cells; n.d.: non-detectable. 
Bars represent mean ± s.d. of triplicate measurements, *: p<0.05, t-test versus WT 
cells. (B) Cx43 expression in osteocytes and osteoblasts was evaluated in the femoral 
mid-diaphysis of Cx43OT and WT littermate mice stained with a non-immune IgG or anti-
Cx43 polyclonal antibody, counterstained with 0.2% methyl green. Bars represent mean 
± s.d., *: p<0.05, t-test versus WT mice, n=6 WT and n=4 Cx43OT. Representative images 
of Cx43 negative (arrow, white) and Cx43 positive (arrow, red) osteocytes are shown. 
Scale bar indicates 25 μm. (C) Cx43 protein levels measured in marrow-flushed cortical 
bone preparations, calvarial bones, and in the soft tissues of Cx43OT and WT mice by 
western blot correct by β-actin levels, n=3. (D) Total body, spinal and femoral BMD were 
measured from 1 to 14 months of age by DXA in females, n=13 WT and n=11 Cx43OT. 
Symbols represent ± s.d., *p<0.05 versus WT littermates by t-test. 
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Figure 2-2. Expression of Cx43 in osteocytes reduces osteocyte apoptosis induced with 
aging. (A) Percentage of apoptotic (TUNEL positive) cortical and cancellous osteocytes, 
as well as, cancellous osteoblasts were scored in vertebral bone sections. Bars represent 
mean ± s.d., *: p<0.05, versus 6-month-old genotype-matched mice by two-way ANOVA, 
tukey, black line: p<0.05, versus old control mice by t.test. 6-month-old mice: n=9 WT and 
n=8 Cx43OT, 14-month-old mice: n=8 WT and n=7 Cx43OT. Representative images of 
TUNEL negative (arrow, white) and positive (arrow, red) osteocytes are shown. Scale bar 
indicates 2.5 μm. (B) Percentage of apoptotic cortical osteocytes were scored in 
longitudinal distal femur sections from 14-month old mice. Bars represent mean ± s.d., *: 
p<0.05 versus WT littermates by t-test, n=7 WT and n=9 Cx43OT. Representative images 
of TUNEL negative (arrow, white) and positive (arrow, red) osteocytes are shown. Scale 
bar indicates 6.25 μm.  
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Figure 2-3. 14-month-old Cx43OT mice exhibit enhanced endocortical bone formation and 
decreased resorption. (A) Circulating levels for P1NP and CTX were measured by ELISA 
in serum collected from 6- and 14-month-old mice. 6-month-old mice: n=10 WT and n=9 
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Cx43OT, 14-month-old mice: n=11 WT and n=9 Cx43OT. (B)Periosteal and endosteal 
MS/BS, MAR, and BFR/BS were measured in unstained sections from the femoral mid-
diaphysis. 6-month-old mice: n=9 WT and n=9 Cx43OT, 14-month-old mice: n=8 WT and 
n=7 Cx43OT. Representative images are shown. Scale bars indicate 100μm. (C) N.Oc/BS, 
Oc.S/BS, ES/BS were scored in femoral cortical mid-diaphysis after staining for 
TRAP/Toluidine blue in Cx43OT and WT mice. 6-month-old mice: n=9 WT and n=9 Cx43OT, 
14-month-old mice: n=5 WT and n=7 Cx43OT. Osteoclasts on the bone surface (arrow, 
red) are shown. (D) Cortical bone geometry was evaluated by μCT in the femoral mid-
diaphysis. 6-month-old mice: n=8 WT and n=9 Cx43OT, 14-month-old mice: n=8 WT and 
n=6 Cx43OT. Representative reconstructed images of the femoral mid-diaphysis are 
shown. Bars represent mean ± s.d., *: p<0.05, versus 6-month-old genotype-matched 
mice by two-way ANOVA, tukey, black line: p<0.05, versus old control mice by t.test. 
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Figure 2-4. Cx43OT mice exhibit increased cortical bone resilience to fracture that is 
maintained with advanced age. Cortical bone biomechanical properties structural (A) and 
material (B) were evaluated by femoral 3-point bending testing. 6-month-old mice: n=7 
WT and n=5 Cx43OT, 14-month-old mice: n=11 WT and n=8 Cx43OT. Bars represent mean 
± s.d., *: p<0.05, versus 6-month-old genotype-matched mice by two-way ANOVA, tukey, 
black line: p<0.05, versus old control mice by t.test.
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Figure 2-5. Cx43OT mice are not protected against age-induced loss of cancellous bone 
mass. (A) Cancellous bone microarchitecture was evaluated by μCT in the distal femur L4 
vertebra. 6-month-old mice: n=7 WT and n=5 Cx43OT, 14-month-old mice: n=14 WT and 
n=11 Cx43OT. Representative reconstructed 3D μCT images are shown. (B) Mechanical 
testing of the structural and material properties was evaluated by axial compression on 
the L4 vertebra. 6-month-old mice: n=7 WT and n=7 Cx43OT, 14-month-old mice: n=13 
WT and n=10 Cx43OT. Bars represent mean ± s.d., *: p<0.05, versus 6-month-old 
genotype-matched mice by two-way ANOVA, tukey, black line: p<0.05, versus old control 
mice by t.test. 
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Figure 2-6. Expression of osteocytic Cx43 does not alter changes in cancellous osteoblast 
or osteoclast activity induced with aging. (A) Vertebral cancellous bone MS/BS, MAR, and 
BFR/BS were measured in unstained longitudinal vertebral sections. 6-month-old mice: 
n=9 WT and n=7 Cx43OT, 14-month-old mice: n=8 WT and n=8 Cx43OT. Representative 
images show green and red fluorochrome levels. (B) N.Ob/BS, Ob.S/BS and O.Th were 
scored in lumbar vertebra sections stained with von Kossa/McNeal. 6-month-old mice: 
n=9 WT and n=8 Cx43OT, 14-month-old mice: n=7 WT and n=7 Cx43OT. Representative 
osteoblast images are shown (arrow, red). (C)Cancellous osteoclasts were scored in 
TRAP/Toluidine blue stained vertebral bone sections. N.Oc/BS, Oc.S/BS, and ES/BS are 
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reported. 6-month-old mice: n=10 WT and n=8 Cx43OT, 14-month-old mice: n=7 WT and 
n=8 Cx43OT. Representative osteoclast images are shown (arrow, black). Bars represent 
mean ± s.d., *: p<0.05, versus 6-month-old genotype-matched mice by two-way ANOVA, 
tukey, black line: p<0.05, versus old control mice by t.test. Scale bars indicates 100μm. 
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Figure 2-7. Osteocyte targeted Cx43 transgene expression in DMP1-8kbCx43/GFP 
(Cx43OT) mice. (A) DNA map of CMV-Cx43/GFP transgene construct. (B) Genotyping of 
mouse founder # 82 and its litter using primers to identify GFP and the transgene 
containing Cx43. +: DMP1-GFP mouse for GFP (upper line) and the construct injected in 
the mice for Cx43 (bottom line). 
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Figure 2-8. Cx43 overexpression alters the percent single- and double-labeled surfaces 
on the periosteum and endosteum of the femur mid-diaphysis. Percentage of single and 
double-labeled surfaces were measured on the periosteal (A) and endosteal (B) surfaces 
in unstained sections from the femoral mid-diaphysis. Bars represent mean ± s.d., *: 
p<0.05, versus 6-month-old genotype-matched mice by two-way ANOVA, tukey, black 
line: p<0.05, versus old control mice by t.test. 
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Figure 2-9. RANKL and the RANKL/OPG mRNA ratio in bone was decreased in old 
Cx43OT compared to WT mice at the same age. Bars represent mean ± s.d., *: p<0.05, 
versus old control mice by t.test. 
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Chapter 3 
Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased 
osteoclastogenesis with aging  
 
Rationale 
Skeletal aging results in apoptosis of osteocytes, cells embedded in bone that 
control the generation/function of bone forming and resorbing cells. Aging also decreases 
Cx43 expression in bone; and osteocytic Cx43 deletion partially mimics the skeletal 
phenotype of old mice. Particularly, aging and Cx43 deletion increase osteocyte 
apoptosis, and osteoclast number and bone resorption on endocortical bone surfaces. 
Based on these findings, we examined herein the molecular signaling events responsible 
for osteocyte apoptosis and osteoclast recruitment triggered by aging and Cx43 
deficiency.  
 
Introduction 
Increasing evidence suggests that the viability of osteocytes embedded within the 
bone mineral matrix is essential for maintaining skeletal homeostasis, as supported by the 
increase in apoptotic osteocytes and prevalence of empty lacunae observed in conditions 
of elevated bone fragility and with old age.75 Osteocytes have long dendritic processes 
that create an extensive network allowing for communication between adjacent osteocytes 
and with osteoblasts and osteoclasts on the bone surface; and disruption of this network 
impairs osteocytic regulation of bone formation and resorption.30 Osteocyte interactions 
with other cells occur through the release of cytokines to the lacunar-canalicular system 
that surrounds osteocytes, as well as through cell-to-cell communication via gap junction 
channels.37 Previous work from our group has demonstrated that the gap junction protein 
connexin 43 (Cx43) is a critical component of the signaling pathway controlling osteocyte 
43 
survival, as evidenced by the increased osteocyte apoptosis in mice lacking Cx43 in 
osteoblasts and osteocytes or only in osteocytes.40, 46 In addition to increased osteocyte 
apoptosis, mice lacking osteocytic Cx43 (Cx43ΔOt) exhibit enhanced endocortical 
resorption, partially mimicking the phenotype of old mice 8 and raising the possibility that 
decreased Cx43 contributes at least in part to the skeletal phenotype of aging. However, 
while it has been shown that Cx43 levels in osteocytes are decreased in old mice,91 the 
signaling pathway activated by Cx43 deficiency involved in osteocyte apoptosis with aging 
is not known. 
One of the potential molecules that could mediate osteocyte apoptosis are 
microRNAs (miRs), single-stranded non-coding RNAs that negatively regulate gene 
expression.58 miRs are involved in cancer cell survival, and in particular, the expression 
of miR21 is upregulated in a variety of cancers, promoting cell survival through the direct 
inhibition of apoptotic genes including phosphatase and tensin homolog (PTEN).59 In 
bone, miRs play an important role in controlling the function and lifespan of both 
osteoclasts and osteoblasts.60 However, the role of miRs on osteocyte apoptosis has not 
been investigated.  
Several models of increased osteocyte death, including ovariectomy, unloading, 
microdamage, and a transgenic model of osteocyte apoptosis induced by diphtheria toxin, 
exhibited co-localization of apoptotic osteocytes and osteoclasts, suggesting that signals 
released by dying osteocytes induce osteoclast recruitment.26-29 However, the nature of 
these signals remains unknown. In osteocytes and other cells, apoptotic cell death results 
in the release of the pro-inflammatory cytokine high-mobility group box-1 (HMGB1), a non-
histone nuclear DNA-binding protein responsible of stabilization of nucleosomal structures 
facilitating gene transcription.50, 51 HMGB1 released from the cells activates the receptor 
for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4), and can 
regulate recruitment and differentiation of osteoclast precursors.54, 55 However, whether 
44 
HMGB1 is involved in osteoclast recruitment and differentiation induced by apoptotic 
osteocytes is not known.   
Based on the results of the current study, we propose that miR21 lies downstream 
of Cx43 in the control of osteocyte viability; and that increased osteocyte apoptosis in the 
absence of Cx43 and with aging is a consequence of disruptions in the PTEN/pAkt 
pathway and reduced response to the insulin like growth factor 1 (IGF-1). Further, the 
increased osteoclastogenic potential of Cx43-deficient osteocytes is a result of elevated 
release of the cytokines RANKL and HMGB1 during apoptosis, and the subsequent 
activation of RAGE on osteoclast progenitors. In conclusion, our data identifies a novel 
Cx43/miR21/HMGB1/RANKL pathway mediated by gap junction communication in 
osteocytes that could be targeted to treat bone fragility in aging.
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Experimental procedures 
Mice. C57BL/6 female mice were purchased from National Institute on Aging and 
sacrificed at 4, 12, 18, 21 and 24 months of age. To delete Cx43 specifically in osteocytes, 
mice were generated using the Cre/LoxP system.46 Cx43fl/fl mice were crossed with mice 
harboring DMP1-8kb-Cre, which express Cre recombinase under control of a DNA 
fragment containing 8kb of the murine dentin matrix protein 1 promoter (abbreviated as 
Cx43DOt). Mice harboring both ‘floxed’ miR21 alleles (abbreviated as miR21fl/fl) were 
generated by M. Ivan and crossed amongst themselves. All mice used were maintained 
in a C57BL/6 background. The protocols involving mice were approved by the Institutional 
Animal Care and Use Committee of Indiana University School of Medicine.  
 
Cell culture, silencing and transient transfections. MLO-Y4 osteocytic and Ob-
6 osteoblastic cells were silenced using short hairpin (sh)RNA Lentiviral Particles (Sigma-
Aldrich), as previously reported,40, 92 and cultures as previously described. The efficiency 
of deletion was determined by quantifying Cx43 protein and mRNA levels by Western 
blotting and by qPCR, respectively. All samples from in vitro studies were collected 24h 
after seeding the cells or 48h after transfection, unless otherwise indicated. The plasmid 
encoding the full length rat Cx43 (abbreviated as Wt) was provided by R. Civitelli 
(Washington University, Saint Louis, MO).93 The mutant Cx43 truncated at amino acid 245 
(abbreviated as Cx43D245)94 and the Cx43 carboxy-terminal tail (abbreviated as Cx43C-tail)94 
were provided by B. Nicholson (University of Texas, Santo Antonio, TX). Cx43 lacking 
seven residues from the internal loop at positions 130-136 (abbreviated as Cx43D130) was 
provided by V.A. Krutovskikh (International Agency for Research on Cancer, Lyon, 
France).95 Cx43Cys-less, which has all cysteine sites on the two extracellular loops replaced 
by alanine (abbreviated as Cx43Cys-less) was provided by G.M. Kidder (University of 
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Western Ontario, Ontario, Canada).77 All of the constructs used in this study are of rat 
origin and have been shown to produce functional proteins. pcDNA3.1 empty vector was 
used as control (Invitrogen). MLO-Y4 osteocytic cells were transiently transfected with 
different DNA constructs together with nuclear GFP using Lipofectamine Plus (Invitrogen) 
reagent with 0.1µg/cm2 as described previously.92 Apoptosis was assessed 48h after 
trasnfection by quantification of cells exhibiting nuclear fragmentation and chromatin 
condensation under an EVOS fluorescence microscope system (Life Technologies, 
Carlsbad, CA). HeLa cells (2x104cells/cm2) were transiently transfected with either empty 
vector or rat Cx43 together with IGFR1 and nuclear GFP using Lipofectamine Plus, as 
published,96 and apoptosis was assessed as indicated below.  
 
Western Blotting analysis. Whole protein extracts from MLO-Y4 osteocytic cells 
or from bone were prepared as published.46, 74 To determine the levels of HMGB1 on 
culture supernatants, proteins concentrated 10x by precipitation using trichloroacetic acid 
(5:1).  Protein lysates were separated on 10% SDS-PAGE gels and electrotransferred to 
polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA). These membranes 
were incubate in blocking solution (5% non-fat milk) for 30 minutes and probed with 
primary antibodies diluted 1:1000 in 5% non-fat milk against a monoclonal anti-PTEN (Sc-
7974), polyclonal anti-GADD153 (Sc-575), anti-lamin B (Sc-6217) (Santa Cruz 
Biotechnology, Santa Cruz, CA), monoclonal anti-Akt (2920), anti-phosphorylated Akt at 
serine 473(4060) (Cell Signaling Technology, Danvers, MA), anti-caspase3 cleaved 
(Asp175) (Thermo Fisher Scientific, Rockford, IL, PA5-23921), anti-connexin43 (C6219) 
and anti-β-actin (A5316) (Sigma Aldrich), and anti-HMGB1 (ab18256) (Abcam, 
Cambridge, MA) overnight at 4ºC, followed by corresponding secondary antibodies 
conjugated with horseradish peroxidase in 5% non-fat milk (Santa Cruz Biotechnology, 
Santa Cruz, CA) for 4 hours at room temperature. After rinsing with TBS-T, the 
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membranes were developed with an enhanced chemiluminescence Western blotting 
substrate kit (Pierce Biotechnology Inc., Rockford, IL). Bands were detected and their 
intensity was quantified using the TotalLab TL 100 software (Durham, NC). 
 
RNA extraction and real-time PCR (qPCR). Total RNA was isolated and purified 
using TRIzol (Invitrogen, Grand Island, NY), as published.83 Reverse transcription was 
performed using a high-capacity cDNA kit (Applied Biosystems, Foster City, CA). qPCR 
was performed using the Gene Expression Assay Mix TaqMan Universal Master Mix with 
an ABI 7900HT real-time PCR system. The house-keeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used. Primers and probes were commercially 
available (Applied Biosystems, Foster City, CA) or were designed using the Assay Design 
Center (Roche Applied Science, Indianapolis, IN). To evaluate miR expression levels, total 
RNA was isolated and purified using TRIzol reagent and 10ng were reversely transcribed 
to cDNA using TaqMan microRNA reverse transcription kit (Applied Biosystems, Carlsbad, 
CA) to detect and quantify mature miR21 (assay ID: 000397), miR18 (assay ID: 000521), 
and miR135 (assay ID: 001230). The reaction mixtures were incubated at 16°C for 30 
minutes, 42°C for 30 minutes, 85°C for 5 minutes, and 4°C for 30 seconds. The values 
were normalized for housekeeping miR135. Relative expression was calculated using the 
∆Ct method. 
 
IGF-1, DEVD, and PTEN inhibitor treatment. MLO-Y4 osteocytic cells or HeLa 
cells were treated with vehicle or 5 ng/mL IGF-1 for 1h, followed by 6h treatment with 
vehicle or 10-6 M dexamethasone. In addition, in a parallel experiment, MLO-Y4 osteocytic 
cells were treated with vehicle or 1µM SF1670 (Abcam Biochemical, Cambridge, MA) for 
30 min and then cultured for 24 hours. For apoptosis inhibition, cells were treated for 1 
hour with 50nM Ac-DEVD-CHO (DEVD, Biotium, Inc., Hayward, CA), a caspase-3/7 
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inhibitor, which was then removed and cells were cultured in fresh media for 24 hours, or 
treated for 24h with 50nM DEVD. To determine the percentage of dead cells, supernatant 
was removed and cells were re-suspended in 25µL of 1x trypan blue. Ten microliters of 
the cell suspension were transferred to a hemocytometer and the number of viable cells 
(clear, transparent) and dead (blue) were counted. Data is reported as percentage of dead 
cells. Cells were transfected with the indicated constructs together with nuclear GFP to 
assess the nuclear morphology only in transfected cells. Forty-eight hours after 
transfection cells were washed to remove dead cells, and treated with 5 ng/mL IGF-1 for 
1h, followed by 10-6 M dexamethasone. Cells were fixed 6h later and the prevalence of 
apoptotic cells exhibiting chromatin condensation and nuclear fragmentation was 
assessed under fluorescence microscopy. Data is reported as percentage of apoptotic 
cells.  
 
miRNA micro array analysis. The effect of Cx43 silencing on miRNA levels in 
MLO-Y4 osteocytic cells was assessed using the Apoptosis-Associated miRNA Plate 
Array, as described by the manufacturer (Signosis Inc., Santa Clara, CA, cat. # MA-1002). 
The values were normalized for U6 RNA. 
 
microRNA silencing and overexpression. MLO-Y4 osteocytic cells silenced or 
not for Cx43 were plated at the density of 2x104 cells/cm2 on 48-well plates coated with 
type I rat tail collagen overnight. Cells were transiently transfected using Lipofectamine 
RNAiMAX reagent (Invitrogen) containing miRIDIAN negative control inhibitor, miR21 
inhibitor, negative control mimic or miR21 mimic (GE Healthcare Bio-Sciences, Pittsburgh, 
PA) at a final concentration of 0.1nM in medium without serum and penicillin/streptomycin 
for 6 hours. Next, medium 2x concentrated was added to each well and then cultured 
overnight. Medium was changed to a regular growing medium and cells were then cultured 
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for an additional 24 hours before measuring cell death by Trypan blue uptake. miR21 
levels were decreased by 60% in MLO-Y4 scramble cells and by 91% in MLO-Y4 Cx43 
shRNA cells treated with miR21 inhibitor, as measured by qPCR. miR21 levels were 
increased by 44% in MLO-Y4 scramble cells and 234% in MLO-Y4 Cx43 shRNA cells 
treated with the miR21 mimic. 
 
Viral infection of calvaria bone ex vivo. Calvariae of miR21fl/fl mice were 
harvested at 5 days of age and two 5mm pieces of the bone were removed using a biopsy 
punch (Integra LifeSciences Corporation, New Jersey, USA). Samples were washed in 
PBS and incubated in a 96-well plate with α-minimal essential medium supplemented with 
10% FBS and 1% penicillin/streptomycin for 6 hours. Bones were then treated with 
2.5µl/well of control adenovirus (Adeno-GFP, cat.#1060) or Cre-recombinase virus 
(cat.#1700) (Vector BioLabs Malvern, PA, USA) diluted in serum-free α-minimal essential 
medium in a final volume of 45 µl overnight. Next, media was removed and samples were 
washed twice with PBS before adding α-minimal essential medium supplemented with 
10% FBS and 1% penicillin/streptomycin and cultured for additional 48h at 37% and 5% 
CO2. mRNA was quantified by qPCR and protein quantified by Western blotting. 
 
Transmission electron microscopy (TEM). Calvaria bones from miR21fl/fl mice 
treated with adenovirus (Adeno-GFP, cat.#1060) or Cre-recombinase virus were 
processed for TEM as previously published.46 Briefly, bones were decalcified and post-
fixed in 2% paraformaldehyde/2% glutaraldehyde in 0.1M cacodylate buffer for 1h, 
followed by 1h-treatment with 1% osmium tetroxide in 0.1M cacodylate buffer. After 
standard dehydration and embedding in Embed 812 (Electron Microscopy Sciences, 
Hatfield PA) the blocks were sectioned at 85nm and placed on copper grids, stained with 
uranyl acetate, and viewed on a Tecnai G2 12 Bio Twin electron microscope (FEI, 
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Hillsboro, OR) at the Electron Microscopy Center of the Department of Anatomy and Cell 
Biology (Indiana University School of Medicine). Digital images were taken with an 
Advanced Microscope Techniques (Danvers, MA) CCD camera.  
 
Osteoclastogenesis in co-cultures and with conditioned medium. Bone 
marrow cells were isolated from C57BL/6 mice by flushing the bone marrow out with α-
minimal essential medium supplemented with 10% FBS and 1% penicillin/streptomycin 
and cultured for 25-48h. Next, non-adherent were collected and 2x105 cells/cm2 were 
seeded on top of MLO-Y4 osteocytic cells silenced or not for Cx43. Cells were cultured in 
the presence of 10 nM 1.25(OH)2 vitamin D3 and 1 μM PGE2. Medium was changed every 
2 days for 5 days, as previously published.97 The conditioned medium from MLO-Y4 
osteocytic cells silenced or not for Cx43 was collected after 24 h and then concentrated 
4x using centricon filters (10kD cut off) (EDM Millipore, Billerica, MA). Media was diluted 
1:4 and added to 48-well plate containing 2x105 non-adherent cells/cm2 with 40 ng/ml 
RANKL and 20 ng/ml M-CSF.83 Growing medium that had not been in contact with the 
cells was used as control. Osteoclasts exhibiting 3 or more nuclei were enumerated after 
staining for TRAPase using a commercial kit (Sigma-Aldrich). Images were acquired using 
a Zeiss Axiovert 35 microscope equipped with a digital camera.  
 
Neutralization of HMGB1 in cell cultures. MLO-Y4 osteocytic cells silenced or 
not for Cx43 were plated at the density of 2x105 cells/cm2 on 6-well plates coated with type 
I rat tail collagen overnight. Cells were either treated with 1 mg/ml GA98 or with 0.5μg/ml 
non-immune (ni) rabbit IgG (Abcam, Cambridge, MA, cat.# ab171870) or neutralizing 
rabbit anti-HMGB1 (Abcam, cat.# ab18256) antibodies for 24h and then concentrated 4x 
using centricon filters (10kD cut off) (EDM Millipore, Billerica, MA). For cultures with 
immunoglobulins, conditioned media was incubated with 10 μl/ml Protein A agarose 
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(Roche Applied Science, Indianapolis, IN, cat.# 11719408001) overnight at 4°C to remove 
the immunoglobulins. 1M HEPES was then added to IgG-depleted conditioning media, 
which was then aliquoted and stored at 80ºC until used.  
 
Soluble RANKL, OPG and HMGB1 levels in conditioned media. Conditioned 
media from MLO-Y4 cells were collected, aliquoted, and stored at -80ºC until used. 
RANKL, OPG and HMGB1 protein levels in the supernatants were determined using 
Quantikine Mouse RANKL Immunoassay (R&D Systems, Inc., Minneapolis, MN, cat.# 
MTR00), Quantikine Osteoprotegerin Immusoassay (R&D Systems, Inc., Minneapolis, 
MN, cat.# MOP00) or HMGB1 Immunoassay (IBL International, Germany, cat.# 
ST51011), respectively. 
 
Statistical analysis. Data were analyzed using SigmaPlot (Systat Software Inc., 
San Jose, CA). All values are reported as the mean ± standard deviation. Differences were 
evaluated either by one- or two-way ANOVA, with post-hoc analysis using Tukey Method 
or by Student’s t-test, as appropriate. Differences were considered significant when 
p<0.05. 
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Results 
Aging and Cx43 deficiency result in increased osteocyte apoptosis. Bones 
from 24-month-old mice exhibited a decrease in Cx43 mRNA levels compared to 4-month-
old mice (Fig. 3-1A), and 21-month-old mice exhibited a 95% decrease in Cx43 protein 
levels, compared to young, 3.5-month-old mice (Fig. 3-1B). Consistent with the increased 
osteocyte apoptosis reported in old humans and mice,8, 45 bones (without bone marrow) 
from 21-month-old mice exhibit increased expression of apoptosis-related genes (Fig. 3-
1C). To further study the connection between reduced Cx43 levels and osteocyte 
apoptosis, we used an in vitro system in which Cx43 was silenced in osteocytic and 
osteoblastic cells. Silencing Cx43 in MLO-Y4 osteocytic and Ob-6 cells using shRNA 
resulted in a significant reduction in mRNA levels (Fig. 3-1D), and ~70% and 60% 
reduction at the protein level respectively, compared to cells treated with scramble shRNA 
(Fig. 3-1E). Decreased Cx43 expression led to increased cell death in culture over time in 
MLO-Y4 osteocytic cells, as previously shown.46 Cx43 deficiency does not increase 
osteoblast apoptosis in vivo, and, similarly, silencing Cx43 in Ob-6 osteoblastic cells did 
not alter viability, compared to scramble shRNA-treated cells (Fig. 3-1F). Cell death in 
MLO-Y4 osteocytic cells lacking Cx43 was reversed by DEVD treatment, an irreversible 
active caspase-3 inhibitor, indicating cell death by apoptosis (Fig. 3-1G). Furthermore, 
mRNA levels of FoxO3, p27 and GADD153, genes involved with apoptosis99 were 
increased in MLO-Y4 Cx43-silenced cells (Fig. 3-1H) but unaltered in Ob-6 cells (Fig. 3-
7A). Consistent with this, protein levels for GADD153 and for the apoptosis marker active 
caspase-3 were increased in Cx43-deficient cells (Fig. 3-1I).  
We next investigated the domain of Cx43 required to maintain cell viability. As 
expected, expression of full-length Cx43 decreased apoptosis in Cx43-silenced MLO-Y4 
cells (Fig. 3-1J and Fig. 3-7B). Similarly, Cx43Δ245, lacking the C-terminus scaffold domain, 
as well as simultaneous transfection with Cx43Δ245 and the C-terminus domain (C-tail), 
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which reassemble to form a complete connexin molecule in the cell,100 reversed the 
increase in apoptosis. On the other hand, this Cx43 mutant is not able to confer 
responsiveness to bisphosphonates or to PTH.92, 96 Cx43-silenced cells expressing the 
Cx43 C-tail alone or Cx43Cys-less, a mutant that due to the lack of Cysteine residues in the 
extracellular domain101 only forms hemichannels and it is unable for form gap junctions,77, 
102 maintained an elevated percentage of apoptosis, similar to vector-transfected cells. 
This contrasts with the reversal of the effect of Cx43 silencing in osteoblastic cells by the 
same Cx43Cys-less mutant.92 Furthermore, expression of Cx43Δ130, a mutant that lacks 
channel permeability,95 not only did not reverse the increase in cell death, but further 
increased apoptosis, compared to Cx43-silenced cells transfected by empty vector.  
 
Decreased Cx43 expression reduces miR21, promoting osteocyte apoptosis. 
We next examined whether increased apoptosis was associated with dysregulation of 
miRs in Cx43-deficient osteocytic cells. Screening of apoptosis-associated miRNAs 
revealed a decrease in the levels of miR21, which promotes survival in various cell types59 
but is of unknown function in osteoblastic cells (Fig. 3-2A). On the contrary, miR218, a 
pro-apoptotic miR, was expressed at higher levels in Cx43-deficient MLO-Y4 cells, 
compared to cells treated with scramble-shRNA. Changes in the expression was 
confirmed by qPCR, which showed that miR21 is decreased by 50% whereas miR218 is 
increased by 500% in Cx43-deficient osteocytic cells (Fig. 3-2B). Consistent with 
increases in miR218, expression of its target IkB kinase B was reduced (not shown). On 
the other hand, silencing Cx43 did not alter the levels of miR21, miR218 (Fig. 3-2C) or IkB 
kinase B (not shown) in Ob-6 osteoblastic cells. In addition, 24-month-old mice exhibited 
a decrease in miR21 levels, compared to young mice, similar to Cx43def cells. The 
expression of miR218 was not significantly changed in the bones from aging mice, 
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although it showed a tendency towards increase in 18-month-old mice (Fig. 3-2D). 
Furthermore, Cx43DOt mice lacking Cx43 in osteocytes exhibit reduced miR21 levels; 
however, miR218 and IkB kinase B were not altered (Fig. 3-2E). 
 
Reduced miR21 levels lead to osteocytic cell death and increased PTEN 
levels in bone. Similar to silencing Cx43 gene, reduction of miR21 expression by 
transfecting a specific oligonucleotide inhibitor induced apoptosis of control osteocytes, 
whereas transfection of a miR21-mimic oligonucleotide resulted in lower levels of dead 
cells in scramble-transfected cells (Fig. 3-3A). Further, miR21 mimic reversed the 
increased apoptosis of Cx43-deficient osteocytes. To further assess the role of miR21 on 
bone cell apoptosis, neonatal calvaria bone from miR21fl/fl mice were treated with 
adenovirus-Cre to delete the miR21 gene, and compared to bone treated with adenovirus-
GFP as control (Fig. 3-3B-E). Addition of adenovirus-Cre resulted in a 91% reduction of 
miR21 levels (Fig. 3-3B). Ultrastructural analysis of osteocytes using transmission electron 
microscopy revealed that adenovirus-Cre-treated calvariae from miR21fl/fl mice exhibited 
abundant empty lacunae (Fig. 3-3C). Furthermore, osteocytes, when present, exhibited 
swollen endoplasmic reticulum, an indicator of cellular stress when compared to calvaria 
bones infected with adenovirus-GFP. Similar to Cx43-deficient cells, bones with deleted 
miR21 exhibited increased expression of the apoptosis-related genes FoxO3 and p27, 
and a tendency towards increased GADD153 levels (Fig. 3-3D). Moreover, protein levels 
of the miR21 target phosphatase PTEN were increased by ~ 2.7-fold (Fig. 3-3E).  
 
Cx43 deficiency and aging result in disruptions in PTEN/pAkt pathway. 
Consistent with the decrease in miR21 expression, protein levels of PTEN were increased 
2.4-fold in Cx43DOt compared to Cx43fl/fl mice (Fig. 3-4A). Further, reduction of Cx43 
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expression in MLO-Y4 osteocytic cells resulted in increased levels of the phosphatase 
PTEN and a decreased phosphorylated Akt, a known target of PTEN (Fig. 3-4B and C). 
Cell death was blocked by the PTEN inhibitor SF1670 (Fig. 3-4D and E), adding support 
for a role of the phosphatase on cell death induced by Cx43 deficiency.  
We next examined whether the pro-survival effect of IGF-1, which is mediated by 
Akt phosphorylation in several cell types, requires Cx43 expression. Because IGF-1 does 
not decrease the low level of cell death in vehicle-treated control cells, we induced 
apoptosis with the synthetic glucocorticoid dexamethasone, as previously reported.103 
IGF-1 prevented dexamethasone-induced apoptosis in scramble-silenced MLO-Y4 
osteocytic cells, and in HeLa cells [which lack endogenous Cx4396] transfected with Cx43, 
but not in Cx43def cells or in vector-transfected HeLa cells (Fig. 3-4F). The levels of dead 
cells were quantified 7h after all detached cells were removed from the cultures, unlike the 
ones shown in previous figures, which were measured at least 24h after washing the 
cultures to remove dead cells. Nevertheless, we still detected an increase in the 
percentage of dead cell in vehicle-treated Cx43 silenced MLO-Y4 cells compared to 
vehicle-treated scramble-shRNA cells (~6% vs. ~4%).   
 
Deletion of Cx43 increases the release of pro-osteoclastogenic cytokines by 
osteocytic cells. We next examined the molecular basis for osteoclast recruitment 
induced by Cx43 deficiency. As found before,46 silencing Cx43 from MLO-Y4 cells results 
in increased RANKL and reduced OPG levels (Fig. 3-5A).  Similar results were found in 
old mice.104, 105 Inhibition of apoptosis with DEVD reversed the increase in RANKL mRNA 
levels, but did not change OPG mRNA levels in Cx43def cells. Furthermore, removal of 
miR21 from bones increased RANKL, but did not alter OPG mRNA levels (Fig. 3-5B). 
Taken together, these pieces of evidence suggest that the increase in RANKL but not the 
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reduction in OPG levels in the absence of Cx43 is due to increased osteocyte apoptosis 
downstream of miR21 downregulation.  
HMGB1, a ubiquitously expressed molecule, has been shown to increase in the 
circulation in rats with aging,106, 107 and to increase RANKL expression in osteocytic cells.50 
However, we did not find changes in HMGB1 levels in the serum of old mice (Fig. 3-8). 
Silencing of Cx43 in MLO-Y4 osteocytic cells resulted in a 77% decrease in the amount 
of intracellular HMGB1, and a 480% increase in the levels of the cytokine in the 
conditioned media, suggesting increased release of HMGB1 (Fig. 3-5C). We also detected 
a tendency towards HMGB1 increase in serum from Cx43ΔOt mice, although it did not 
reach significance (Fig. 3-8).  
Inhibition of apoptosis with DEVD or blockage of HMGB1 activity with glycyrrhizic 
acid (GA) reversed the increase in RANKL mRNA levels, and the release of RANKL to the 
extracellular media (Fig. 3-5D). In addition, the levels of HMGB1 in conditioned media 
were reversed to control levels in cells treated with DEVD, and attenuated in cells treated 
with GA (Fig. 3-5E). GA binds to HMGB1 and blocks HMGB1 chemoattractant and 
mitogenic activities,108 and, unlike its analog glycyrrhetinic acid, does not inhibit connexin 
channel activity in MLO-Y4 osteocytic cells.96 Addtion of a neutralizing anti-HMGB1 
antibody to Cx43-silenced MLO-Y4 cells partially reversed the increase in RANKL mRNA 
without affecting OPG levels, resulting in a significant decrease in RANKL/OPG ratio, 
compared to cells treated with non-immune IgG (Fig. 3-5F).  
Increased osteoclastogenesis is inhibited by blocking apoptosis of Cx43-deficient 
MLO-Y4 osteocytic cells. We next investigated whether deletion of Cx43 in osteocytic cells 
resulted in enhanced osteoclastogenic potential. Increased number of multinucleated 
TRAP-positive osteoclasts were observed in co-cultures of non-adherent bone marrow 
cells (osteoclast precursors) with Cx43-silenced MLO-Y4 cells (Fig. 3-6A). In addition, 
conditioned media from cells silenced for Cx43 induced more osteoclasts than media from 
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control cells (Fig. 3-6B), indicating that factors secreted by the osteocytic cells are 
responsible for the increased osteoclast differentiation. Inhibition of apoptosis of Cx43def 
cells with DEVD reduced the osteoclastogenic potential of the conditioned media, which 
was now similar to conditioned media from scramble-shRNA-treated cells. Furthermore, 
the expression of osteoclast markers was increased in bone marrow cells treated with 
conditioned media from Cx43-deficient cells, whereas their levels were similar to controls 
when the conditioned media was obtained from cells treated with DEVD (Fig. 3-6C). 
Treatment with boxA, which antagonizes HMGB1 binding to its receptor RAGE,109 
decreased osteoclast formation induced by conditioned media from Cx43-deficient cells 
(Fig. 3-6D), suggesting the HMGB1 released by osteocytic cells is responsible for the 
increase in osteoclast differentiation via activating RAGE.   
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Discussion 
In the current study, we dissected the molecular signaling pathway underlying 
osteocyte apoptosis triggered in the absence of osteocytic Cx43 and by aging (Fig. 3-6E). 
In addition, we unveiled the molecular link between osteocyte apoptosis and targeted 
osteoclastic bone resorption. Based on our evidence, we propose that old age and 
absence of osteocytic Cx43 cause decreased miR21 levels, and the associated increased 
PTEN protein levels and decreased Akt activation, resulting in osteocyte apoptosis. 
Apoptotic osteocytes release more HMGB1, which in turn activates RAGE in osteoclast 
precursors to induce osteoclast differentiation.  
Similar to the current report, immunohistochemistry studies showed that Cx43 
expression in osteocytes decreases in old mice.91 On the other hand, the expression of 
Cx43 is not decreased in osteoblastic cells isolated from old rats.110 This evidence 
suggests that Cx43 expression decreases in osteocytes but not in osteoblasts with aging.  
Deletion of Cx43 from osteocytes in mice and stable silencing of Cx43 in MLO-Y4 
osteocytic cells results in spontaneous cell death by a caspase3-dependent mechanism, 
demonstrating the requirement of Cx43 in the survival of osteocytes46 and this report. The 
survival effect of Cx43 requires intact intercellular gap junction communications, but does 
not involve the scaffold or regulatory domains present in Cx43 C-terminus. This is 
consistent with our previous study showing that expression of a truncated Cx43 lacking 
the C-terminus domain restores osteocyte viability in mice lacking Cx43 in osteocytes.49 
Similarly, the altered bone material mechanical properties, with decreased stiffness, of 
mice lacking osteocytic Cx43 is reversed by the truncated Cx43. These findings suggest 
that the trans-membrane and cytoplasmic amino-terminal domains are sufficient to 
maintain osteocyte viability and preserve normal cortical bone geometry and material 
properties. Future studies using mice overexpressing Cx43 in osteocytes (currently under 
development in our laboratory) will allow us to determine whether maintenance of Cx43 
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levels reverses the increased osteocyte apoptosis and, at least partially, the skeletal 
phenotype of old mice.  
The underlying molecular mechanisms that lead to increased osteocyte apoptosis 
in the absence of Cx43 and in old age remained unclear. We now propose the existence 
of a signaling cascade that maintains cell viability through the regulation of miR21 
downstream of Cx43 (Fig. 3-6E). Although we also found that miR218 levels are increased 
in Cx43def cells, this increase was not reproduced in bones from old mice or mice lacking 
Cx43 in osteocytes, suggesting that whereas miR21 is regulated by Cx43, signals other 
than Cx43 are involved in miR218 regulation in vivo.  
Several pieces of evidence support the role of miR21 on osteocyte apoptosis. First, 
both Cx43ΔOt mice and Cx43-deficient osteocytic cells exhibit accelerated cell death and 
express lower levels of miR21, a pro-survival miR.59 Further, miR21 deletion by 
adenovirus-Cre in miR21fl/fl calvaria bones increases the expression of apoptosis related 
genes; and reducing miR21 expression using oligonucleotide inhibitors induces apoptosis 
of control osteocytic cells. Conversely, a miR21 oligonucleotide mimic attenuates Cx43-
deficient osteocyte apoptosis, supporting the idea that miR21 reduction causes the 
increased osteocyte apoptosis in the absence of Cx43. Consistently, the expression of 
both Cx43 and miR21 are reduced in old bones, suggesting that the decreases in Cx43 
and miR21 levels contribute to the decreased osteocyte viability in old age. Although the 
mechanism by which reduced Cx43 expression leads to decrease in miR21 levels is not 
known, these 2 genes are not located in the same gene locus,111 excluding the possibility 
that a deletion of one gene removes the other one.  
In addition to inducing apoptosis, miR21 deletion increases RANKL expression. 
The regulation of RANKL expression in Cx43-deficient osteocytes could be a 
consequence of increased apoptosis in the absence of miR21, or to the lack of direct 
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actions of miR21 on the RANKL gene. However, miR21 deletion reduces RANKL 
expression in multiple myeloma-exposed bone marrow cells,112 suggesting that direct 
actions of the microRNA on gene expression are not the cause of increased RANKL levels 
in our study. It is therefore likely that the changes in RANKL expression in cells in which 
miR21 was deleted is a consequence of increased apoptosis. Future studies are needed 
to further support this conclusion. 
The mechanism by which old age leads to increased osteocyte apoptosis is not 
completely understood. Previous studies showed that the survival effect of IGF-1 is 
reduced in osteoblastic cells isolated from old (24-month-old) compared to young (1.5-
month-old) and adult (6-month-old) mice, even though the levels of the IGF-1 receptor is 
increased in the older mice.113 The resistance of bone marrow cells from old mice to IGF-
1 effect was associated with reduced activation of Akt, a known mediator of survival 
induced by the cytokine.114 We now propose that reduced response to IGF-1 in old animals 
is due to decreased Cx43/miR21 levels, counteracting the effect of IGF-1 on the 
PTEN/pAkt pathway. Consistent with this notion, IGF-1 prevents apoptosis of osteoblastic 
cells115, 116 and Cx43 is required for the survival effect of IGF-1 in cardiomyocyte 
precursors.117  
Osteocyte apoptosis has been shown to precede and to be associated with 
increased targeted recruitment of osteoclasts along adjacent bone surfaces in several 
animal models [recently reviewed by us24, 75]. Consistently, we showed that osteocyte 
specific Cx43 deletion leads to accumulation of apoptotic osteocytes, and an associated 
increase in osteoclasts in some adjacent areas on endocortical bone surfaces.46 
Additionally, Cx43-deficient osteocytic cells exhibit an increase in the RANKL/OPG ratio, 
facilitating osteoclast formation. However, increased populations of osteocytes with 
reduced OPG levels are present even in areas lacking osteoclasts in Cx43ΔOt mice, 
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suggesting that apoptotic osteocytes release other signals that are required for osteoclast 
recruitment. The specific molecules underlying this increased osteoclast recruitment were 
heretofore unknown. We now show that Cx43-deficient osteocytes release elevated levels 
of the pro-inflammatory cytokine HMGB1. Similarly, induction of MLO-Y4 osteocytic cell 
apoptosis with TNFα/cycloheximide increases HMGB1 release.50 However, in Yang’s 
study, addition of HMGB1 to the cells increased Akt phosphorylation, rather than 
decreased it, as reported here. This evidence suggests that the changes in Akt activity in 
the Cx43-deficient cells is not a response to the released HMGB1, but the result of the 
increase in PTEN levels downstream of miR21 downregulation.    
We also found that inhibition of osteocyte apoptosis with DEVD or treatment with 
a HMGB1 neutralizing antibody or GA, an inhibitor of HMGB1 action,98 reduces RANKL 
expression in Cx43-deficient cells. This is consistent with previous work showing that 
apoptotic MLO-Y4 osteocytic cells release HMGB1.51, 118 Further, HMGB1 is chemotactic 
for osteoclasts and triggers osteoclastogenesis by activating RAGE.53-55 Consistently, 
inhibition of apoptosis prevents RANKL and HMGB1 release, and attenuates the 
enhanced osteoclastogenesis and osteoclast marker expression induced by conditioned 
media from Cx43-deficient osteocytes. In addition, the HMGB1-RAGE receptor antagonist 
boxA109 blocks osteoclastogenesis induced by conditioned media from Cx43-deficient 
osteocytes. Thus, we propose that HMGB1 released by Cx43-deficient osteocytes 
enhances osteoclastogenesis by increasing RANKL in osteocytes and, at the same time, 
directly stimulating osteoclast precursor differentiation at least partially through activation 
of RAGE. Future studies will allow us to further elucidate the mechanisms by which 
apoptotic osteocytes in Cx43ΔOt and old mice release HMGB1 and the role of the RAGE 
and TLR4 receptors on the induction of osteoclast recruitment.  
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In summary, we propose that gap junction communications through Cx43 channels 
maintain osteocyte viability via downstream regulation of miR21, leading to the 
subsequent inhibition of PTEN activity and preservation of the Akt survival pathway (Fig. 
3-6E). Additionally, our findings support a model where reduced Cx43 levels in osteocytes 
in old animals lead to apoptosis and the release of RANKL and HMGB1, which signal 
osteoclasts to increase resorption along associated bone surfaces. We therefore identified 
a novel Cx43/miR21/HMGB1/RANKL pathway mediated by gap junction communications 
in osteocytes that could be targeted to treat bone fragility with aging. 
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Figure 3-1. Aging and deletion of Cx43 in MLO-Y4 osteocytic cells leads to increased 
apoptosis. (A) Cx43 mRNA levels in calvaria from 4- to 24-month-old mice measured by 
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qPCR and corrected by GAPDH (Cx43 n = 5–9). (B) Cx43 protein levels in L5 vertebra 
from mice at 3.5 and 21 months of age were assessed by Western blotting and normalized 
by β-actin (n = 6–7). (C) mRNA levels for the indicated apoptosis-associated genes in tibia 
from young and old mice. (D) Cx43 protein expression was measured in MLO-Y4 
osteocytic (n = 6–9) and Ob-6 (n = 3) expressing (scramble) or lacking (shRNA) Cx43 by 
qPCR and corrected by GAPDH. (E) Cx43 protein expression was measured in MLO-Y4 
osteocytic and Ob-6 osteoblastic cells by Western blot analysis and normalized by β-actin 
(n = 4). (F) Cell death assessed in MLO-Y4 osteocytic cells (n = 3) and in Ob-6 cells (n = 6) 
expressing or not Cx43 by Trypan blue uptake after culturing them for the indicated times. 
(G) MLO-Y4 osteocytic cells silenced or not for Cx43 were treated for 1 or 24 h with DEVD 
and percentage of cells undergoing cell death were assessed by Trypan blue uptake 
(n = 6). (H) Gene expression was measured by qPCR and corrected by GAPDH (n = 6–
9). (I) Protein expression for GADD153 and active caspase-3 assessed by Western 
blotting (n = 4). (J) MLO-Y4 osteocytic cells were transiently transfected with empty vector 
or the indicated Cx43 constructs together with nGFP. Apoptosis was determined by 
evaluating nuclear morphology of the transfected (green fluorescent) cells. A 
representative image of cells exhibiting nuclear fragmentation (arrow) compared to other 
cells with normal morphology is shown. Bars and dots represent mean ± SD. *P < 0.05 vs. 
4 months of age, by one-way ANOVA (A), *P < 0.05 vs. young (B and C) or vs. scramble 
shRNA cells (D-I), by t-test. *P < 0.05 vs. vector-transfected scramble shRNA 
cells, # P < 0.05 vs. vector-transfected Cx43 shRNA cells by one-way ANOVA (J). 
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Figure 3-2. Cx43 deficiency and old age results in decreased miR21 expression. (A) 
Profile of 48 apoptosis-associated miRNA assessed in MLO-Y4 osteocytic cells 
expressing or not for Cx43 using an miRNA plate array and corrected by U6 RNA (n = 3). 
(B) Changes in the expression of miR21 and miR218 in MLO-Y4 osteocytic cells were 
validated by qPCR and corrected by miR135 (n = 3). (C) Expression of miR21 and 
miR218 corrected by miR135 in Ob-6 osteoblastic cells (n = 3). (D) miRNA expression in 
calvaria from 4- to 24-month-old mice measured by qPCR and corrected by miR135 
(n = 5–9). Bars represent mean ± SD. # P < 0.05 vs. 12 months of age, by one-
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way ANOVA. (E) Gene and miRNA expression in calvaria from Cx43fl/fl and Cx43ΔOt mice 
measured by qPCR and corrected by miR135 (miR21 and miR218) or GAPDH (Ikβ kinase 
B). Bars represent mean ± SD (n = 5–8). *P < 0.05 vs. Cx43fl/fl mice, by t-test.
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Figure 3-3. Deletion of miR21 is sufficient to induce osteocyte apoptosis and 
increase PTEN levels in bone. (A) MLO-Y4 osteocytic cells were transfected with the 
indicated oligonucleotides, and cell death was assessed by Trypan blue uptake (n = 6). 
*P < 0.05 vs. corresponding scramble shRNA cells, by t-test. (B) Neonatal calvariae from 
miR21fl/fl mice at 5 days of age were treated with adenovirus-Cre to delete miR21 gene. 
miR21 levels corrected by miR135 measured by qPCR. Representative images of viral 
infection efficiency under fluorescence microscope in adenovirus-GFP calvariae and 
adenovirus-Cre (without GFP expression) calvariae (inset) are shown. Scale bar indicates 
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100 μm. (C) TEM images of neonatal calvariae from miR21fl/fl mice treated with 
adenovirus-GFP (control) or adenovirus-Cre. Images are representative of three samples. 
Asterisks indicate empty lacunae, and arrows point at the endoplasmic reticulum. Scale 
bars indicate 2 μm. (D) Gene expression measured in calvaria by qPCR and corrected 
by GAPDH (n = 3). Bars represent mean ± SD. (E) PTEN expression in calvaria was 
assessed 48 h after miR21 deletion by Western blotting and normalized to lamin B levels 
(n = 3). (B–E) *P < 0.05 vs. corresponding cells infected with adenovirus-GFP, by t-test. 
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Figure 3-4. Cx43-deficiency and aging leads to disruptions in PTEN/pAkt pathway and 
abolishes the anti-apoptotic effect of IGF-1. (A) PTEN expression in ulna from Cx43fl/fl and 
Cx43ΔOt mice at 4.5 months of age assessed by Western blotting and normalized by lamin 
B (n = 3). *P < 0.05 vs. Cx43fl/fl mice, by t-test. Bars represent mean ± SD. 
(B,C) PTEN and phosphorylated Akt (pAkt) were analyzed in MLO-Y4 osteocytic cell 
lysates by Western blotting (n = 3–4). *P < 0.05 vs. corresponding scramble shRNA cells, 
by t-test. (D) MLO-Y4 osteocytic cells were treated with vehicle or 
the PTEN inhibitor SF1670 for 30 min, the media were changed, and the cells were 
cultured for additional 24 h. Percentage of dead cells was assessed by Trypan blue uptake 
(n = 3). *P < 0.05 vs. corresponding scramble shRNA cells by two-way ANOVA. (E) pAkt 
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and total Akt were analyzed by Western blotting (n = 3). *P < 0.05 vs. corresponding 
scramble shRNA cells, by t-test. (F) MLO-Y4 osteocytic cells expressing or not Cx43 and 
HeLA cells transfected with empty vector or Cx43 together with IGF receptor 1 
and nGFP were treated with vehicle or IGF-1 for 1 h, followed by 6-h treatment with 
vehicle or dexamethasone. Cell death was assessed by Trypan blue uptake (for MLO-Y4 
cells) or by nuclear morphology (for HeLa cells) (n = 3). *P < 0.05 vs. vehicle-treated cells 
for each condition, by two-way ANOVA. 
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Figure 3-5. Increased osteocyte apoptosis with reduced Cx43 and miR21 leads to 
increased RANKL/OPG ratio. (A) Expression of the indicated genes and in MLO-Y4 cells 
expressing or lacking Cx43 treated with vehicle or DEVD for 1 h and measured 24 h later. 
Bars represent mean ± SD (n = 6). *P < 0.05 vs. corresponding shRNA scramble cells 
and # P < 0.05 vs. vehicle-treated Cx43 shRNA cells by two-way ANOVA. 
(B) mRNA levels for the indicated genes in calvaria from miR21fl/fl mice treated with 
adenovirus-GFP or adenovirus-Cre (n = 3). Bars represent mean ± SD (n = 3). *P < 0.05 
vs. adenovirus-GFP-treated bone, by t-test. (C) HMGB1 protein expression corrected by 
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β-actin measured in cell lysate and conditioned medium of MLO-Y4 osteocytic cells by 
Western blotting (n = 3). (D,E) mRNA levels for RANKL and concentration 
of sRANKL and HMGB1 in conditioned media from MLO-Y4 cells expressing or not Cx43, 
and treated with vehicle, DEVD or GA were measured by qPCR and ELISA, respectively 
(n = 3). (F) Expression of the indicated genes corrected by GAPDH in MLO-Y4 cells 
expressing or not Cx43 and treated with nonimmune (ni) IgG or neutralizing anti-HMGB1 
antibodies for 24 h (n = 6). *P < 0.05 vs. corresponding shRNA scramble cells 
and # P < 0.05 vs. ni IgG-treated Cx43 shRNA cells by two-way ANOVA. 
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Figure 3-6. Blockage of apoptosis in Cx43-silenced MLO-Y4 osteocytic cells reduces their 
osteoclastogenic potential. (A) Bone marrow cells isolated from C57Bl/6 mice and co-
cultured with MLO-Y4 osteocytic cells expressing or not Cx43 for 7 days. Multinucleated 
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(≥ 3 nuclei) osteoclasts were enumerated. Bars represent mean ± SD (n = 4). *P < 0.05 
vs. shRNA scramble cells by t-test. (B,C) Bone marrow cells were cultured in the presence 
of conditioned media from MLO-Y4 osteocytic cells expressing or not Cx43 and treated 
for 1 h with vehicle or DEVD. (B) Multinucleated osteoclasts and representative images of 
cultured osteoclasts stained by TRAP and (C) mRNA expression for the indicated genes 
assessed by qPCR were measured after 7-day culture. Bars represent mean ± SD (n = 4). 
*P < 0.05 vs. vehicle-treated shRNA scramble cells, and # P < 0.05 vs. vehicle-treated 
Cx43 shRNA cells, by two-way ANOVA. Scale bars indicate 200 μm. (D) Multinucleated 
osteoclasts were enumerated after treatment of nonadherent bone marrow cells with 
conditioned media from MLO-Y4 osteocytic cells expressing or not Cx43 in the presence 
of vehicle or boxA. Bars represent mean ± SD (n = 4). *P < 0.05 vs. corresponding 
shRNA scramble cells, by two-way ANOVA. Representative images of cultured 
osteoclasts stained by TRAP are shown. Scale bars indicate 100 μm. (E) Working model 
showing decreased osteocytic Cx43 leads to a reduction in miR21 levels which, in turn, 
leads to an increase in PTEN levels and consequently a reduction in Akt activation. 
Decreased Akt activity leads to increased expression of the apoptosis-related genes p27, 
FoxO3, and GADD153 resulting in caspase-3-mediated apoptosis. At the same time, 
apoptotic osteocytes release RANKL and HMGB1, which induce osteoclast differentiation 
and recruitment. 
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Figure 3-7. Deletion of Cx43 does not affect Ob-6 cells but leads to caspase3-mediated 
apoptosis in MLO-Y4 osteocytic cells. (A) mRNA levels were measured in Ob-6 cells 
expressing (scramble) or lacking (shRNA) cx43 by qPCR and corrected by GAPDH. Bars 
represent mean ± S.D. (n=3). *p<0.05 versus scramble cells, by t-test. (B) MLO-Y4 
osteocytic cells were transiently transfected with empty vector or the indicated Cx43 
constructs together with YFP-DEVD-caspase3 sensor. *p<0.05 versus vector-transfected 
scramble shRNA cells, #p<0.05 versus vector-transfected Cx43 shRNA cells by one-way 
ANOVA. Representative images of cells are shown. Scale bars indicate 50µm. 
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Figure 3-8. HMGB1 levels are not altered systemically with aging or in osteocytic Cx43-
deficient mice. Serum HMGB1 levels were assessed in C57BL/6 mice (n=8-10) and in 
osteocytic Cx43-defient mice (n=6-7) by ELISA. 
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Chapter 4 
Sex divergent role of osteocytic miR21 in the maintenance of osteocyte viability 
and regulation of bone turnover 
 
Rationale 
Osteocytes play a critical role in mediating cell-cell communication and regulating 
bone homeostasis, and osteocyte apoptosis is associated with increased bone resorption. 
miR21, an oncogenic microRNA, regulates bone metabolism by acting directly on 
osteoblasts and osteoclasts, but its role in osteocytes is not clear. Based on our previous 
findings and the notion that osteocyte apoptosis triggers osteoclast differentiation and 
recruitment, we proposed that induction of osteocyte apoptosis upon miR21 deletion 
would lead to subsequent increases in bone resorption and decreases bone strength. The 
purpose of this series of studies was to determine the skeletal effects of osteocytic miR21 
deletion, and identify if miR21 has sex-divergent effects in bone.  
 
Introduction  
Osteocytes are the most prevalent and long-living type of cell in bone.30 Extensive 
evidence suggests that osteocytes embedded in the bone matrix are targets of bone acting 
stimuli, and that osteocyte lifespan affects skeletal homeostasis.32, 40, 42, 43 Osteocytes 
regulate bone remodeling by modulating osteoclasts and osteoblasts through direct cell-
cell interactions and via extracellular signaling through the release of soluble factors.30, 75 
Additionally, osteocyte viability is reduced in conditions of increased bone fragility26, 32-34 
and conversely, agents that preserve bone strength prevent osteocyte apoptosis.32, 40, 42, 
43 Moreover, osteocyte apoptosis and the prevalence of empty lacunae are increased in 
old mice and humans.8, 45 However, the molecular mechanisms that lead to increased 
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osteocyte apoptosis and the osteocyte-derived signaling factors that control bone 
metabolism in old age are not completely understood. 
Recent work has identified microRNAs (miRs) as negative regulators of gene 
expression.60 miRs are ~18-22-nucleotide long noncoding RNAs that regulate a plethora 
of cellular processes and dysregulation of particular miRs have been associated with 
numerous human diseases. Changes in miR expression can also contribute to the effects 
of aging in several organs.120 In particular, alterations in miR21 abundance, a miR 
predominantly regarded as a pro-survival and oncogenic, have been detected in 
numerous pathologies. In bone, miR21 has been shown to directly regulate osteoblast 
and osteoclast differentiation and function.121 However, the role of miR21 in osteocytes 
and its effects on bone turnover remain unclear.  
We previously demonstrated several putative pro-survival miRs are dysregulated 
in MLO-Y4 osteocytic cells in the absence of Cx43. In particular, miR21 levels are 
significantly decreased in Cx43-deficient cells, which undergo spontaneous apoptosis in 
culture; and addition of a miR21 mimic sufficiently restores the viability of these cells.119 
Conversely, inhibition of miR21 induces osteocyte apoptosis in control MLO-Y4 osteocytic 
cells. Further, we found that bones from mice lacking osteocytic Cx43 and from old female 
mice express lower levels of miR21 compared to control Cx43f/f and young mice, 
respectively.59 Based on these findings and the notion that osteocyte apoptosis triggers 
osteoclast differentiation and recruitment,24 a simplistic model would predict apoptotic 
effects on osteocytes upon miR21 deletion, with subsequent increases in bone resorption 
and decreases bone strength. However, given the complex nature of miR regulation, both 
intra- and extracellular, in nearly every cell in the body, it should not have been surprising 
that this hypothesis was overly simplistic. Here, we provide experimental evidence that in 
vivo effects of the miR21 locus are more nuanced, and identify for the first time a sex-
divergent impact of miR21 on osteocyte biology. We show that miR21 regulates osteocyte 
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viability in a sex-dependent manner, preserving osteocyte viability in females but reducing 
osteocyte viability in males. Further, we demonstrate that osteocytic miR21 regulates 
osteocyte cytokine production and bone turnover in a sex-specific manner. In particular, 
we found miR21 deletion differentially altered osteocyte cytokine production, as well as, 
several related signaling pathways in females and males. Despite these changes, miR21 
deletion enhanced bone mechanical properties in both sexes, albeit to a greater extent in 
males. Taken together, these results suggest that miR21 exerts a sex-divergent role in 
osteocytes, regulating bone mass and architecture through non-cell autonomous effects 
on osteoblasts and osteoclasts, whereas, miR21 has sex-independent effects on bone 
mechanical properties.
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Materials and Methods  
Mice. The miR21 floxed mouse strain was engineered with lox cassettes on both 
sides of the mmu-miR-21 genomic locus (named miR21f/f).119 To generate mice lacking 
the miR21 gene preferentially in osteocytes miR21f/f mice were crossed with DMP1-8kb-
Cre mice46 to obtain female and male miR21f/f and miR21f/f;DMP1-8kb-Cre (miR21Δot) 
mice. All mice were of the C57BL/6 background. Mice were fed a regular diet and water 
ad libitum and maintained on a 12h light/dark cycle. The protocols involving mice were 
approved by the Institutional Animal Care and Use Committee of Indiana University School 
of Medicine. 
 
RNA extraction and qRT-PCR. Total RNA was isolated using TRIzol (Invitrogen, 
Grand Island, NY), as published.83 Reverse transcription was performed using a high-
capacity cDNA kit (Applied Biosystems, Foster City, CA). qPCR was performed using the 
Gene Expression Assay Mix TaqMan Universal Master Mix with an ABI 7900HT real-time 
PCR system, and gene expression was corrected by the levels of the house-keeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primers and probes were 
commercially available (Applied Biosystems, Foster City, CA) or were designed using the 
Assay Design Center (Roche Applied Science, Indianapolis, IN). miR21 (assay ID: 
000397) and miR135 (assay ID: 001230) expression levels were evaluated as previously 
published.119 miR21 levels were normalized to the housekeeping miR135. Relative 
expression was calculated using the ∆Ct method. 
 
Body weight and bone mineral density (BMD) by dual energy x-ray 
absorptiometry (DXA). BMD was measured monthly from 1 to 4 months of age by DXA 
PIXImus densitometry (G.E. Medical Systems, Lunar Division, Madison, WI).83 Body 
weight was measured at the time of the DXA scan. BMD measurements included total 
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BMD (whole body BMD, excluding the head and tail), femoral BMD (entire femur) and 
spinal BMD (L1-L6 vertebrae). Calibration was performed using a standard control 
phantom before scanning, as recommended by the manufacturer.  
 
μCT analysis. Femur and lumbar vertebra (L4) samples were harvested from 4-
month-old female and male mice. The female bones were scanned using the Scanco µCT-
35 system (Scanco Medical AG, Brüttisellen, Switzerland) using a 50kV source, 120 mA, 
151 milliseconds integration time, and 10µm voxel resolution.83 The male bones were 
scanned using a 65kV source, 0.5mm Al filter, 0.7 degree rotation and two-image 
averaging with an isotropic voxel size of 9μm using a SkyScan 1176 system (SkyScan, 
Kontich, Belgium).90 Two different systems were used due to constrained availability of 
the instruments. The terminology and units used for µCT are those recommended by the 
American Society for Bone and Mineral Research (ASBMR).84  
 
Bone histomorphometry. Femur and vertebra harvested from 4-month-old 
female and male mice were fixed in 10% neutral buffered formalin and embedded using 
previously established methods at the ICMH Histology and Histomorphometry Core.90 To 
allow for dynamic histomorphometric analysis mice were injected intraperitoneally with 
calcein (20 mg/kg; Sigma) and alizarin red (20 mg/kg; Sigma) 7 and 2 days prior to 
sacrifice, respectively. Dynamic histomorphometry was performed on unstained methyl 
methacrylate-embedded L1-L3 vertebra (sagittal) and femur mid-diaphysis (transverse) 
sections using an epifluorescence microscope. Osteoclasts were quantified in 
TRAPase/Toluidine blue stained femur mid-diaphysis and vertebra sections and 
osteoblasts in von Kossa/McNeal stained-sections using static histomorphometric 
analysis. Histomorphometric analysis was performed using OsteoMeasure high resolution 
digital video system (OsteoMetrics Inc., Decatur, GA, USA). The terminology and units 
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used are those recommended by the ASBMR Histomorphometry Nomenclature 
Committee.85 
 
Biomechanical testing. Three-point bending testing of the femoral mid-diaphysis 
was performed following previously published protocols.49, 90 Briefly, bones were thawed 
to room temperature, hydrated in 0.9% saline, and loaded until failure at 2 mm/min with 
force versus displacement data collected at 10Hz using a servo-hydraulic test system 
(TestResources Inc., Shakopee, MN, USA). Femora were loaded until failure in an 
anterior–posterior direction with the upper contact area at the mid-diaphysis (50% total 
bone length) and the bottom contact points centered around this point and separated by 
8mm. Cross-sectional moment of inertia and anterior–posterior diameter were determined 
by μCT and were used to calculate material-level properties, as previously described.49 
 
Ex vivo bone organ cultures. Long bones were isolated from 2-month-old female 
and male miR21f/f and miR21Δot mice. Bone-marrow cells (BMCs) were flushed out with α-
minimal essential medium (MEM) and osteocyte-enriched long bones were cultured ex 
vivo in α-MEM supplemented with 10% FBS and 1% penicillin/streptomycin (P/S) for 48h. 
Conditioned media was collected and stored at -20°C until used for the osteoclastogenesis 
assays and cytokine arrays.  
 
Osteoclast assays. BMCs were isolated from C57BL/6 mice by flushing the bone 
marrow out with α-MEM supplemented with 10% FBS and 1% P/S and cultured for 48h.83, 
119 Next, non-adherent cells were collected and 2x104 cells/cm2 were seeded on 96-well 
plates and cultured with conditioned media collected from ex vivo cultures of osteocyte-
enriched marrow-flushed long bones isolated from miR21f/f and miR21Δot female and male 
mice. Additionally, BMCs isolated from the miR-21f/f and miR21Δot female and male mice 
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were cultured in α-MEM supplemented with 10% FBS and 1% P/S for 48h. Next, non-
adherent cells were collected and 2x104 cells/cm2 were seeded on 96-well plates. RANKL 
(80 ng/ml) and M-CSF (20 ng/ml) were added to induce osteoclast differentiation and 
media was changed every 3 days for 7 days. Cells were stained using a TRAPase kit 
(Sigma-Aldrich) and mature osteoclasts exhibiting 3 or more nuclei were quantified. 
Images were acquired using a Zeiss Axiovert 35 microscope equipped with a digital 
camera. Osteoclast size and number of nuclei were quantified using ImageJ.  
 
Multiplex cytokine and cell-signaling assays. Cytokines in serum and 
conditioned media released from osteocyte enriched ex vivo bone organ cultures of female 
and male miR21f/f and miR21Δot mice, were measured using the Bioplex protein array 
system at the Multiplex analysis core at IUSM. For the cytokine assay, premixed magnetic 
beads of the Milliplex mouse cytokine/chemokine 32 plex [Eotaxin/CCL11, G-CSF, GM-
CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 
(p70), IL-13, IL-15, IL-17A/CTLA8, IP-10/CXCL10, KC/GROα/CXCL1, LIF, LIX, MCP-
1/CCL2, M-CSF, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, MIP-2/CXCL2, 
RANTES/CCL5, TNFα, VEGF-A] kit was used (Milliplex, Burlington, MA). Cell-signaling 
pathway alterations induced by deletion of osteocytic miR21 were examined in female and 
male miR21f/f and miR21Δot calvaria bone lysates. For cell-signaling assays, premixed 
magnetic beads of the Milliplex multi-pathway 9-plex [Akt/PKB, CREB, ERK/MAPK 1/2, 
JNK/SAPK1, NF-κβ, p38/ SAPK2A/B, p70S6 Kinase, STAT3, STAT5A/B] phosphoprotein 
and total kits were used. 
 
Cell culture and lentiviral transfection. miR21-silenced MLO-Y4 osteocytic cells 
were generated using short hairpin (sh)RNA Lentiviral Particles (Sigma-Aldrich Chemical 
Co., St. Louis, MO, USA), as previously reported,40, 46 and cultured as previously 
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described. MLO-Y4 osteocytic cells silenced or not for Cx43 were plated at the density of 
2 x 104 cells cm-2 on 48-well plates coated with type I rat tail collagen and cultured 
overnight. Cells were transiently transfected using Lipofectamine RNAiMAX reagent 
(Invitrogen) containing miRIDIAN negative control inhibitor, miR21 inhibitor, negative 
control mimic, or miR21 mimic (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) at a 
final concentration of 0.1 nM in medium without serum and penicillin/ streptomycin for 6 h. 
Next, 2x concentrated medium was added to each well and then cultured overnight. 
Medium was changed to a regular growing medium, and cells were then cultured for an 
additional 24 h before isolating mRNA. miR21 levels were decreased by 60% in MLO-Y4 
scramble cells and by 91% in MLO-Y4 Cx43 shRNA cells treated with miR21 inhibitor, as 
measured by qPCR. miR21 levels were increased by 44% in MLO-Y4 scramble cells and 
234% in MLO-Y4 Cx43 shRNA cells treated with the miR21 mimic. 
 
Whole-mount skeletal staining. Cartilage and mineralized tissue were analyzed 
in 6-day old newborn mice using alizarin red/alcian blue staining, as previously 
published.122 
 
Circulating metabolites. Blood was collected by cheek bleeding after 6 hours of 
fasting. Plasma was separated, aliquoted, and stored at −80 °C until used. Plasma N-
terminal propeptide of type I procollagen (P1NP) (Immunodiagnostic Systems Inc., 
Fountain Hill, AZ, USA, cat.#AC-33F1) and C-telopeptide fragments (CTX) (cat.#AC-
06F1) were measured as described by the manufacturer. Alkaline phosphatase (ALP) 
activity was assessed by a standard automated method using a Randox Daytona chemical 
analyzer (Northern Ireland, United Kingdom).  
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Statistical analysis. Data were analyzed using SigmaPlot. All values are reported 
as the mean ± standard deviation. Data were evaluated by Student’s t-test or two-way 
ANOVA and differences with p<0.05 were considered statistically significant. 
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Results 
miR21 regulation of osteocyte viability and mitochondrial function is sex-
dependent. To investigate the role of osteocytic miR21 locus in vivo, we generated a 
mouse model in which miR21 was deleted from osteocytes (Fig. 4-1A). Targeted-deletion 
of miR21 in osteocytes decreased miR21 levels ~50% in calvaria bone lysates of both 
female and male miR21Δot compared to control miR21f/f mice (Fig. 4-1B). Interestingly, 
basal miR21 levels were higher in miR21f/f females than males, suggesting a sex-related 
difference in miR21 expression in bone. Additionally, we detected decreases in mRNA 
levels of vacuole membrane protein-1 (VMP1) in both female and male miR21Δot 
compared to control miR21f/f mice, due to overlap between miR21 and the 3’ UTR of VMP1 
(Fig. 4-7). However, no sex-specific differences in VMP1 expression were detected in 
control mice.  
Similar to our previous findings in Cx43-deficient osteocytic cells,119 in females, the 
RANKL/OPG mRNA ratio was increased in bones from miR21Δot compared to miR21f/f 
mice (Fig. 4-1C). Additionally, female miR21Δot mice exhibited higher expression of the 
apoptosis-associated gene P27, as well as tendencies towards higher Gadd153 and 
Foxo3 (Fig. 4-1D).  
Moreover, miR21 inhibition in control MLO-Y4 osteocytic cells, which are derived 
from a female mouse, increased the RANKL/OPG mRNA ratio and the expression of the 
apoptosis associated-genes (P27, Gadd153, and Foxo3) (Fig. 4-8A). Conversely, 
transfection of a miR21 mimic decreased the RANKL/OPG mRNA levels and apoptosis-
related gene expression (Fig. 4-8B). Further, overexpression of miR21 in Cx43-deficient 
MLO-Y4 cells, which exhibit increased levels of apoptosis and express low levels of miR21 
compared to scramble-silenced cells,119 attenuated the increased RANKL/OPG mRNA 
ratio and apoptosis associated-gene expression (Fig. 4-9).   
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While no changes in RANKL or OPG gene expression were detected in the 
miR21Δot compared to miR21f/f males (Fig. 4-1E), interestingly, our findings suggest that 
miR21 negatively regulates osteocyte viability. Specifically, miR21Δot males exhibited 
lower levels of the apoptosis-associated genes (p27, Gadd153 and Foxo3) (Fig. 4-1F). 
Consistent with the sex-divergent effects of osteocytic miR21 deletion on the apoptosis-
associated genes and RANKL/OPG mRNA levels, miR21 deletion differentially altered 
mitochondrial gene expression in females and males. Specifically, miR21Δot females, but 
not males exhibited significantly lower levels of several mitochondria-associated genes, 
whereas in males, the expression of ND2 was increased (Fig. 4-1G,H).  
 
Removal of osteocytic miR21 differentially regulates bone turnover in 
females and males. To determine whether removal of osteocytic miR21 also regulates 
bone mass and bone cell activity in a sex-dependent manner, we next examined the bone 
phenotype of miR21Δot and miR21f/f mice of each sex. In females, deletion of miR21 from 
osteocytes did not alter the distribution of cartilage and mineralized bone in newborn mice 
(Fig. 4-10). Similarly, total, spinal and femoral BMD were not affected by miR21 deletion 
in females up to 4 months of age, although slight increases in body weight were detected 
between 3 and 4 months of age in miR21Δot compared to miR21f/f mice (Fig. 4-2A). On the 
other hand, in males, total, spinal and femoral BMD were all significantly increased by 4 
months of age in miR21Δot compared to miR21f/f mice, while body weight was unaltered 
(Fig. 4-2B). 
Osteocytic miR21 deletion led to sex-specific changes in bone cell activity and 
bone geometry in both cortical and cancellous bone compartments. In females, dynamic 
bone histomorphometry analysis of the femur mid-diaphysis showed that, while the bone 
formation parameters on the periosteal surface were not changed, MS/BS (the mineralized 
surface per total bone surface) and BFR/BS (bone formation rate per bone surface) were 
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significantly lower on the endocortical surface in miR21Δot compared to miR21f/f mice (Fig. 
4-3A). Conversely, in males, dynamic histomorphometry analysis of the femur mid-
diaphysis showed that all bone formation measurements, MAR (mineral apposition rate), 
MS/BS, and BFR/BS, were increased on the periosteal surface, whereas no changes in 
bone formation were detected on the endocortical surface (Fig. 4-3B). Further, static 
histomorphometry analysis of the endocortical femur surface in females revealed a 
reduction in osteoclast number and surface per bone surface (N.Oc/BS and Oc.S/BS) in 
miR21Δot compared to miR21f/f mice (Fig. 4-3C). Consistent with the histomorphometric 
findings in cortical bone, decreases in circulating serum levels of the bone turnover 
makers, CTX, P1NP, and ALP were also detected in the female miR21Δot compared to 
miR21f/f mice (Fig. 4-11). In contrast to the reduced osteoclasts parameters in the miR21Δot 
females, in males, N.Oc/BS and Oc.S/BS were higher in the miR21Δot compared to miR21f/f 
mice (Fig. 4-3D). 
Consistent with the sex-related alterations in bone cell activity induced by 
osteocytic miR21 deletion, sex-dependent changes in femur cortical bone geometry were 
also revealed by µCT analysis of the femur mid-diaphysis. In females, the suppressed 
endocortical bone turnover did not alter cortical bone geometry (Fig. 4-3E), whereas in 
males, the µCT parameters, tissue area (TA), bone area (BA), cortical thickness (C.Th), 
marrow cavity area, and moment of inertia were all increased in miR21Δot compared to 
miR21f/f mice (Fig. 4-3F).  
Sex-dependent alterations in bone turnover and architecture were also detected 
on cancellous surfaces within the vertebra. However, unlike the decrease in formation 
detected on the endocortical femur surface in females, removal of osteocytic miR21 did 
not alter cancellous osteoblast number or activity (Fig. 4-4A,B). On the other hand, 
reductions in Oc.S/BS were detected on the cancellous surface of miR21Δot compared to 
miR21f/f female mice, while N.Oc/BS was unchanged (Fig. 4-4C). In males, no significant 
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changes in cancellous osteoblast number or surface per cancellous bone surface 
(N.Ob/BS and Ob.S/BS) were detected in miR21Δot compared to miR21f/f mice (Fig. 4-4D). 
However, the dynamic histomorphometry bone formation parameter MS/BS was 
significantly higher in the male miR21Δot mice, suggestive of higher amounts of bone 
forming surface (Fig. 4-4E). Similar to N.Ob/BS and Ob.S/BS, no significant differences in 
vertebral cancellous N.Oc/BS and Oc.S/BS were detected in the male miR21Δot compared 
to the miR21f/f mice (Fig. 4-4F).  
Despite the small changes in cancellous bone cell activity, µCT analysis detected 
significant alterations in cancellous bone architecture. In females, µCT of the vertebra 
revealed a slight increase in Tb.th (trabecular thickness) (Fig. 4-4G). On the other hand, 
in males µCT analysis detected significant increases in almost all the vertebral cancellous 
architecture parameters examined, including BV/TV (bone volume/tissue volume), Tb.Th, 
Tb.N (trabecular number), and material density miR21Δot compared to miR21f/f mice (Fig. 
4-4H). Similar alterations in cancellous architecture of the distal femur were also detected 
in female and male miR21Δot compared to miR21f/f mice (Fig. 4-12). 
 
Sex-divergent miR21 regulation of osteocyte cytokine production and 
release differentially controls osteoclastogenesis. Consistent with the in vivo 
decreases in osteoclast number and surface in the miR21Δot compared to miR21f/f female 
mice, less mature osteoclasts were generated in vitro from female miR21Δot compared to 
miR21f/f non-adherent BMCs (Fig. 4-5A). On the other hand, in vitro generation of mature 
osteoclasts from male miR21Δot and miR21f/f non-adherent BMCs did not differ (Fig. 4-5B).   
To further examine the mechanisms underlying the sex-specific osteoclast effects 
of osteocytic miR21 removal, we generated osteoclasts from wildtype BMCs cultured with 
CM from osteocyte-enriched miR21Δot and miR21f/f bone cultures, as illustrated in Fig. 4-
5C. Consistent with our in vivo results, addition of 50% CM from miR21Δot females led to 
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0.7-fold less mature osteoclasts (Fig. 4-6D), while addition of only 25% CM was not 
sufficient to reduce osteoclast number or gene expression (Fig. 4-13A). Conversely, 
addition of 50% CM from miR21Δot males led to 3.8-fold more osteoclasts that were larger 
in size (Fig 4-5E), and addition of 25% CM led to a tendency towards increase in osteoclast 
number and significantly increased osteoclast gene expression (Fig. 4-13B).  
Next, we investigated the effects of osteocytic miR21 deficiency on osteocyte 
cytokine production and release. Consistent with the sex-dimorphic effects on 
osteoclastogenesis, mRNA levels of several pro-osteoclastogenic cytokines, IL-6, MCP-
1, M-CSF, and VEGF-A were reduced in bone lysates from female, but not male miR21Δot 
compared to miR21f/f mice (Fig. 4-5F,G). Further, osteocytic-miR21 deletion induced sex-
specific inflammatory cytokine protein alterations in CM from marrow-flushed osteocyte-
enriched bone. In CM from miR21Δot female bones, M-CSF and VEGF protein levels 
showed tendencies towards decrease, whereas, in CM from miR21Δot male bones, M-CSF 
and VEGF protein levels were increased, although MCP-1 levels were decreased (Fig. 4-
5H,I and Tables 4-5A,B). Interestingly, in serum from these mice, an opposite pattern of 
expression was observed for several inflammatory cytokines altered in CM from miR21Δot 
bones (Table 4-6A,B). These pieces of evidence suggest that removal of osteocytic miR21 
alters osteoclastogenesis by modifying osteocyte-derived inflammatory cytokine 
production and release in the local bone microenvironment (Fig. 4-5J).  
In addition, we detected sex-dependent decreases in the mRNA levels of several 
cytokines known to inhibit osteoblast differentiation and activity. Specifically, in bone 
lysates from miR21Δot females, only SOST mRNA levels were reduced (Fig. 4-14A). On 
the other hand, in miR21Δot male bones, IL-1β, DKK1, and SOST mRNA expression was 
significantly decreased compared to miR21f/f mice (Fig. 4-14B).  
Moreover, consistent with the sex-divergent effects of osteocytic-miR21 deletion 
on osteocyte cytokine production, sex-specific changes in several signaling pathways 
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previously shown to be involved in regulating cytokine production and secretion were 
detected by Milliplex cell-signaling array analysis in bone lysates (Fig. 4-6A and Tables 4-
1,2). Specifically, decreases in phosphorylated/total levels of ERK1/2 (-38%), STAT3 (-
26%) and p38 (-28%) were detected in miR21Δot females, but not in males. Moreover, 
miR21Δot females exhibited a tendency towards increased phosphorylated/total NF-κB 
(+23%) levels. Further, while miR21Δot males exhibited increased phosphorylated/total 
p70S6K (+22%) levels, females exhibited a tendency towards decreased p70S6K (-15%) 
levels. On the other hand, osteocytic miR21 deficiency induced similar decreases in JNK 
signaling in both females (-35%) and males (-28%), although significance was only 
reached in female mice. 
 
miR21 has sex-independent effects on bone mechanical properties. Despite 
the sex-specific effects of osteocytic miR21 deficiency on bone cell activity and 
architecture, femoral bone mechanical properties were significantly higher in both female 
and male miR21ΔOt mice compared to the respective miR21f/f controls. In particular, in 
females, femur mechanical testing by 3-point bending detected significantly higher post-
yield and total displacement (+35% and +29%), post-yield and total work (+19% and 
+17%), as well as the post-yield material property total strain (+26%), in miR21Δot 
compared to miR21f/f mice (Table 4-3). No changes in the pre-yield mechanical properties 
at either the structural or material levels were detected in the female mice. In males, even 
greater increases were detected in post-yield and total displacement (+94% and +60%), 
post-yield and total work (+71% and +56%), as well as the post-yield material properties, 
total strain and toughness (+56% and +28%) in miR21Δot compared to miR21f/f mice (Table 
4-4). On the other hand, decreases in the pre-yield structural property, displacement to 
yield, and the pre-yield material property, yield stress, were detected in the male miR21Δot 
compared to miR21f/f mice. Taken together, these findings suggest that bones from 
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miR21Δot mice are more ductile, providing a potential mechanical advantage since the 
bones are more tolerant to damage accrual and, thus, less brittle and less susceptible to 
fracture. Given differences exist both at the structural and material level, it suggests that 
fundamental differences in the properties of the matrix underlie the enhanced mechanical 
properties. 
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Discussion 
There is growing evidence that osteocytes are key regulators of bone homeostasis 
and orchestrators of bone cell activity.30 In previous studies, we showed that miR21 
expression is low in the absence of osteocytic Cx43 and in old female mice, and low miR21 
levels are responsible for the increase in osteocyte apoptosis in the Cx43-deficient cells.119 
Additionally, we demonstrated that osteocyte apoptosis directly promotes osteocyte 
cytokine production and stimulates osteoclast differentiation.  
Here we offer additional insights into the role of miR21 in osteocytes. We now 
provide evidence that the miR21 locus exerts a sex-divergent role in osteocytes controlling 
osteocyte viability and regulating bone mass/geometry through paracrine actions on 
osteoblasts and osteoclasts. Further, we reveal a potential mechanism by which miR21 
removal from osteocytes differentially alters bone turnover by sex-specific regulation of 
key signaling pathways in osteocytes as well as cytokine production/secretion. Interesting, 
we also demonstrate that despite these sex-divergent effects on osteocyte viability and 
bone turnover, osteocytic miR21 negatively influences bone mechanical properties in a 
sex-independent manner.  
First, we demonstrate that miR21 differentially controls osteocyte viability in 
females and males. Consistent with our previous findings examining the role of miR21 in 
Cx43 deficiency and aging,119 in females, removal of osteocytic miR21 increased 
osteocyte apoptosis and suppressed mitochondrial gene transcription. These anti-
apoptotic effects of miR21 are consistent with numerous studies showing that miR21 
promotes cell survival by directly targeting and inhibiting FasL and PTEN.123-125 In 
particular, we previously demonstrated that increases in osteocyte apoptosis in Cx43-
deficient osteocytic cells and bones from old female mice, are due to low miR21 levels 
which increase PTEN levels and consequently reduce Akt signaling.119 In cardiac tissue, 
miR21 has been shown to directly promote mitochondrial cytochrome B translation and 
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reduce reactive oxygen species (ROS) production.126 Additionally, miR21 promotes 
mitochondrial homeostasis and adaptation in mTORc1-activated cells.127 Further, miR21 
promotes cancer cell-survival by down-regulating PTEN and consequently activating the 
PI3K/AKT/mTOR pathway.128 Consistent with these pieces of evidence as well as our 
current findings showing that miR21 exerts sex-divergent effects on osteocyte viability and 
mitochondria function, we detected sex-dependent alterations in phosphorylated levels of 
the mTOR substrate, p70S6K. Specifically, miR21Δot males exhibited significantly higher 
p70S6K levels, whereas, miR21Δot females showed trends towards lower Akt and p70S6K 
levels. Interestingly, consistent with our findings in miR21Δot males, several other studies 
have found that inhibition of miR21 protects against fibrosis by improving mitochondrial 
function.129, 130 Taken together these pieces of evidence highlight the possibility that miR21 
regulation of mTORc1 signaling in osteocytes may underlie these sex-divergent effects on 
osteocyte viability and mitochondrial function, however, additional studies are needed to 
clearly elucidate the specific mechanisms by which osteocytic miR21 exerts these sex-
divergent effects. Nevertheless, our findings highlight a novel sex-divergent role of miR21 
in osteocytes and raise the possibility that similar sex-divergent miR21 regulation exists in 
other tissues. 
Further, consistent with the effects of osteocytic miR21 removal on osteocyte 
viability, RANKL/OPG mRNA levels were only increased in bones from miR21Δot females. 
Surprisingly, despite the RANKL/OPG ratio changes osteoclast differentiation and 
resorption were attenuated in miR21Δot females, but elevated in miR21Δot males. Similar 
to our findings in miR21Δot females, Hu et. al, found that osteoclast function was inhibited 
in global miR21 deficient (miR21-/-) mice in spite of the fact that RANKL production and 
secretion were increased.131 However, since mice were not separated by gender and 
because miR21, which is known to regulate osteoclast differentiation and survival,112, 124 
was globally deleted, it is unclear if the inhibitory effects on osteoclasts in this study were 
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due to a lack of miR21 regulation in osteocytes or a direct result of miR21 deficiency in 
osteoclasts. In our study, we found that addition of osteocyte-enriched bone culture CM 
from miR21Δot females suppressed osteoclasts, whereas CM from miR21Δot males 
stimulated osteoclasts, suggesting that these effects are due to the lack of miR21 in 
osteocytes. Furthermore, the fact that these results occurred independently of whether 
female or male BMCs were used, suggests that the sex-specific effects of osteocytic 
miR21 removal on osteoclasts are due to miR21 regulation in osteocytes rather than direct 
effects on osteoclasts.  
In addition, miR21 regulation in osteoblasts has been shown to promote 
differentiation and mineralization, by targeting/inhibiting the expression of SMAD7, a 
negative regulator of osteoblast proliferation, differentiation, and mineralization.132 
Consistent with this, osteoblast differentiation and activity were altered in miR21-/- mice.131 
When cultured ex vivo osteogenic differentiation potential of miR21-/- BMCs was 
decreased, while colony forming efficiency and proliferation rates were increased. 
Interestingly, despite these changes, osteoblast number and activity were unaltered in 
vivo, possibly because mice of both sexes were combined in the in vivo study. In the 
current study, we found that osteocytic miR21 deletion also altered osteoblast number and 
activity in a sex- and site-dependent manner. Further, consistent with the effects on bone 
cell differentiation and activity, osteocytic miR21 deficiency induced sex- and 
compartment-specific effects on bone mass and architecture. Future studies will be 
performed to determine whether the mild effect of miR21 deletion on bone mass and 
architecture is exacerbated with aging.  
Based on the non-cell autonomous effects on osteoclasts and osteoblasts 
detected in the miR21Δot mice, we next investigated the effects of miR21 regulation on 
osteocyte cytokine production and release. Consistent with the sex-dimorphic effects on 
osteoclasts and osteoblasts we found that mRNA levels of several cytokines were reduced 
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in bones from female, but not male miR21Δot mice. On the other hand, we detected 
decreases in the mRNA levels of IL-1β and DKK1, which negatively regulate osteoblast 
differentiation and activity, in bones from miR21Δot males, but not females. Further, in CM 
from miR21Δot bones, M-CSF and VEGF protein levels were increased in males, but 
showed tendencies towards decrease in females. Additionally, given the changes in IL-6 
expression detected at the mRNA level it is also possible that IL-6 levels are altered in the 
miR21Δot CM, however because the levels were greater than the standard use in the 
multiplex assays we were unable to measure them. Interestingly, we also found several 
cytokines exhibited an opposite pattern of expression in serum compared to CM from 
miR21Δot bones, suggesting that that removal of osteocytic miR21 exerts non-cell 
autonomous effects on osteoclasts and osteoblasts by locally rather than systemically 
altering osteocyte-derived cytokine levels.  
In addition to these sex-specific alterations in cytokine production and secretion in 
the miR21Δot mice, we found osteocytic miR21 deficiency altered osteocyte signaling 
pathways in a sex-dependent manner. Interestingly, several signaling pathways that are 
regulated by previously identified miR21 target genes were downregulated in miR21Δot 
females, but not males, as illustrated in Fig. 4-6A. In particular, phosphorylated ERK1/2, 
p38, and STAT3 levels were significantly reduced, whereas, phosphorylated NF-κB levels 
showed tendencies towards increase in miR21Δot female bones. Consistent with these 
findings, previous studies have shown that miR21 directly targets inhibitors of ERK1/2 
(Spry1/2), p38 (SMAD7) and STAT3 (PIAS3).132-134 Additionally, miR21 targets PDCD4, 
which in turn activates NF-κB signaling.131, 135  
Further, consistent with the reduced cytokine levels detected in the miR21Δot 
females, several studies demonstrated that ERK1/2, p38, and STAT3 pathways regulate 
VEGF and IL-6 secretion.136-138 Notably, in MLO-Y4 osteocytic cells, advanced glycation 
end products (AGEs) induce apoptosis and stimulate IL-6 and VEGF production and 
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secretion, and conversely, inhibition of the ERK1/2, p38, and STAT3 signaling pathways 
attenuates these effects of AGEs on osteocyte viability and cytokine production.139 
Further, under mechanical loading, STAT3 and ERK1/2 signaling pathways stimulate 
osteoblast differentiation and osteoclast activity by inducing IL-6.140 Taken together these 
findings highlight the possibility that downregulation of the ERK1/2, p38, and STAT3 
signaling pathways may contribute to the reduced IL-6 and VEGF production in miR21Δot 
females. Further, our findings that STAT3 signaling and mitochondrial metabolism are 
both reduced in the miR21Δot females, are consistent with the previously established role 
STAT3 in regulating cellular respiration and mitochondrial metabolism.141 Nevertheless, 
while these findings suggest that miR21 regulates osteocyte signaling pathways and 
cytokine production/secretion in sex-specific manner, additional studies are required to 
clearly elucidate the molecular events mediating these autocrine and paracrine effects of 
osteocytic miR21 on bone metabolism.   
 Alterations in miR21 expression have been detected in numerous diseases. 
However, the tissue-specific roles of miR21 under physiological and pathological 
conditions remains unclear. In some cases miR21 has been shown to promote disease 
progression, while in others miR21 is protective.142, 143 While there are several potential 
explanations for the varying results regarding the role of miR21 in different tissues under 
normal and disease conditions, given the findings of our present study, it is possible that 
the differential effects of miR21 are due to differential sex-dependent roles of miR21. 
Consistent with this notion, work by Queirós et. al, detected sex differences in the 
expression of several miRs including miR21, as well as, miR24, miR27a, miR27b, 
miR106a and miR-106b that negatively regulate MAPK/ERK signaling in the heart.144 
Additionally, the latter study showed that estrogen modulates the expression of these 
miRs in a sex-specific manner via estrogen receptor (ER) β. Further, in bone, studies have 
shown induction of miR21 during osteoclastogenesis preserves survival through negative 
98 
regulation of FasL and estrogen stimulates osteoclast apoptosis by antagonizing 
miR21.124 Taken together these pieces of evidence highlight the possibility that sex-
divergent effects of miR21 in osteocytes are due to estrogen mediated regulation of 
miR21. Thus, given the increasing number of pharmaceutical companies working to 
develop miR-based drugs combined with the growing number of studies identifying 
gender-dependent adverse drug reactions,145 our findings highlight the importance of 
considering sex-dependent miR roles when developing therapeutics. 
Interestingly, despite these sex-specific effects of osteocytic miR21 deficiency, 
both female and male miR21ΔOt mice exhibited markedly higher femoral cortical bone 
mechanical properties compared to the respective miR21f/f controls. In particular, our 
findings that osteocytic miR21 deficiency enhanced the femur post-yield mechanical 
properties, suggest that bones from miR21Δot mice are more ductile, providing a potential 
mechanical advantage since the bones are more tolerant to damage accrual and, thus, 
less brittle and less susceptible to fracture. As improvements in mechanical properties 
cannot be accounted for by the alterations observed at the cellular and structural level, it 
is likely that they result from differences in the matrix itself. Traditionally, alterations in 
post-yield properties are due to collagen structure/cross-linking. Consistent with having 
changes in collagen, JNK signaling, which is increased with aging146 and shown here to 
be decreased in both female and male miR21Δot mice, has previously been shown to 
impair collagen synthesis in osteoblasts and inversely correlate with the expression of 
collagen genes (Col2A1, Col5A1, Col5A3, Col8A1, and Col8A2) which are decreased in 
osteoblasts from old animals.146 These pieces of evidence highlight a possible mechanism 
by which osteocytic miR21 deficiency improves bone mechanical properties by stimulating 
collagen synthesis via downregulation of JNK signaling. However, extensive additional 
studies are required to uncover the molecular and tissue-level mechanisms by which 
osteocytic miR21 negatively influences bone mechanical integrity.  
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Moreover, consistent with these negative sex-independent effects of miR21 on 
bone mechanical properties, several studies have found that miR21 levels are upregulated 
in serum, bone tissue, and bone cells (osteoblasts and osteoclasts) of osteoporotic 
patients compared to controls.147 Additionally, miR21 levels were strongly inversely 
correlated with BMD and fracture incidence in osteoporotic patients. Thus, our findings 
that removal of osteocytic miR21 enhances bone biomechanical properties in both sexes, 
suggest a therapeutic potential of miR21 antagomir treatment to prevent bone fragility in 
aging in females and males. Further, given the fact that altered miR21 expression is most 
commonly seen under pathological conditions, our results provide a basis for future 
studies to test whether osteocytic miR21 deficiency protects against bone loss induced 
under pathological conditions i.e. sex-steroid deficiency, unloading, or aging. 
Collectively, our findings provide evidence that the miR21 locus exerts a sex-
divergent role in osteocytes, directly regulating cell viability/mitochondrial function in 
osteocytes and subsequently altering bone metabolism and architecture through 
paracrine actions on osteoblasts and osteoclasts. Further, despite these sex-dependent 
effects, removal of osteocytic miR21 enhances bone mechanical properties in both sexes. 
Overall, our findings provide novel insights into the sex-dependent and -independent 
mechanisms by which miR21 regulation in osteocytes alters bone, summarized in Fig. 4-
6B, which offer a basis for future studies that could eventually lead to new therapeutic 
targets to treat bone fragility.
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Figure 4-1. Sex-dependent miR21 regulation of osteocyte viability and mitochondrial 
function. (A) Scheme illustrating generation of mouse model with osteocyte-targeted 
miR21 deletion. (B) miR-21 levels in calvaria bones from female and male miR21f/f and 
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miR21Δot mice by qPCR and corrected by miR135 (n= 10-14). Bars represent mean ± s.d., 
*p<0.05 versus miR21f/f mice, #p<0.05 versus miR21f/f females, by two-way ANOVA. (C) 
RANKL and OPG levels and (D) mRNA expression of apoptosis-associated genes 
measured in calvaria bones from female miR21f/f and miR21Δot mice (n= 10-14). (E) 
RANKL and OPG levels and (F) mRNA expression of apoptosis-associated genes 
measured in calvaria bones from male miR21f/f and miR21Δot mice (n= 10). mRNA 
expression of mitochondrial genes in calvaria bones from (G) female and (H) male miR21f/f 
and miR21Δot mice (n= 10). Bars represent mean ± s.d., *p<0.05 versus miR21f/f, by t-test. 
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Figure 4-2. Removal of osteocytic miR21 regulates body weight and bone mass accrual 
in a sex-dependent manner. Body weight, and total, spinal and femoral BMD (DXA) were 
assessed monthly from 1 to 4 months of age in (A) female and (B) male miR21f/f and 
miR21Δot mice (n=12-16). Bars represent mean ± s.d., *p<0.05 versus miR21f/f at the same 
age, by t-test. 
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Figure 4-3. Osteocytic-miR21 deletion leads to sex-specific changes in femoral cortical 
bone turnover and architecture. (A-B) Mineral apposition rate (MAR), mineralizing surface 
(MS)/BS, and bone formation rate (BFR)/BS were measured in unstained cross-sections 
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of the femoral mid-diaphysis on the endosteal and periosteal surfaces of (A) female and 
(B) male miR21f/f and miR21Δot mice (n=9-10). Representative fluorescent images are 
shown, scale bar indicates 25µm. (C-D) Osteoclast number (N.Oc)/BS and surface 
covered by osteoclasts (Oc.S)/BS were scored on the endosteal surface of femoral mid-
diaphysis bone sections stained for TRAPase/T. blue of (C) female and (D) male miR21f/f 
and miR21Δot mice (n=10). Representative images from osteoclasts on the bone surface 
(magenta, arrow) are shown, scale bar indicates 25µm. (E-F) Cortical bone geometry in 
the femoral mid-diaphysis of (E) female and (F) male miR21f/f and miR21Δot mice was 
assessed by µCT (n=12). Representative reconstructed images are shown. Bars 
represent mean ± s.d., *p<0.05 versus miR21f/f, by t-test. 
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Figure 4-4. Sex-dependent alterations in vertebral cancellous bone turnover and 
architecture induced with removal of osteocytic-miR21. (A-F) Number of osteoblasts 
(N.Ob)/BS and bone surface covered by osteoblasts (Ob.S)/BS were scored in lumbar 
vertebra from (A) female and (D) male miR21f/f and miR21Δot mice bone sections stained 
with von Kossa/McNeal (n=7-10). Representative images of osteoblasts are shown, scale 
bar indicates 25µm. Mineral apposition rate (MAR), mineralizing surface (MS)/BS, and 
bone formation rate (BFR)/BS measured in unstained sections of the lumbar vertebra from 
(B) female and (E) male miR21f/f and miR21Δot mice (n=8-10). Representative fluorescent 
images are shown, scale bar indicates 25µm. Osteoclast number (N.Oc)/BS and surface 
covered by osteoclasts (Oc.S)/BS were scored on the cancellous bone surface of the 
lumbar vertebra from (C) female and (F) male miR21f/f and miR21Δot mice stained for 
TRAPase/T. blue (n=9-10). Representative images from osteoclasts on the bone surface 
(magenta, arrow) are shown, scale bar indicates 25µm. (G-H) Analysis of cancellous bone 
microarchitecture in L4 vertebra from (G) female and (H) male miR21f/f and miR21Δot mice 
assessed by µCT (n=12-14). Representative 3D images of vertebral cancellous bone are 
shown. Bars represent mean ± s.d., *p<0.05 versus miR21f/f, by t-test. 
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Figure 4-5. Sex-specific regulation of osteoclast differentiation following osteocytic-miR21 
removal. (A-B) Non-adherent BMCs harvested from female and male miR21f/f and 
miR21Δot were differentiated into osteoclasts with RANKL/M-CSF for 7 days. Osteoclast 
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number per well, average osteoclast size and number of nuclei per osteoclast were scored 
for (A) female and (B) male miR21f/f and miR21Δot non-adherent BMCs (n=4). 
Representative images from mature osteoclasts stained for TRAPase are shown, scale 
bar indicates 100µm. (C) Illustration of experimental design in which non-adherent BMCs 
isolated from wild-type C57BL/6 mice were treated with CM from ex vivo cultures of long 
bones from female and male miR21f/f and miR21Δot and supplemented with RANKL/M-
CSF for 7 days. (D-E) Osteoclast number per well, average osteoclast size and number 
of nuclei per osteoclast were scored for female non-adherent BMCs treated with CM from 
(D) female and (E) male miR21f/f and miR21Δot (n=6). Representative images from mature 
osteoclasts stained for TRAPase are shown, scale bar indicates 100µm. (F-G) mRNA 
expression of pro-inflammatory cytokine genes in calvaria bones from (F) female and (G) 
male miR21f/f and miR21Δot mice. (H-I) Pro-inflammatory cytokine protein levels in CM from 
ex vivo marrow-flushed osteocyte enriched bone cultures from (H) female and (I) male 
miR21f/f and miR21Δot mice, measured by Milliplex cytokine array. Bars represent mean ± 
s.d., *p<0.05 versus miR21f/f, by t-test. (J) Illustration of the proposed model by which 
removal of osteocytic miR21 modulates pro-inflammatory cytokine production and 
osteoclast differentiation.   
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Figure 4-6. Working models illustrating the proposed autocrine and paracrine effects of 
osteocytic miR21 removal. (A) Figure illustrating the sex-specific regulation of key cell-
signaling pathways in osteocytes by miR21, in turn, leads to sex-dependent alterations in 
osteocyte viability and mitochondrial function. Previously identified miR21 targets are 
shown in grey and proteins altered in the current study are shown in black. Direction of 
changes in protein levels are indicated using arrows for miR21Δot female (pink) and male 
(green) mice. (B) Working model showing the proposed sex-dependent mechanisms by 
which miR21 regulation in osteocytes alters bone metabolism and geometry through 
paracrine actions on osteoblasts and osteoclasts. At the same time, removal of osteocytic 
miR21 enhances bone mechanical properties in a sex-independent manner.  
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Figure 4-7. VMP1 mRNA levels are decreased in both female and male miR21Δot 
compared to control miR21fl/fl mice. mRNA levels of vacuole membrane protein-1 (VMP1) 
measured in calvaria bones from female and male miR21fl/fl and miR21Δot mice. Bars 
represent mean ± s.d., *p<0.05 versus miR21fl/fl, by t-test. 
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Figure 4-8. miR21 maintains osteocyte viability and regulates RANKL/OPG levels in 
control MLO-Y4 osteocytic cells. RANKL and OPG levels and apoptosis-associated gene 
expression (Gadd153, Foxo3, and P27) in miR-21 (A) antagomir and (B) mimic transfected 
MLO-Y4 osteoctyic cells. Bars represent mean ± s.d., *p<0.05 versus negative control, by 
t-test. 
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Figure 4-9. miR21 has similar effects on osteocyte viability and RANKL/OPG levels in 
Cx43-deficient MLO-Y4 osteocytic cells. RANKL and OPG levels and apoptosis-
associated gene expression (Gadd153, Foxo3, and P27) in miR-21 (A) antagomir and (B) 
mimic transfected Cx43-deficient MLO-Y4 cells. Bars represent mean ± s.d., *p<0.05 
versus negative control, by t-test. 
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Figure 4-10. Deletion of miR21 from osteocytes did not alter the distribution of cartilage 
and mineralized bone in newborn mice. Representative images of whole body 
preparations (n=3/genotype) stained by Alcian blue/alizarin red in 7-day-old mice for 
evaluation of cartilage (blue) and calcified tissue (magenta). 
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Figure 4-11. Osteocytic miR21 deficiency suppresses bone turnover in female mice. 
Circulating markers of bone resorption (CTX, n=10-15) and formation (P1NP, 10-14 and 
ALP, n=10-12) measured in serum of 4-month-old female miR21f/f and miR21Δot mice by 
ELISA.  
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Figure 4-12. Removal of osteocytic alters distal femur cancellous architecture in a sex-
dependent manner. Analysis of the distal femur cancellous bone microarchitecture of 
female and male miR21f/f and miR21Δot mice was assessed by µCT (n=12-14). Bars 
represent mean ± s.d., *p<0.05 versus miR21f/f, by t-test. 
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Figure 4-13. Sex-specific regulation of osteoclast differentiation following osteocytic-
miR21 removal. Osteoclast number per well and gene expression levels were measured 
in non-adherent BMCs treated with 25% conditioned media from (A) female and (B) male 
miR21f/f and miR21Δot (n=6). Representative images from mature osteoclasts stained for 
TRAPase are shown, scale bar indicates 100µm.  
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Figure 4-14. Sex-dependent decreases in anti-osteoblastic cytokine mRNA levels in the 
absence of osteocytic miR21. mRNA levels of IL-1β, DKK1, and SOST measured in 
calvaria bones from (A) female and (B) male miR21f/f and miR21Δot mice (n=10).  Bars 
represent mean ± s.d., *p<0.05 versus miR21f/f, by t-test. 
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Table 4-1. 9-Plex cell-signaling array results in bones from female miR21∆ot mice.   
 
 miR21f/f miR21∆ot  % change p-value 
CREB 0.012 ± 0.002 0.012 ± 0.005 0.56 0.98 
JNK 0.390 ± 0.123 0.298 ± 0.04 -35.44 0.03 
NF-κB 0.024 ± 0.002 0.030 ± 0.005 22.68 0.06 
ERK 1/2 0.034 ± 0.009 0.021 ± 0.006 -37.81 0.03 
AKT 0.851 ± 0.297 0.745 ± 0.158 -12.54 0.49 
P70S6K 0.245 ± 0.054 0.209 ± 0.041 -14.52 0.23 
STAT3 0.055 ± 0.013 0.040 ± 0.011 -27.65 0.05 
STAT5 0.577 ± 0.121 0.576 ± 0.086 -0.253 0.98 
P38 0.533 ± 0.071 0.392 ± 0.113 -26.48 0.03 
 
*p<0.05 versus miR-21f/f mice, by t-test (n=5-6) 
 
Table 4-2. 9-Plex cell-signaling array results in bones from male miR21∆ot mice.   
 
 miR21f/f miR21∆ot  % change p-value 
CREB 0.011 ± 0.005 0.011 ± 0.002 -0.76 0.97 
JNK 0.424 ± 0.128 0.295 ± 0.089 -27.58 0.11 
NF-κB 0.028 ± 0.006 0.028 ± 0.006 -1.29 0.92 
ERK 1/2 0.037 ± 0.017 0.031 ± 0.009 -16.22 0.46 
AKT 0.610 ± 0.085 0.605 ± 0.088 -0.79 0.93 
P70S6K 0.241 ± 0.045 0.294 ± 0.028 21.87 0.04 
STAT3 0.046 ± 0.018 0.050 ± 0.010 8.08 0.67 
STAT5 0.585 ± 0.155 0.526 ± 0.041 -10.02 0.39 
P38 0.540 ± 0.127 0.575 ± 0.122 6.37 0.64 
 
*p<0.05 versus miR-21f/f mice, by t-test (n=5-6) 
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Table 4-3. Mechanical strength in cortical bone in female miR21∆ot mice.   
 
 miR21f/f miR21∆ot  % change 
Yield Force (N) 8.978 ± 0.602 8.66 ± 0.486 -3.53 
Ultimate Force (N) 11.662 ± 1.013 11.628 ± 1.168 -0.29 
Pre-Yield Displacement 
(µm) 215.073 ± 22.801 221.153 ± 23.920  
2.83 
Post-yield 
Displacement (µm) 981.928 ± 380.192 1328.576 ± 292.795* 
35.30 
Total Displacement 
(µm) 1197.002 ± 376.015 1549.729 ± 285.952* 
29.47 
Stiffness (N/mm) 47.874 ± 6.39 45.632 ± 4.105 -4.68 
Pre-yield Work (mJ) 1.049 ± 0.171 1.019 ± 0.1349 -2.82 
Post-yield Work (mJ) 8.200 ± 1.991 9.791 ± 1.303* 19.40 
Total Work (mJ) 9.249 ± 1.910 10.811 ± 1.298* 16.88 
Yield Stress (MPa) 36.905 ± 4.038 35.253 ± 4.983 -4.48 
Ultimate Stress (MPa) 47.798 ± 4.570 47.076 ± 5.806 -1.51 
Pre-yield Strain (µɛ) 19432.98 ± 1646.98 19533.12 ± 2215.71 0.52 
Total Strain (µɛ) 108546.8 ± 34714.9 137001.5 ± 27440.5* 26.21 
Modulus (GPa) 2.156 ± 0.195 2.094 ± 0.239 -2.89 
Resilience (MPa) 0.391 ± 0.077 0.368 ± 0.080 -5.74 
Toughness (MPa) 3.449 ± 0.818 3.875 ± 0.660 12.33 
 
*p<0.05 versus miR-21f/f mice, by t-test (n=10-12) 
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Table 4-4. Mechanical strength in cortical bone in male miR21∆ot mice.   
 
 miR21f/f miR21∆ot  
% 
chang
e 
Yield Force (N) 11.086 ± 1.858 10.032 ± 2.292 -9.51 
Ultimate Force (N) 13.039 ± 1.500 13.507 ± 1.276 3.59 
Pre-Yield 
Displacement (µm) 306.050 ± 57.920 257.687 ± 50.334* 
-15.80 
Post-yield 
Displacement (µm) 511.277 ± 191.202 992.232 ± 372.887* 
94.07 
Total Displacement 
(µm) 786.897 ± 124.494 1260.106 ± 366.007* 
60.14 
Stiffness (N/mm) 42.591 ± 4.177 44.465 ± 4.182 4.40 
Pre-yield Work (mJ) 1.654 ± 0.533 1.249 ± 0.538 -24.49 
Post-yield Work (mJ) 5.563 ± 1.693 9.537 ± 2.676* 71.43 
Total Work (mJ) 6.981 ± 1.325 10.879 ± 2.793* 55.83 
Yield Stress (MPa) 84.042 ± 14.228 70.200 ± 17.563* -16.47 
Ultimate Stress (MPa) 98.449 ± 7.539 94.338 ± 7.406 -4.18 
Pre-yield Strain (µɛ) 44489.068 ± 8781.447 38232.606 ± 7489.234 
-14.06 
Total Strain (µɛ) 119759.5 ± 24724.3 186827.1 ± 56494.9* 56.00 
Modulus (GPa) 2.237 ± 0.163 2.067 ± 0.299 -7.62 
Resilience (MPa) 1.813 ± 0.545 1.037 ± 0.272* -42.78 
Toughness (MPa) 9.095 ± 3.038 11.635 ± 2.375* 27.92 
 
*p<0.05 versus miR-21f/f mice, by t-test (n=10-12). 
 
122 
Table 4-5A. Conditioned media cytokines in female miR21∆ot mice.  
 
 miR21f/f miR21∆ot  % change p-value 
IL-6 OOR> OOR>   
Eotaxin 16.63 ± 14.14 6.81 ± 1.52 -59.05 0.12 
IFN-g 2.78 ± 0.60 1.88 ± 1.40 -32.43 0.27 
IL-1a 19.86 ± 9.73 4.67 ± 4.89 -26.16 0.27 
IL-2 OOR< OOR<   
IL-3 OOR< OOR<   
IL-4 1.15 ± 0.41 1.00 ± 0.25 -12.88 0.47 
IL-5 13.99 ± 6.58 9.66 ± 2.73 -30.94 0.17 
IL-7 OOR< OOR<   
IL-9 133.69 ± 41.57 126.19 ± 22.48  -5.61 0.71 
IL-10 5.11 ± 2.24 3.55 ± 1.06  -30.60 0.15 
IL-12(p40) OOR< OOR<   
IL-12(p70) 13.48 ± 6.96 13.34 ± 4.45  -1.03 0.97 
IL-13 OOR< OOR<   
IL-15 4.05 ± 2.50 6.00 ± 3.53  47.96 0.46 
IP-10 117.55 ± 48.07 70.89 ± 49.31  -39.69 0.15 
LIF 358.56 ± 202.19 326.44 ± 127.57  -8.96 0.75 
LIX 63.85 ± 58.73 40.30 ± 19.16  -36.88 0.37 
M-CSF 12.70 ± 8.09 6.7 ± 2.54  -51.44 0.09 
MIG 109.53 ± 38.44 86.11 ± 18.64  -21.38 0.21 
MIP-1β 48.52 ± 31.58 26.94 ± 5.81  -44.47 0.13 
MIP-2 45.33 ± 14.96 44.95 ± 13.45  -0.84 0.97 
G-CSF 1127.08 ± 931.54 1026.83 ± 595.91  -8.89 0.83 
IL-1β 9.52 ± 6.59 8.66 ± 2.21 -9.15 0.77 
IL-17 1.00 ± 0.60 0.91 ± 0.43 -9.47 0.76 
KC 379.31 ± 656.65 269.09 ± 302.65 -29.06 0.72 
MCP-1 607.36 ± 615.80 264.68 ± 130.32 -56.42 0.21 
MIP-1α 36.17 ± 13.52 29.95 ± 6.53 -17.21 0.34 
RANTES OOR< OOR<   
TNF-α 7.84 ± 6.71 4.28 ± 1.03  -45.39 0.23 
GM-CSF 23.13 ± 12.14 19.84 ± 6.10  -14.21 0.57 
VEGF 204.67 ± 110.32 132.28 ± 25.83  -35.37 0.15 
 
*p<0.05 versus miR-21f/f mice, by t-test (n=3-6). Values outside the standard curve are 
denoted by “OOR<” or “OOR>” (Out of Range). 
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Table 4-5B. Conditioned media cytokines in male miR21∆ot mice.   
 
 miR21f/f miR21∆ot  % change p-value 
IL-6 OOR> OOR>   
Eotaxin 8.22 ± 6.34 6.43 ± 4.13 -21.81 0.57 
IFN-g 2.70 ± 0.58 2.54 ± 1.05 -6.06 0.75 
IL-1a 15.90 ± 2.24 13.06 ± 4.64 -17.88 0.21 
IL-2 OOR< OOR<   
IL-3 OOR< OOR<   
IL-4 0.94 ± 0.20 0.82 ± 0.13 -13.25 0.23 
IL-5 8.55 ± 2.52 6.01 ± 1.69 -29.77 0.07 
IL-7 OOR< OOR<   
IL-9 122.17 ± 18.99 142.73 ± 18.89 16.84 0.09 
IL-10 4.88 ± 3.10 3.37 ± 0.82 -30.94 0.28 
IL-12(p40) OOR< OOR<   
IL-12(p70) 16.24 ± 3.16 14.74 ± 4.05  -9.29 0.49 
IL-13 OOR< OOR<   
IL-15 3.78 ± 2.44 5.80 ± 6.45 53.63 0.53 
IP-10 46.00 ± 17.06 76.65 ± 57.81  64.44 0.26 
LIF 432.25 ± 99.60 422.48 ± 178.49  -2.26 0.91 
LIX 61.89 ± 14.19 41.35 ± 20.70  -33.19 0.07 
M-CSF 4.45 ± 0.97 7.11 ± 1.81  59.64* 0.01 
MIG 75.46 ± 18.73 83.83 ± 26.69  11.10 0.54 
MIP-1β 27.84 ± 5.88 23.54 ± 1.77  -15.44 0.12 
MIP-2 56.2 ± 16.81 38.11 ± 12.07  -32.19 0.06 
G-CSF 1576.48 ± 377.85 1029.03 ± 1013.82  -34.73 0.24 
IL-1β 9.56 ± 3.46 9.75 ± 2.73 1.99 0.92 
IL-17 1.14 ± 0.23 1.04 ± 0.48 -9.20 0.64 
KC 269.79 ± 160.04 97.42 ± 99.26 -63.89 0.06 
MCP-1 443.16 ± 243.87 184.39 ± 154.34 -58.39 0.05 
MIP-1α 29.1 ± 3.34 28.18 ± 3.75 -53.15 0.66 
RANTES OOR< OOR<   
TNF-α 4.48 ± 0.34 4.29 ± 0.57 -4.17 0.50 
GM-CSF 24.80 ± 3.05 21.60 ± 6.18 -12.88 0.28 
VEGF 117.78 ± 15.83 176.17 ± 42.68 49.58* 0.01 
 
*p<0.05 versus miR-21f/f mice, by t-test (n=5-6). Values outside the standard curve are 
denoted by “OOR<” or “OOR>” (Out of Range). 
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Table 4-6A. Circulating serum cytokines in female miR21∆ot mice.   
 
 miR21f/f miR21∆ot  % change p-value 
IL-6 3.05 ± 0.81 2.72 ± 1.73 -10.93 0.69 
Eotaxin 352.56 ± 78.76 456.28 ± 28.73 29.42 0.07 
IFN-g 2.36 ± 1.12 3.50 ± 2.50 48.52 0.36 
IL-1a 485.87 ± 142.59 570.13 ± 242.07 17.34 0.52 
IL-2 OOR< OOR<   
IL-3 OOR< OOR<   
IL-4 1.29 ± 0.08 1.27 ± 0.12 -1.43 0.78 
IL-5 6.02 ± 5.17 4.37 ± 0.69 -27.42 0.61 
IL-7 0.52 ± 0.58 0.73 ± 0.35 39.96 0.67 
IL-9 150.02 ± 45.49 242.73 ± 47.33 61.80* 0.02 
IL-10 1.92 ± 1.26 1.36 ± 0.99 -29.31 0.60 
IL-12(p40) 8.26 ± 3.66 11.2 ± 5.95 35.62 0.38 
IL-13 49.86 ± 6.71 54.72 ± 13.06 9.74 0.47 
IL-15 OOR< OOR<   
IP-10 94.59 ± 17.53 89.72 ± 11.15 -5.15 0.68 
LIF 0.53 ± 0.24 0.73 ± 0.40 36.25 0.38 
LIX 5412.89 ± 507.07 4805.08 ± 789.90 -11.23 0.20 
M-CSF 1.74 ± 1.13 4.29 ± 2.68 146.74 0.22 
MIG 28.21 ± 9.26 20.64 ± 8.43 -26.81 0.28 
MIP-1β 31.82 ± 5.11 30.24 ± 11.00 -4.96 0.77 
MIP-2 143.02 ± 23.73 161.64 ± 125.87 13.02 0.32 
G-CSF 266.61 ± 127.57 334.97 ± 96.01 25.64 0.44 
IL-1β OOR< OOR<   
IL-17 2.40 ± 0.40 2.16 ± 0.39 -10.13 0.42 
KC 63.79 ± 25.20 38.54 ± 10.70 -39.58 0.16 
MCP-1 OOR< OOR<   
MIP-1α 53.21 ± 10.17 54.71 ± 3.97 2.83 0.82 
RANTES 17.32 ± 3.39 19.06 ± 1.51 10.04 0.44 
TNF-α OOR< OOR<   
GM-CSF OOR< OOR<   
VEGF 2.04 ± 0.13 1.99 ± 0.33 -2.29 0.76 
 
*p<0.05 versus miR-21f/f mice, by t-test (n=5-6). Values outside the standard curve are 
denoted by “OOR<” or “OOR>” (Out of Range). 
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Table 4-6B. Circulating serum cytokines in male miR21∆ot mice.   
 
 miR21f/f miR21∆ot  % change p-value 
IL-6 5.10 ± 1.67 2.89 ± 0.61 -43.36* 0.03 
Eotaxin 383.39 ± 96.47 362.02 ± 29.98 -5.57 0.65 
IFN-g 3.56 ± 2.27 3.26 ± 0.87 -8.95 0.77 
IL-1a 461.29 ± 152.52 555.22 ± 168.37 20.36 0.36 
IL-2 OOR< OOR<   
IL-3 OOR< OOR<   
IL-4 1.33 ± 0.16 1.23 ± 0.05 -7.33 0.23 
IL-5 4.63 ± 2.23 3.76 ± 31.73 -18.71 0.51 
IL-7 1.93 ± 0.75 1.08 ± 0.42  -43.90 0.05 
IL-9 199.95 ± 59.46 306.70 ± 166.10 53.39 0.17 
IL-10 4.06 ± 2.38 1.71 ± 1.34  -57.84 0.11 
IL-12(p40) 19.23 ± 12.26 10.49 ± 3.90 -45.42 0.16 
IL-13 58.91 ± 6.97 39.62 ± 8.74  -32.74* 0.003 
IL-15 OOR< OOR<   
IP-10 93.45 ± 19.30 72.30 ± 2.60  -22.64 0.04 
LIF 1.36 ± 0.94 1.59 ± 1.71 16.47 0.79 
LIX 4533.92 ± 612.33 5945.02 ± 417.71  31.12 0.003 
M-CSF 3.52 ± 2.19 1.60 ± 1.73 -54.66 0.16 
MIG 26.31 ± 10.45 19.02 ± 13.81  -27.71 0.34 
MIP-1β 42.28 ± 6.52 37.51 ± 6.23  -11.29 0.25 
MIP-2 160.42 ± 51.29 158.60 ± 34.38 -1.13 0.95 
G-CSF 260.20 ± 39.29 273.27 ± 52.75  5.02 0.65 
IL-1β OOR< OOR<   
IL-17 2.77 ± 0.45 2.16 ± 0.10 -22.17* 0.02 
KC 147.50 ± 1694.10 48.51 ± 19.63 -67.12 0.22 
MCP-1 OOR< OOR<   
MIP-1α 56.25 ± 12.62 50.33 ± 12.57 -10.53 0.46 
RANTES 20.56 ± 5.59 16.25 ± 3.80  -20.94 0.18 
TNF-α OOR< OOR<   
GM-CSF OOR< OOR<   
VEGF 2.17 ± 0.21 1.93 ± 0.84  -10.90* 0.04 
 
*p<0.05 versus miR-21f/f mice, by t-test (n=5-6). Values outside the standard curve are 
denoted by “OOR<” or “OOR>” (Out of Range).
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Chapter 5 
Short-term pharmacologic inhibition of RAGE suppresses bone turnover and 
muscle atrophy in aging  
 
Rationale 
Osteoporosis and sarcopenia are two major clinical complications among the 
growing list of chronic diseases that primarily affect elderly individuals. Persistent low-
grade inflammation, one of the major drivers of aging, is also associated with both bone 
and muscle dysfunction in aging. Particularly, chronic activation of the receptor for 
advanced glycation end products (RAGE) and elevated levels of its ligands HMGB1, 
AGEs, S100 proteins and Aβ fibrils have been linked to bone and muscle loss in various 
pathologies. Further, genetic or pharmacologic RAGE inhibition has been shown to 
preserve both bone and muscle mass. However, whether short-term pharmacologic 
RAGE inhibition can prevent bone and muscle loss in early aging is unknown. To address 
this question, we treated young (4-mo) and middle-aged (15-mo) C57BL/6 female mice 
with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially developed to treat 
Alzheimer’s disease.  
 
Introduction 
Due to the advances in healthcare over the last several decades, people are now 
living longer than ever before. Paradoxically, this has created a new clinical challenge, i.e. 
a vast array of chronic degenerative diseases, including heart disease, cancer, diabetes, 
neurodegeneration, often accompanied by the development of debilitating conditions, 
such as sarcopenia and osteoporosis.1-3 To combat these pathologies of aging, there has 
been growing interest in geroscience, a research field focused on identifying/targeting 
common biological mechanisms that drive aging and underlie aging-related pathologies.3, 
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148 Recent advancements in this field have identified several common key risk factors, 
such as chronic-low grade inflammation, cellular senescence, metabolic dysfunction, 
macromolecular damage, genomic instability, reduced responsiveness to stress and 
altered proteostasis, associated with numerous of these ‘comorbidities of aging’.1, 2, 148-150 
However, to date, most work has focused primarily on the mechanisms underlying 
cardiovascular disease, cancer and neurodegeneration; whereas, the mechanisms 
underlying debilitating aging-related conditions, such as sarcopenia and osteoporosis, 
have been less studied. Given the skyrocketing number of individuals with osteoporosis 
[affecting ~1:2 women of all ages, and ~1:4 men over age 50 and costing the US ~$25.3 
billion a year in healthcare expenses4, 5] and the increasing incidence of sarcopenia 
[affecting ~13% of Americans over age 55 and costing the US ~$18.5 billion a year in 
related-health expenses151, 152], there is an essential need to better understand the 
mechanisms leading to musculoskeletal pathology.  
Further, considering the growing evidence showing the interconnected relationship 
between bone and skeletal muscle153-155, and the fact that most elderly patients with bone 
and muscle loss are also affected by other aging-related comorbidities3, 156, there is a 
crucial need to identify therapeutics capable of simultaneously targeting and treating 
multiple pathologies. 
Low-grade chronic inflammation is one factor identified as a key driver of numerous 
aging-related pathologies.157, 158 Various cell types release inflammatory cytokines, which 
not only regulate immune response, but also modulate key cellular processes: 
differentiation, proliferation, apoptosis, and autophagy throughout the organism.157-159 In 
particular, emerging evidence suggests that inflammatory cytokine signaling plays a role 
in regulating bone and skeletal muscle metabolism under both physiological and 
pathological conditions.160, 161 Consistently, chronic low-grade inflammation has been 
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identified as a major contributor of dysfunction in both musculoskeletal tissues in aging.162-
164 
Particularly, elevated RAGE [receptor for advanced glycation end-products] 
signaling has been shown to contribute to the onset/progression of various aging-related 
pathologies.158, 165 RAGE is a multi-ligand pattern recognition receptor, which binds and 
mediates the cellular response to a range of endogenous damage-associated molecular 
pattern molecules (DAMPs) including advance glycation end-products (AGEs), HMGB1, 
S100 proteins, Aβ fibrils, and DNA/RNA.166, 167 Under physiological conditions, RAGE is 
expressed at low levels, but during conditions of chronic inflammation RAGE is 
constitutively activated due to the accumulation of its ligands.158, 166  
Numerous studies have demonstrated beneficial effects with RAGE inhibition 
[genetic and pharmacological] in various aging-related pathologies including diabetes, 
cardiovascular disease, neurodegeneration, and cancer.168 Further, inhibition of RAGE 
signaling has been shown to protect against disease-induced bone and muscle loss. 
Particularly, in bone, genetic RAGE deficiency prevented against OVX induced bone loss; 
and consistently, blockade of cellular RAGE using soluble RAGE diminished alveolar bone 
loss in a murine model of diabetic periodontal disease.169, 170 Additionally, in skeletal 
muscle, young mice fed a diet high in AGEs exhibited impaired skeletal muscle growth 
and contractile function.171 Interestingly, AGEs were found to induce skeletal muscle 
atrophy by stimulating RAGE-mediated AMPK down-regulation, an effect that was 
attenuated in RAGE deficient mice.172 Moreover, high intracellular levels of RAGE ligand, 
S100B, known to inhibit myogenic differentiation by repressing the myogenic regulatory 
factors MyoD and myogenin, were detected in muscle satellite cells isolated from aged 
subjects.173 Taken together, these pieces of evidence highlight the potential involvement 
and the therapeutic opportunity to target/inhibit RAGE signaling during the 
onset/progression of bone and muscle pathology in aging. 
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Small-molecule RAGE inhibitors have been developed and their therapeutic utility 
has been evaluated in pre-clinical and clinical studies over the last decade.174 For 
example, TTP488 (Azeliragon, AZ), a small-molecule compound that prevents RAGE from 
binding to AGEs, HMGB1, S100 proteins, and Aβ fibrils (Fig. 5-1A), has been evaluated 
for the treatment of Alzheimer’s disease in pre-clinical and clinical studies.175-177 However, 
whether pharmacological inhibition of RAGE affects bone and muscle in young individuals, 
and whether it attenuates the loss of bone and muscle mass in aging is not known. In this 
study we examined the possibility of repurposing the Alzheimer’s drug, AZ, to prevent 
aging-induced osteoporosis and sarcopenia. Here we report that while RAGE inhibition 
does not attenuate the effects of aging on bone, it attenuates the effects of aging on 
skeletal muscle. 
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Materials and Methods 
Osteoclastogenesis assay. Non-adherent BMCs (6x104 cells/cm2) were plated 
on a 96-well plate with α-minimal essential medium (MEM) supplemented with 10% FBS 
and 1% penicillin/streptomycin (P/S) plus recombinant murine M-CSF (20 ng/ml) and 
soluble RANKL (80 ng/ml) (PeproTech Inc., Rocky Hill, NJ, USA) with either 100ng/mL AZ 
or veh. Media was changed every 2 days for 7 days.119 Mature osteoclasts (>3 or more 
nuclei) were quantified after staining for TRAPase using a commercial kit (Sigma-Aldrich, 
Saint Louis, MO, USA, cat.#387A). Images were acquired using a Zeiss Axiovert 35 
microscope equipped with a digital camera (Carl Zeiss, Thronwood, NY, USA). mRNA 
was isolated from parallel cultures and gene expression was measured by qPCR (Applied 
Biosystems, Foster City, CA, USA). 
 
RNA extraction and qPCR. Total RNA was isolated using TRIzol (Invitrogen, 
Grand Island, NY, USA), as published.83, 119 Reverse transcription was performed using a 
high-capacity cDNA kit (Applied Biosystems, Foster City, CA, USA). qPCR was performed 
using the Gene Expression Assay Mix TaqMan Universal Master Mix with an ABI 7900HT 
real-time PCR system. The house-keeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used. Primers and probes were commercially available 
(Applied Biosystems, Foster City, CA, USA) or were designed using the Assay Design 
Center (Roche Applied Science, Indianapolis, IN, USA). Relative expression was 
calculated using the ∆Ct method.178  
 
Mice and treatment. 4- (young, n=10) and 15-month-old mice (middle-aged, 
n=10) C57BL/6 female mice were obtained from National Institute on Aging (NIA) and 
received daily intraperitoneal injection of veh (1.7% DMSO) or 100µg/day (young mice) 
and 110µg/day (middle-aged mice) of AZ (DC Chemicals, Shanghai, P.R., China, cat.# 
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DC8338), to account for body weight differences, for 28 days. Mice were assigned an ID 
number and the age/treatment were recorded in a database. Investigators performing 
endpoint measurements were only given the mouse ID. Mice were randomized and 
assigned to each experimental group based on spinal BMD. Mice (4-5/cage) were fed a 
regular diet (Envigo, Indianapolis, IN) and water ad libitum, and maintained on a 12h 
light/dark cycle. Animals were sacrificed between 3-5 hours after last injection. All 
experiments were carried out as planned. No mortality was recorded throughout the 
experiment, although 2 mice exhibited signs of infections near the injection sites. In 
addition, AZ administration induced splenomegaly (Fig. 5-13), but no other signs of 
distress were recorded. Young mice received IP injections of calcein (30 mg/kg; Sigma-
Aldrich, Saint Louis, MO, USA) and alizarin red (50 mg/kg; Sigma) 7 and 2 days before 
sacrifice, respectively and aged mice received IP injections of calcein (30 mg/kg; Sigma-
Aldrich, Saint Louis, MO, USA) and alizarin red (50 mg/kg; Sigma) 10 and 3 days before 
sacrifice, respectively, to allow for dynamic histomorphometric measurements.90 The 
longer duration between labels in aged mice was done to help facilitate the differentiation 
of the two labels given the slower bone formation rate. 
 
Bone histomorphometry. Femora and lumbar vertebrae (L1–L3) were dissected 
and fixed in 10% neutral buffered formalin as previously published.90 Static 
histomorphometric analysis was performed on the cancellous surface of sequential methyl 
methacrylate embedded lumbar vertebrae sections stained with von Kossa/McNeal 
[osteoblasts] and TRAPase/Toludine blue [osteoclasts]. Additionally, osteoclasts were 
quantified on the endocortical surface paraffin embedded TRAPase/Toludine blue stained 
femur cortical bone cross-sections. Dynamic histomorphometric measurements were 
performed in unstained plastic embedded femoral mid-diaphysis and lumbar vertebrae 
bone sections.83 Histomorphometric analysis was performed using OsteoMeasure high-
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resolution digital video system (OsteoMetrics Inc., Decatur, GA, USA).90 The terminology 
and units used are those recommended by the Histomorphometry Nomenclature 
Committee of the American Society for Bone and Mineral Research.85  
 
Serum biochemistry. Blood was collected by cheek bleeding after 3 h of fasting. 
Plasma was separated, aliquoted, and stored at − 80°C.49 N-terminal propeptide of type I 
procollagen (P1NP) (Immunodiagnostic Systems Inc., Fountain Hill, AZ, USA, cat.#AC-
33F1) and C-telopeptide fragments (CTX) (RatLaps, Immunodiagnostic Systems Inc., 
Fountain Hill, AZ, USA, cat.#AC-06F1) were measured as previously published.90  
 
Osteoblast mineralization assay. Adherent-BMCs were cultured for 10 days in 
α-MEM supplemented with 10% FBS and 1% penicillin/streptomycin in the presence of 50 
μM ascorbic acid and 10 mM β-glycerol phosphate, as previously described.179 Cells were 
fixed with 3.7% paraformaldehyde in PBS for 1 hour, rinsed twice with distilled water, and 
stained for 10 min with 40 mM Alizarin Red S (pH 4.2) at room temperature under shaking. 
Cells were then washed 5 times with water, followed by a 15 min-wash with PBS. Alizarin 
Red S was extracted by adding 1% cetylpyridinium chloride for 15 min at room 
temperature with shaking. OD was measured at 490 nm.  
 
Apoptosis. Osteocyte apoptosis was detected in paraffin-embedded femur cross-
sections using previously published protocols.46 Briefly, femora were deparaffinized, 
treated with 3% H2O2 to inhibit endogenous peroxidase activity, blocked and then 
incubated with rabbit monoclonal anti-active caspase-3 antibody (1:75; Thermo Fisher 
Scientific In., Rockford, IL, USA, cat.#PA5-23921).180 Sections were then incubated with 
anti-rabbit biotinylated secondary antibody followed by avidin conjugated peroxidase 
(Vectastain Elite ABC Kit; Vector Laboratories Inc., Burlingame, CA, USA). Color was 
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developed with a diaminobenzidine substrate chromogen system (Acros Organics, New 
Jersey, USA). Cells expressing the protein of interest are stained in brown, whereas 
negative cells are green-blue. Nonimmune IgG was used as negative control.  
 
Ex vivo bone organ cultures. Long bones were isolated from 4- and 16-month-
old female C57BL/6 mice and BMCs were flushed out with α-MEM. Osteocyte-enriched 
marrow-flushed long bones were cultured ex vivo in α-MEM supplemented with 10% FBS 
and 1% P/S with veh or AZ (100ng/mL) and cultured for 24 hours. Following treatment, 
bones were collected, frozen in liquid nitrogen, and stored at − 80°C. Gene expression 
was measured by qPCR (Applied Biosystems, Foster City, CA, USA). 
 
Bone mineral density (BMD) and body composition (fat and lean mass) by 
dual energy x-ray absorptiometry (DXA). Bone mineral density (BMD) and body 
composition were measured monthly by dual X-ray absorptiometry (DXA) using a PIXImus 
densitometer (G.E. Medical Systems, Lunar Division, Madison, WI, USA).181 BMD 
measurements included total BMD (excluding the head and tail), entire femur (femoral 
BMD) and L1–L6 vertebra (spinal BMD).90 Body composition included body weight, fat 
mass, and lean mass. Calibration was performed before scanning with a standard 
phantom, as recommended by the manufacturer.  
 
Micro-computed tomography (μCT) analysis. Femora and L4 vertebrae were 
dissected, wrapped in saline-soaked gauze and frozen at − 20°C.90 Vertebra and femora, 
6 bones per scan, were scanned using a 65kV source, 0.5mm Al filter, 0.7 degree rotation 
and two-image averaging with an isotropic voxel size of 9μm using a SkyScan 1176 
system (SkyScan, Kontich, Belgium). Scans were reconstructed and analyzed using 
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manufacturer software. Nomenclature is reported in accordance with the guidelines for 
μCT.84  
 
Biomechanical testing. Femoral three-point bending testing was performed 
following previously published protocols.90 Structural mechanical properties, ultimate load, 
stiffness, displacement and work were determined from the load–deformation curves 
using standard definitions while material-level estimations of properties were calculated 
using standard equations. Cross-sectional moment of inertia and anterior–posterior 
diameter were determined by μCT and were used to calculate material-level properties, 
as previously described.90 
 
Muscle weight. Skeletal muscles gastrocnemius, tibialis anterior, quadriceps and 
soleus, were harvested and weighed immediately following dissection. Muscle weight was 
corrected by total body weight and reported as the percentage of muscle per body weight. 
After weighing, muscles were snap frozen and store at -80°C until used for gene 
expression analysis.    
 
Muscle histology and morphometric analysis. The forearms of mice were 
removed and fixed in 10% neutral buffered formalin. Forearms were cross-sectioned, 
demineralized and embedded in paraffin and then sectioned on a microtome. Tissue 
morphology was assessed on 4 μm–thick cross-sections of muscles sections stained with 
hematoxylin and eosin (H&E) dye. Myofiber cross-sectional area (CSA) was analyzed on 
H&E-stained forearm muscle section images using image J analysis software and tablet 
input device.182 
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C2C12 cell culture and myotube diameter measurement. C2C12 myoblasts 
were grown and seeded onto 12-well plates (7,500 cells/cm2). The cells were then 
exposed to DMEM supplemented with horse serum for five days, then subsequently 
treated for 48 hrs with 5% serum from young or aged animals treated with veh or AZ. 
Myotubes were fixed using chilled acetone/methanol (1:1) and washed with PBS, stained 
using a primary antibody against myosin heavy chain (#MF-20, Developmental Studies 
Hybridoma Bank, Iowa City, IA) overnight at 4⁰C, then stained with Alexaflour 594-labeled 
secondary antibody (Invitrogen, Grand Island, NY) at room temperature for one hour. 
Myotubes were imaged using an Axio Observer.Z1 motorized microscope (Zeiss, 
Oberchoken, Germany). Average myotube diameter was measured per field of view using 
Image J analysis software183 and a Cintiq pen tablet input device (Wacom, Vancouver, 
WA).  
 
Western blot analysis. Ubiquitin-conjugated protein levels were evaluated in 
protein lysates isolated from the quadriceps of young and aged veh- and AZ-treated mice. 
Protein lysates were separated on 10% SDS–PAGE gels (BioRad) and electrotransferred 
to nitrocellulose membranes (Millipore, Billerica, MA, USA). Membranes were then 
incubated in blocking solution (SEABlock) for 60 min and probed with primary antibodies 
diluted 1:1000 in SeaBLOCK + 0.2% Tween against a monoclonal anti-Ubiqutin (#3933, 
Cell Signaling Technologies, Danvers, MA) overnight at 4°C, followed by corresponding 
secondary fluorescent antibodies diluted 1:10,000 in SEABlock + 0.2% Tween for 1 h at 
room temperature. After rinsing with PBS-T, the membranes were developed using LICOR 
imaging. Bands were detected using an Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, NE, USA), and their intensity was quantified using ImageJ. 
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Statistical analysis. Data were analyzed by using SigmaPlot (Systat Software 
Inc., San Jose, CA, USA). All values are reported as the mean ± standard deviation. 
Differences were evaluated either by two-way ANOVA with post-hoc analysis using Tukey 
Method or by Student’s t-test, as appropriate. Differences were considered significant 
when p<0.05.  
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Results 
 AZ differentially alters bone metabolism through direct and indirect actions. 
To test the effects of pharmacological RAGE inhibition using the small-molecule inhibitor, 
AZ (Fig. 5-1A), on osteoclast differentiation, we first treated wildtype non-adherent bone 
marrow cells (BMC) isolated from 4-month-old (young) or 16-month-old (middle-aged) 
C57BL/6 female mice with vehicle (veh) or AZ in vitro. Consistent with previous findings 
in global genetic RAGE knockout mice,184 a lower number of mature osteoclasts (≥3 
nuclei) developed from young or middle-aged BMCs treated with AZ (Fig. 5-1B). Further, 
more osteoclast were developed when cells were isolated from middle-aged mice. Based 
on these findings, we next investigated the effects in vivo of systemic AZ administration 
on osteoclast differentiation/activity and whether it prevents bone loss in aging. To this 
end we treated female wild type C57BL/6 4-month-old (young) and 15-month-old (middle-
aged) mice daily with AZ 100µg/d (young), 110µg/d (middle-aged), or veh for 28 days (Fig. 
5-1C).   
 Bone histomorphometric analysis of veh-treated mice revealed no alterations in 
osteoclast number (N.Oc/BS) or surface (Oc.S/BS) per bone surface on the femur 
endocortical or vertebral cancellous bone surfaces (Fig. 5-1D,E) with aging, although, 
vertebral cancellous osteoclast number per tissue area (N.Oc/T.Ar) was lower in middle-
aged compared to young veh-treated mice. Further, vertebral cancellous bone perimeter 
(B.Pm) was decreased in the middle-aged compared to young mice (Fig. 5-1E). Vertebral 
cancellous osteoclast number per tissue area (N.Oc/T.Ar) was lower in middle-aged 
compared to young veh-treated mice. Consistently, serum bone resorption marker, C-
terminal telopeptide (CTX), levels were lower (Fig. 5-1F) and osteoclast gene expression 
was significantly decreased in middle-aged compared to young veh-treated mice (Fig. 5-
7).  
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 Consistent with the in vitro findings, static histomorphometric analysis revealed 
that AZ treatment in young and middle-aged mice significantly reduced the number of 
osteoclasts on the vertebral cancellous and femoral endocortical bone surfaces (Fig. 5-
1D,E). However, AZ treatment did not alter the expression of any osteoclast-related genes 
in the tibia, aside from an increase in calcitonin receptor (Fig. 5-7). Further, we were 
surprised to find that serum CTX levels were higher in the AZ-treated mice at both ages 
(Fig. 5-1F), suggesting that more bone surfaces are being resorbed in the presence of AZ.   
 We next examined the effects of aging and AZ treatment on osteoblast 
differentiation and function. Histomorphometric analysis revealed that vertebral cancellous 
osteoblast number per tissue area (N.Ob/T.Ar) was significantly decreased in middle-aged 
compared to young veh-treated mice, although due the decreased vertebral cancellous 
B.Pm in the middle-aged mice osteoblast number and surface per bone surface (N.Ob/BS 
and Ob.S/BS) were unchanged (Fig. 5-1G). Further, veh-treated middle-aged mice 
exhibited lower serum bone formation marker, pro-collagen type 1 N-terminal propeptide 
(P1NP) levels (Fig. 5-1H), and gene expression analysis detected similar decreases in 
mRNA levels for osteoblastic genes with aging (Fig. 5-8). However, no aging-related 
changes in mineral apposition rate (MAR), mineralizing surface (MS)/BS, or bone 
formation rate (BFR)/BS were detected by dynamic histomorphometric analysis of the 
vertebral cancellous bone of young and middle-aged veh-treated mice (Fig. 5-1I). On the 
other hand, age-related alterations in bone formation were detected on the surfaces of the 
femur mid-diaphysis (Fig. 5-9), suggesting that in the middle-aged veh-treated control 
mice only cortical bone formation was altered.  
 In contrast to the effects of AZ on osteoclasts, the effects on osteoblasts were age-
dependent. Specifically, while vertebral cancellous osteoblast parameters, N.Ob/T.Ar, 
N.Ob/BS and Ob.S/BS were lower with AZ treatment in mice at both ages, uncorrected 
N.Ob was only lower in the middle-aged AZ-treated mice (Fig. 5-1G). Consistently, 
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dynamic histomorphometric analysis only detected decreases in bone formation in the 
vertebral cancellous and femur mid-diaphysis endocortical bone in the middle-aged, but 
not young AZ-treated mice (Fig. 5-1I,5-8). Additionally, in vitro treatment of young and 
middle-aged primary adherent BMCs had age-dependent effects, increasing 
mineralization in young cells, but attenuating mineralization in aged cells (Fig. 5-1J). On 
the other hand, systemic in vivo AZ treatment decreased serum P1NP levels in both young 
and aged mice (Fig. 5-1H). Further, osteoblast gene expression was decreased in the tibia 
with AZ treatment in both ages (Fig. 5-7). Taken together these results suggest that 
inhibition of RAGE signaling may differentially affect osteoblast differentiation/activity, at 
least on the vertebral cancellous surface, in an age-dependent manner.  
 
 Inhibition of RAGE signaling increases osteocyte apoptosis and pro-
inflammatory cytokine production. Based on the notion that osteocytes are key 
regulators of bone turnover and to the idea that aging-related reductions in osteocyte 
viability contribute to bone loss,7 we next sought to test the effects of AZ treatment on 
osteocytes. We first measured osteocyte apoptosis in active capase3-stained femur 
cortical bone cross-sections. Aging did not alter the proportion of active capase3 positive 
apoptotic osteocytes, as found before by TUNEL staining,8 but the number of empty 
lacunae (an indication of dying osteocytes) was increased in middle-aged compared to 
young veh-treated mice (Fig. 5-2A). Additionally, osteocyte gene expression was 
decreased with aging (Fig. 5-2B), and consistent with the decreased osteoclast 
parameters observed in the middle-aged mice, RANKL/OPG gene expression was lower 
in middle-aged mice compared to young animals (Fig. 5-2C).  
 AZ treatment did not alter the proportion of active capase3-positive apoptotic 
osteocytes, but significantly increased empty lacunae prevalence in young and middle-
aged mice (Fig. 5-2A). Consistently, the expression of the osteocyte genes Sost and 
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DMP1 was decreased with AZ treatment in both ages (Fig. 5-2B), whereas, AZ treatment 
increased the RANKL/OPG ratio in bones from middle-aged mice and led to higher 
inflammatory cytokine IL-6 and MCP-1 gene expression in bones from young and middle-
aged mice (Fig. 5-2C). Further, gene expression analysis detected tendencies towards 
increase in the expression of the apoptosis-associated genes p27 and Foxo3, and a 
significant increase in the RANKL/OPG mRNA ratio, and in the levels of IL-6 and MCP-1 
in ex vivo AZ treated osteocyte-enriched bone organ cultures (Fig. 5-2D-F). Taken 
together these findings highlight the possibility that the in vivo alterations in osteoclast 
activity induced with AZ treatment may be a combination of the direct and indirect effects 
associated with RAGE inhibition in osteoclasts and osteocytes, as illustrated in Fig. 5-2G.  
 
 Short-term systemic RAGE inhibition with AZ treatment does not 
significantly alter bone architecture or mechanical properties. Dual energy x-ray 
absorptiometry (DXA) analysis showed that spinal bone mineral density (BMD) was 
significantly decreased with aging, whereas, total and femoral BMD were unchanged in 
the middle-aged compared to young veh-treated mice (Fig. 5-3A). On the other hand, 
micro-computed tomography (μCT) analysis and 3-point femoral biomechanical testing 
detected the expected changes in bone geometry and mechanics, respectively. 
Specifically, lumbar vertebra and distal femur trabecular BV/TV (bone volume/tissue 
volume) and trabecular number (Tb.N) were decreased, whereas trabecular spacing 
(Tb.S) was increased in the middle-aged mice compared to young veh-treated mice (Fig. 
5-3B,C). In addition, femur cortical BA/TA (bone area/ tissue area) was decreased, 
whereas, polar mean moment of inertia (MMI), a measurement of resistance to bending, 
marrow cavity widening, and bone tissue porosity were increased with aging (Fig. 5-3D). 
Further, the biomechanical properties at the structural and material levels were all 
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decreased in the middle-aged compared to young veh-treated mice, with the exception of 
stiffness, which was increased with aging (Table 5-1).  
 Consistent with the changes in bone cell differentiation/activity, DXA analysis 
revealed that AZ treatment decreased total and femoral BMD in young and middle-aged 
mice, without affecting spinal BMD (Fig. 5-3A). However, despite the effects on BMD, no 
changes in bone geometry (trabecular and cortical) or biomechanical properties following 
systemic short-term AZ treatment in mice at either age were detected by μCT analysis or 
3-point femoral biomechanical testing, respectively (Fig. 5-3B-D and Table 5-1).   
 
 Systemic RAGE inhibition prevents the loss of lean muscle mass and 
preserves the function of cellular processes required to maintain skeletal muscle 
homeostasis in aging.  Based on the previous reports that both aging and RAGE 
signaling alter adipose and skeletal muscle mass,171 we next tested the effects of systemic 
AZ treatment on these tissues. As expected, body weight of middle-aged compared to 
young veh-treated mice was increased (Fig. 5-4A), and body composition was altered, 
with greater fat mass and lower lean mass compared to young veh-treated mice (Fig. 5-
4B). Consistently, gastrocnemius, tibialis anterior, and quadriceps mass corrected by body 
weight were all decreased in the middle-aged veh-treated mice (Fig. 5-4C). Further, gene 
expression analysis detected decreases in the expression of MyoD with aging (Fig. 5-4D). 
Moreover, histomorphometric analysis of H&E-stained forearm skeletal muscle revealed 
decreases in the average myofiber cross-sectional area (CSA) in middle-aged compared 
to young veh-treated mice (Fig. 5-5A,B). Interestingly, in vitro treatment of C2C12 
myotubes with 5% serum from middle-aged compared to young veh-treated mice also 
reduced average myotube diameter and led to a leftward shift in the representative 
histograms of the distribution of myotube diameter (Fig. 5-5C,D), suggesting that 
circulating serum factors may contribute to aging-induced muscle atrophy. Consistent with 
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the increased muscle atrophy, ubiquitinated protein levels and expression of the E3 
ubiquitin ligases Atrogin-1 and MuRF-1, generally overexpressed in conditions associated 
with muscle atrophy,185, 186 were increased in the skeletal muscles of middle-aged 
compared to young veh-treated mice (Fig. 5-5E,F).  
In young mice, AZ decreased body weight (Fig. 5-4A), and altered body 
composition reducing the fat mass and increasing lean mass (Fig. 5-4B). Consistently, 
gastrocnemius and tibialis anterior muscle mass (Fig. 5-4C), as well as myogenin and 
MyoD expression, measured in the tibialis anterior muscle (Fig. 5-4D), were increased 
with AZ treatment. However, quadriceps muscle weight was decreased (Fig. 5-4C) and 
the level of ubiquitinated proteins appear to increase with treatment in the young mice 
(Fig. 5-5E). Notably, addition of serum from the young AZ-treated mice to C2C12 
myotubes also significantly reduced myofiber size and histomorphometric analysis of 
H&E-stained forearm muscle revealed decreases in the average myofiber CSA in young 
AZ-treated mice (Fig. 5-5B,C). 
In middle-aged mice, AZ had similar effects on body composition, reversing the 
aging-associated increases in body weight (Fig. 4-4A), as well as, the alterations in body 
composition by reducing the fat mass and increasing lean mass (Fig. 5-4B). Further, AZ 
reversed the aging-induced loss of the gastrocnemius, tibialis anterior, and quadriceps 
muscle mass in the middle-aged treated mice (Fig. 5-4C). Consistently, RAGE inhibition 
increased myogenin expression at both ages, and restored MyoD levels in the middle-
aged mice (Fig. 5-4D). Moreover, while AZ did not completely reverse the aging-induced 
decreases in myofiber CSA (Fig. 5-5B), in vitro treatment of C2C12 myoblasts with serum 
from the middle-aged AZ-treated mice did not result in the decreased myotube diameter 
that was induced by serum from the middle-aged veh-treated mice (Fig. 5-5C,D).  
Consistent with these findings, AZ attenuated the aging-induced increases in 
ubiquitinated protein levels and the mRNA levels of Atrogin-1 (Fig. 5-5E,F). Further, AZ 
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treatment reversed the aging-associated alterations in the expression of genes involved 
in the regulation of skeletal muscle cellular processes. Particularly, autophagy- and 
mitochondria-related gene expression was decreased with aging, and AZ treatment 
increased expression of these genes in young and middle-aged mice (Fig. 5-10), 
suggesting that in vivo AZ treatment may protect against aging-induced muscle atrophy, 
in part, by preserving the proper functioning of cellular processes normally required to 
maintain skeletal muscle homeostasis and metabolism. On the other hand, while aging 
increased Atrogin-1 and MuRF-1 levels in bone, as previously shown with glucocorticoid 
administration,187 AZ did not block these increases (Fig. 5-11).  
 
AZ treatment reverses the aging-induced metabolic alterations in skeletal 
muscle but not in bone. Despite the similar aging-induced loss of bone and muscle 
mass, the findings from the present study reveal that aging differentially alters skeletal 
muscle and bone metabolism. Particularly, gene expression analysis of skeletal muscles 
from young and middle-aged veh-treated mice demonstrated that aging decreased 
glucose transporter (Glut1-4) gene expression (Fig. 5-6A). Further, gene expression of 
glycolytic enzymes (PGK1, LDHA, PDK1) was decreased with aging, whereas the levels 
of enzymes involved in the regulation of oxidative metabolism (PGC-1α and PPAR-α) were 
unchanged or showed tendencies towards increase with aging in the veh-treated mice 
(Fig. 5-6B,C).  In contrast, in bone, Glut3 gene expression was decreased with aging, 
whereas, Glut1 and Glut2 expression was significantly increased and Glut4 was not 
changed with aging (Fig. 5-6D). Further, LDHA and PGK1 expression was increased with 
aging, whereas PGC-1α and PPAR-α expression was unaltered in bone samples from 
middle-aged compared to young veh-treated mice (Fig. 5-6E,F).  
We next examined the metabolic effects of AZ treatment in skeletal muscle and 
bone. In skeletal muscle, AZ increased glucose transporter, Glut1, Glut3, and Glut4, gene 
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expression, and led to a tendency towards increase in Glut2 gene expression in mice at 
both ages (Fig. 5-6A). Further, in skeletal muscle PGK1 and LDHA expression was 
increased, while the PGC-1α and PPAR-α expression was unchanged with AZ treatment 
in young and middle-aged mice (Fig. 5-6B,C). In bone, AZ treatment increased Glut1 and 
Glut3 gene expression and led to a tendency towards increase in Glut2 gene expression, 
while Glut4 was not changed (Fig. 5-6D). Similarly, LDHA, PGK1, and PGC1α expression 
was increased in bone lysates from AZ-treated mice at both ages (Fig. 5-6E,F). 
Interestingly, we also found that the mRNA expression of leptin and IGF-1, factors known 
to alter cell metabolism, were also differentially altered with aging in skeletal muscle and 
bone tissue lysates (Fig. 5-12). However, AZ led to similar decreases in leptin levels in 
both tissues at both ages.
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Discussion 
Inflammation is a complex biological process initiated in many cell types in 
response to various stimuli, which stimulates the secretion of numerous factors and 
subsequently mediates processes such as protective immunity, tissue repair and damage 
resolution.149 Further, while acute inflammation stimulates repair, chronic-sustained 
inflammation leads to progressive damage.162 Particularly, chronic low-grade inflammation 
has been associated with numerous age-related degenerative diseases and with related 
debilitating conditions, such as sarcopenia and osteoporosis.158, 165 Several potential 
mechanisms of age-associated chronic inflammation have been proposed, including the 
accumulation senescent cells, impaired mitochondrial function, reduced levels of 
autophagy, and altered NF-κB signaling,149, 162 which are also seen in bone and skeletal 
muscle with aging.188, 189 
Consistently, sustained RAGE signaling, a known regulator of NF-κB, has been 
shown to contribute to the onset/progression of various aging-related pathologies.158, 165 
Particularly, several pieces of evidence have highlighted the potential involvement of 
elevated RAGE signaling in the onset/progression of bone and muscle pathology in 
aging.169-171 However, given the physiological importance of inflammation, whether 
blocking RAGE can reverse aging-related pathologies, particularly, osteoporosis and 
sarcopenia, remains unknown.  
In this study, we tested the effects of short-term systemic administration of the 
small-molecule RAGE inhibitor, AZ, on bone and skeletal muscle in aging using a series 
of in vitro and in vivo experiments. Overall, our findings provide evidence that short-term 
pharmacologic RAGE inhibition has effects on bone and muscle metabolism in young and 
middle-aged mice.  
  Consistent with previous findings in global genetic RAGE knockout mice,170, 190, 191 
RAGE inhibition by AZ treatment decreased osteoclast differentiation in vitro. However, in 
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vivo AZ administration suppressed bone remodeling and led to a small but significant 
decrease in BMD in young and middle-aged mice. These findings are consistent with 
previous studies showing that femoral cancellous bone accrual and architecture were 
decreased, and femur osteoblast gene (ALP, Cola1, Runx2, and Osterix) expression was 
lower in 4-month-old RAGE knockout compared to control wildtype mice.192 Interestingly, 
despite these cellular changes, bone geometry and strength were maintained. 
Nevertheless, our findings provide further support for the important physiological role of 
RAGE signaling in bone. However, opposed to previous findings in RAGE knockout mice, 
our results suggest that direct versus indirect effects of RAGE inhibition in bone cells 
differentially regulates bone metabolism. 
Particularly, the differential direct versus indirect effects of AZ on osteoclasts may 
be due to the increases in cell death and inflammatory cytokine production in osteocytes 
both in vitro and in vivo. Hence, despite the direct inhibitory effects of AZ treatment on 
osteoclasts, the effects of RAGE inhibition in osteocytes may indirectly promote bone 
resorption. Considering previous reports that NF-κB signaling is required for proper 
osteoclast function and that AGE-RAGE mediated activation NF-κB signaling induces 
osteoclastogenesis184, 193 coupled with the known anti-apoptotic effects of NF-κB 
signaling,194 inhibition of NF-κB signaling may mediate the differential effects of AZ.  
Given the cell type specific effects of AZ, future studies will be designed to examine 
whether administering a different dose or altering the treatment regimen [intermittent vs 
chronic], previously seen with other therapeutics, could optimize the beneficial effects of 
AZ on bone. For example, depending on the mode of administration, intermittent vs 
chronic, parathyroid hormone (PTH), has anabolic or catabolic actions on the skeleton.195 
Notably, the catabolic actions of PTH have been shown to result from indirect actions on 
osteoclasts mediated through direct actions on osteoblasts and osteocytes, by modulating 
RANKL and MCP-1 levels,196-198 both of which were increased by AZ.  
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In addition to the skeletal effects of AZ, we found that treatment reversed the aging-
induced alterations in body composition, leading to lower fat and higher lean body mass 
compared to veh-treated control mice at both ages. These findings are consistent with 
recent studies demonstrating that RAGE signaling regulates the metabolic and 
inflammatory response to high fat feeding in mice.199 In this study, genetic RAGE 
deficiency and administration of systemic soluble RAGE, a decoy receptor RAGE isoform, 
reduced fat mass in high fat diet fed mice. Although, despite the beneficial effects of AZ 
administration on the skeletal muscle of middle-aged mice, AZ had differential effects on 
skeletal muscles of young animals. Specifically, while several similar positive effects were 
detected in the tibialis anterior muscle, quadriceps mass was decreased and ubiquitin-
mediated protein degradation was increased in young AZ-treated mice.  
Nevertheless, consistent with the beneficial effects on lean body mass, we found 
that AZ treatment reversed the aging-induced decreases in skeletal muscle mass and 
attenuated several aging-induced changes known to be associated with chronic 
inflammation, including NF-κB signaling, mitochondrial function and autophagy. 
Specifically, AZ preserved the expression of known myogenic regulatory factors, such as 
myogenin and MyoD, and attenuated ubiquitin-mediated protein degradation in the aged 
mice. Consistently, it has been suggested that activation of NF-κB post-transcriptionally 
reduces the cellular levels of MyoD.200 Further, deletion of the β subunit of the inhibitor of 
NF-κB kinase, IKKβ, reduces inflammation, leading to improved skeletal muscle strength, 
maintained mass, and enhanced regeneration.201 
  In addition, AGEs induce skeletal muscle atrophy and dysfunction in diabetic mice 
via RAGE-mediated AMPK-induced downregulation of the Akt pathway.172 In this study, 
Atrogin-1 levels were attenuated following RAGE inhibition and consistent with this, 
Atrogin-1 has been previously shown to directly suppress MyoD expression, inhibiting 
protein synthesis and inducing aging-related skeletal muscle atrophy.202 Consistently, 
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reports suggest that the association between Atrogin-1 and skeletal muscle atrophy may 
be more related to its inhibitory effects on protein synthesis.203, 204 Taken together these 
pieces of evidence suggest that in middle-aged mice AZ treatment may restore key cellular 
processes normally involved in the maintenance of skeletal muscle mass by directly 
inhibiting AGE-RAGE signaling or by downregulating NF-κB signaling in the skeletal 
muscle. 
  However, given the increased myotube diameter in C2C12 cultures exposed to 
serum from middle-aged AZ-treated mice, it is also possible that the observed beneficial 
effects are due to systemic alterations rather than direct effect of AZ in skeletal muscle. 
Thus, additional studies are needed to understand the mechanisms underlying the 
beneficial effects of systemic AZ treatment on skeletal muscle in middle-aged mice. 
Additionally, whether AZ administration also improves muscle function remains to be 
elucidated.  
Nevertheless, our findings suggest that systemic AZ treatment in middle-aged 
mice might contribute to reverse the derangements observed in the skeletal muscle 
primarily by correcting the aging-associated metabolic defects and by preventing the 
effects of AGEs and potentially other RAGE ligands. Indeed, our findings that AZ treatment 
prevents against the aging-related decreases in skeletal muscle glucose transporter gene 
expression, are consistent with reports that AGEs inhibit insulin actions in skeletal muscle 
and induce interference of glucose uptake.205 In particular, AGE-RAGE binding induces 
inflammation, triggering ER-stress and initiating the unfolded protein response (UPR), 
which subsequently promotes nuclear translocation of NF-κB.206, 207 Further, recent work 
demonstrated that nuclear NF-κB directly binds and represses Slc2a4 gene transcription, 
suppressing GLUT4 expression and disrupting glucose uptake.208 Thus, our findings that 
aging decreased skeletal muscle GLUT4 gene expression, an effect reversed by AZ 
administration, suggest that systemic RAGE inhibition reverses the aging-induced 
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alterations in skeletal muscle glucose uptake, potentially by blocking AGE actions on 
skeletal muscle.  
Further, AZ treatment reversed the aging-induced declines in the expression of 
skeletal muscle glycolytic, but not oxidative metabolism enzymes, which is consistent with 
reports that NF-κβ activation primarily induces fast-twitch, glycolytic muscle fiber 
atrophy.209 However, despite the findings that AZ treatment had similar effects on glucose 
transporter and glycolytic enzyme gene expression in bone, aging had opposite effects on 
their expression in bone and skeletal muscle. Altogether, these findings suggest that aging 
differentially effects glucose uptake and metabolism in the different tissues, which 
highlights a potential mechanism underlying the differential effects of AZ treatment on 
bone and skeletal muscle in aging. 
In conclusion, our study suggests that short-term pharmacologic RAGE inhibition 
has distinct effects on bone and muscle metabolism. Thus, while AZ treatment did not 
attenuate the aging-induced alterations in bone, it did rescue some of the changes in 
skeletal muscle. In particular, our data conclusively validate the role of RAGE signaling in 
promoting musculoskeletal derangements associated with aging, thus making it an 
interesting therapeutic target. Altogether, our findings strongly support that idea that AZ 
may represent a novel therapeutic option for the treatment of aging-induced sarcopenia. 
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Figure 5-1. AZ differentially alters bone metabolism through direct and indirect actions.  A) 
Illustration of AZ mechanism of action. B) Mature osteoclasts/well generated in vitro from 
non-adherent BMCs from young and middle-aged WT female mice (n=6). Representative 
images are shown, scale bar indicates 50µm. C) Illustration of in vivo experimental design. 
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Osteoclasts on D) femoral cortical mid-diaphysis and E) vertebral cancellous TRAP/T.blue 
stained sections (n=8-9). Representative images are shown (black arrows point at 
osteoclasts), scale bar indicates 25µm. F) Serum CTX levels in young and aged veh and 
AZ-treated mice (n=10). G) Osteoblasts on von Kossa/McNeal stained vertebra sections 
(n=7-10). Representative images are shown, scale bar indicates 25µm. H) Circulating 
serum PINP levels in young and middle-aged veh- and AZ-treated mice (n=8-10). I) 
Dynamic histomorphometric parameters in unstained vertebra sections (n=8-10). J) 
Mineralization assay of primary osteoblasts generated in vitro from adherent-BMCs from 
young and aged WT mice (n=5). Bars represent mean ± SD, black line: p<0.05, vs young 
mice and *p<0.05, vs veh-treated mice by two-way ANOVA, Tukey.   
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Figure 5-2. Systemic RAGE inhibition with AZ treatment increases osteocyte apoptosis 
and pro-inflammatory cytokine production. A) Active-caspase3 positive apoptotic 
osteocytes and number of empty lacunae scored in active caspase3 stained bone sections 
(n=8-10). Representative images of active caspase3-positive osteocytes (arrow, black), 
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scale bar indicates 10µm. B) Osteocytic gene and C) cytokine mRNA levels in tibia from 
young and middle-aged veh and AZ-treated mice (n=7-10). D) Illustration of bone organ 
culture experimental design. mRNA expression of E) apoptosis-associated and F) pro-
inflammatory cytokines in marrow-flushed bone cultures (n=3-5). Bars represent mean ± 
SD, black line: p<0.05, vs young mice and *p<0.05, vs veh-treated mice by two-way 
ANOVA, Tukey. G) Illustration of proposed AZ direct and indirect effects on bone cells.  
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Figure 5-3. Short-term AZ treatment decreases bone mass accrual, but not bone 
architecture in young or middle-aged mice. A) BMD of young and middle-aged mice 
following veh- or AZ-treatment (n=8-10). Cancellous microarchitecture evaluated by µCT 
in the B) L4 vertebra and C) distal femur (n=8-9). Representative images are shown. D) 
Cortical bone geometry evaluated by µCT in the femoral mid-diaphysis (n=8-9). 
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Representative images are shown. Bars represent mean ± SD, black line: p<0.05, vs 
young mice and *p<0.05, vs veh-treated mice by two-way ANOVA, Tukey.  
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Figure 5-4. AZ treatment reverses the loss of skeletal muscle mass induced with aging. 
A) Body weight, B) fat and lean mass indicated as percentage of body weight (n=8-10), 
C) muscle weights (n=8-9), D) myogenesis and satellite cell marker mRNA expression in 
tibialis anterior muscle (n=7-9) of young and aged mice. Bars represent mean±SD, black 
line: p<0.05, vs young mice and *p<0.05, vs veh-treated mice by two-way ANOVA, Tukey.   
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Figure 5-5. AZ treatment restores the function of cellular processes required to maintain 
skeletal muscle homeostasis in aging. A) low- and high-magnification images of forearm 
muscle cross-sections, muscle of interest is circled in black, scale bar indicates 50µm, and 
B) average myofiber cross-sectional area (CSA) (n=6-8). C) Average myotube diameter 
per field and D) distribution of myotube diameter of serum-treated C2C12 cells (n=10). 
Representative images are shown, scale bar indicates 50µm. E) Ubiquitin-conjugated and 
GAPDH protein patterns in skeletal muscle (n=6). F) mRNA levels of atrophy-related 
genes in tibialis anterior muscle (n=7-9). Bars represent mean ± SD, black line: p<0.05, 
vs young mice and *p<0.05, vs veh-treated mice by two-way ANOVA, Tukey. 
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Figure 5-6. Systemic inhibition of RAGE signaling reverses the aging-induced metabolic 
alterations in skeletal muscle, but not in bone. Glucose transporter GLUT1-4, and 
glycolytic and oxidative enzyme mRNA levels in tibialis anterior muscle (A-C) and in tibia 
(D-F) (n=7-9). Bars represent mean ± SD, black line: p<0.05, vs young mice and *p<0.05, 
vs veh-treated mice by two-way ANOVA, Tukey. 
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Figure 5-7. Osteoclast gene expression was decreased in aged mice and Azeliragon 
treatment did not significantly alter osteoclast genes at either age. Osteoclast-related gene 
mRNA expression in whole tibia samples isolated from young and middle-aged vehicle- 
and Azeliragon-treated mice. Bars represent mean ± SD, black line: p<0.05, versus young 
mice by two-way ANOVA, Tukey, *p<0.05, versus vehicle-treated mice by two-way 
ANOVA, Tukey.  
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Figure 5-8. Aging and Azeliragon treatment decreased osteoblast gene expression. 
mRNA expression of osteoblast-related genes in whole tibia samples isolated from young 
and aged vehicle- and Azeliragon-treated mice. Bars represent mean ± SD, black line: 
p<0.05, versus young mice by two-way ANOVA, Tukey, *p<0.05, versus vehicle-treated 
mice by two-way ANOVA, Tukey.  
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Figure 5-9. Azeliragon decreased bone formation in middle-aged, but not young mice. 
Mineral apposition rate (MAR), mineralizing surface (MS)/BS, and bone formation rate 
(BFR)/BS measured in unstained sections of the femoral mid-diaphysis from young and 
aged vehicle- and Azeliragon-treated mice. Bars represent mean ± SD, black line: p<0.05, 
versus young mice by two-way ANOVA, Tukey, *p<0.05, versus vehicle-treated mice by 
two-way ANOVA, Tukey.  
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Figure 5-10. Azeliragon treatment restored mRNA levels of several autophagy- and 
mitochondria-related genes decreased with aging. mRNA levels of A) autophagy- and B) 
mitochondria-related genes measured in tibialis anterior muscle samples isolated from 
young and middle-aged vehicle- and Azeliragon-treated mice. Bars represent mean ± SD, 
black line: p<0.05, versus young mice by two-way ANOVA, Tukey, *p<0.05, versus 
vehicle-treated mice by two-way ANOVA, Tukey.  
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Figure 5-11. In bone, Azeliragon treatment did not alter E3 ubiquitin ligase expression. 
mRNA levels of Atrogin-1 and Murf1 measured in whole-tibia bones from young and 
middle-aged vehicle- and Azeliragon-treated mice. Bars represent mean SD, black line: 
p<0.05, versus aged mice by two-way ANOVA, Tukey, *p<0.05, versus vehicle-treated 
mice by two-way ANOVA, Tukey (n=7-9). 
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Figure 5-12. Aging differentially alters hormone-related gene, Leptin and IGF1, expression 
in bone and skeletal muscle. mRNA levels of Leptin and IGF1, measured in A) tibialis 
anterior muscle and B) whole-tibia bones from young and middle-aged vehicle- and 
Azeliragon-treated mice. Bars represent mean ± SD, black line: p<0.05, versus young 
mice by two-way ANOVA, Tukey, *p<0.05, versus vehicle-treated mice by two-way 
ANOVA, Tukey. 
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Figure 5-13. Azeliragon administration induced splenomegaly. Spleen weight of young 
and middle-aged mice expressed as percentage of body weight (n=8-9). Bars represent 
mean SD, black line: p<0.05, versus aged mice by two-way ANOVA, Tukey, *p<0.05, 
versus vehicle-treated mice by two-way ANOVA, Tukey.  
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Table 5-1. Biomechanical properties measured in the femoral mid-diaphysis by 3-point 
bending test. 
 
 
#p<0.05, versus aged mice by two-way ANOVA, Tukey, *p<0.05, versus vehicle-treated 
mice by two-way ANOVA, Tukey. 
 
 vehicle  5-month-old 
RAGE 
inhibitor 
5-month-old 
vehicle  
16-month-old 
RAGE 
inhibitor 
 16-month-
old 
Yield Force (N) 12.67 ± 2.38 14.81± 2.26 9.08 ± 3.37# 9.23 ± 4.16 
Ultimate Force 
(N) 15.09 ± 0.93 15.70 ± 1.31 16.86 ± 1.52 15.69 ± 2.87 
Displacement 
to Yield (µm) 
372.58 ± 
37.86 
419.13 ± 
51.66 
256.65 ± 
122.07# 
280.42 ± 
137.34 
Postyield 
Displacement 
(µm) 
642.63 ± 
344.32 
439.93 ± 
147.15 
332.56 ± 
150.72# 
394.35 ± 
70.29 
Total 
Displacement 
(µm) 
991.91 ± 
327.71 
773.72 ± 
172.42 
584.99 ± 
92.72# 
633.75 ± 
119.06 
Stiffness 
(N/mm) 34.27 ± 3.79 36.11 ± 2.88 44.02 ± 8.09# 43.81 ± 7.84 
Work to Yield 
(mJ) 2.64 ± 0.76 3.35 ± 0.80 1.47 ± 1.27# 1.66 ± 1.25 
Postyield Work 
(mJ) 6.85 ± 3.20 5.55 ± 1.48 4.25 ± 1.84# 4.56 ± 0.73 
Total Work 
(mJ) 9.23 ± 3.19 8.39 ± 2.47 6.16 ± 1.77# 5.52 ± 1.26 
Yield Stress 
(MPa) 75.51 ± 19.78 71.99 ± 21.16 
48.16 ± 
18.39# 49.46 ± 22.18 
Ultimate 
Stress (MPa) 91.83 ± 11.62 86.58 ± 9.87 89.98 ± 10.44 84.14 ± 12.12 
Strain to Yield 
(mɛ) 
365.29 ± 
56.95 
341.73± 
111.10 
307.97 ± 
152.87 
301.48 ± 
147.93 
Total Strain 
(mɛ) 
933.81 ± 
322.76 
713.88 ± 
165.82* 
630.26 ± 
106.21# 
687.64 ± 
113.83 
Modulus (GPa) 2.16 ± 0.38 2.12 ± 0.15 2.20 ± 0.34 2.18 ± 0.47 
Resilience 
(MPa) 1.50 ± 0.54 1.69 ± 0.47 0.85 ± 0.75# 0.95 ± 0.72 
Toughness 
(MPa) 5.20 ± 2.14 4.03 ± 1.05 3.56 ± 1.10# 3.53 ± 1.01 
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Chapter 6 
High mobility group box1 (HMGB1) protein regulates osteoclastogenesis through 
direct actions on osteocytes and osteoclasts in vitro  
 
Rationale 
Old age and Cx43 deletion in osteocytes are associated with increased osteocyte 
apoptosis and osteoclastogenesis. We previously demonstrated that apoptotic osteocytes 
release elevated concentrations of the pro-inflammatory cytokine, high mobility group 
box1 protein (HMGB1) and apoptotic osteocyte conditioned media (CM) promotes 
osteoclast differentiation. Further, prevention of osteocyte apoptosis blocks osteoclast 
differentiation and attenuates the extracellular release of HMGB1 and RANKL. Moreover, 
sequestration of HMGB1, in turn, reduces RANKL production/release by MLO-Y4 
osteocytic cells silenced for Cx43 (Cx43def), highlighting the possibility that HMGB1 
promotes apoptotic osteocyte-induced osteoclastogenesis. However, the role of HMGB1 
signaling in osteocytes has not been well studied. Additionally, the mechanisms underlying 
its release and the receptor(s) responsible for its actions are not clear. Here, we assessed 
the effects of HMGB1 signaling in osteoclasts and osteocytes. Further, we tested whether 
RAGE signaling in osteoclasts regulates the stimulatory effects of apoptotic osteocytes on 
osteoclastogenesis. 
 
Introduction  
Over the last decade the interconnected bidirectional link between the skeleton 
and immune system has been extensively demonstrated, leading to creation of the 
osteoimmunology field.211, 212 In particular, numerous studies have reported that 
inflammatory conditions increase the risk of developing osteoporosis.189, 213 Consistent 
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with this, emerging evidence suggests that inflammatory cytokines function as local 
regulators of bone cell function under physiological conditions and in disease states.184, 213   
  In particular, cytokines and growth factors produced and released by osteocytes 
control osteoblast and osteoclast differentiation and activity, thereby regulating bone 
remodeling. It has long been proposed that maintenance of osteocyte viability is a key 
process by which osteocytes control bone remodeling.30 Osteocyte viability is reduced in 
conditions of increased bone fragility,26, 32-34, 51 and, conversely, agents that preserve bone 
strength prevent osteocyte apoptosis.32, 40, 42, 43 Moreover, osteocyte apoptosis and the 
prevalence of empty lacunae are increased in old mice and humans.8, 45 
  In previous work, we demonstrated that deletion of the gap junction protein, 
connexin (Cx) 43 from osteocytes increases osteocyte apoptosis and leads to the 
accumulation of osteoclasts on the adjacent bone surfaces.46 Consistent with these 
findings, Cx43-deficient mice exhibit a skeletal phenotype resembling that of bones from 
old mice and humans, with bone marrow cavity widening, periosteal expansion, and 
defective bone material properties.38, 46 Further, more osteoclasts developed from bone 
marrow cells (BMCs) cultured in the presence of MLO-Y4 osteocytic cells silenced for 
Cx43 (Cx43def), or treated with conditioned media (CM) from Cx43def cells, compared to 
scramble (scr) control cells.119 Consistent with this, Cx43def osteocytic cells undergo 
accelerated apoptosis and release increased concentrations of soluble (s)RANKL and 
high mobility group box 1 (HMGB1), which promote osteoclast resorption.119  
The pro-inflammatory cytokine HMGB1 is a multifunctional redox sensitive protein 
expressed and released by most cell types including bone cells (osteoclasts, osteoblasts, 
osteocytes), which exerts various cellular compartment-specific functions.191 Additionally, 
following its extracellular secretion, HMGB1 operates as a damage associated molecular 
pattern (DAMP) protein, and mediates a variety of cellular processes by interacting with 
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two receptors, the receptor for advanced glycation end products (RAGE) and the toll-like 
receptor 4 (TLR4).52  
In bone cells, HMGB1 signaling has been shown to modulate key cellular 
processes including differentiation, proliferation, apoptosis, and autophagy, and 
subsequently regulate bone tissue homeostasis, turnover, and repair.50, 51, 53, 54, 119, 214, 215 
For example, in mesenchymal stem cells (MSCs) and osteoblasts, HMGB1 signaling 
stimulates the release of cytokines and osteogenic MSC differentiation.215, 216 Consistent 
with these findings, HMGB1 has beneficial effects on bone repair and promotes facture 
healing.53, 217, 218 In osteoclasts, HMGB1-RAGE signaling regulates RANKL-induced 
osteoclast differentiation and activity.54 Further, epidermal growth factor-mediated 
HMGB1 release induces RANK expression via CD68 in patients with autoimmune 
disease, suggesting that extracellular HMGB1 promotes osteoclast differentiation in 
human diseases.219 In osteocytes, aside from the reports by our groups,50, 119 showing that 
HMGB1 is secreted from dying osteocytes, the role of HMGB1 signaling in osteocytes has 
not been well studied. Further, the mechanisms underlying its release and the receptor(s) 
responsible for its actions is not clear.  
 In the current study, we assessed the effects of HMGB1 signaling in osteoclasts 
and osteocytes. Further, we tested whether RAGE signaling in osteoclasts regulates the 
stimulatory effects of apoptotic osteocytes on osteoclastogenesis. Overall our results 
suggest that, in osteoclasts, direct HMGB1 actions affect early stages of osteoclast 
differentiation through TLR4 activation in bone marrow macrophages (BMMs), followed by 
RAGE activation in pre-osteoclasts. Further, in osteocytes, direct HMGB1 actions 
stimulate pro-osteoclastogenic signal release from Cx43def osteocytes. These findings 
demonstrate that HMGB1 exerts dual effects on bone cells, stimulating osteoclast 
differentiation through RAGE and TLR4 activation in osteoclasts and inducing pro-
osteoclastogenic cytokine secretion from osteocytes. Thus, direct actions of HMGB1 
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signaling in osteoclasts and osteocytes, rather than indirect effects of apoptotic osteocyte-
derived extracellular HMGB1 appear to underlie the stimulatory effects of apoptotic 
osteocytes on osteoclasts.   
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Materials and Methods 
Cell culture. MLO-Y4 osteocytic cells stably silenced for Cx43 (Cx43def) or 
scramble shRNA controls were produced using lentivial shRNA transfection, as previously 
published.119, 220 2 x 104 cells/cm2 MLO-Y4 osteocytic cells were seeded on collagen-
coated 48-well plates and and cultured for 12 hours. RAGE-deficient non-adherent BMCs 
were isolated from two global RAGE knockout mouse models. BMCs isolated from global 
RAGE knockout mice, previous reported by Philip et al.,192 were co-cultured with MLO-Y4 
osteocytic cells. Additionally, BMCs were isolated from RAGE knockout mice generated 
by CRISPR/Cas9 as detailed in the supplemental information (Fig. 6-5). The efficiency of 
the knock out was determined in genomic DNA by PCR and in lung lysates by Western 
blotting (Fig. 6-6). BMCs were cultured with conditioned media from ex vivo long bone 
cultures of young and old female C57BL/6 mice.  
 
RNA extraction and real-time PCR (qPCR). RNA was isolated and purified using 
TRIzol, as published.119 Briefly, a high-capacity cDNA kit was used to perform reverse 
transcription and then Gene Expression Assay Mix TaqMan Universal Master Mix with an 
ABI 7900HT real-time PCR system was used to perform qPCR. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as the house-keeping gene. Primers and 
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probes were already available at the vendor site, or designed with the Assay Design 
Center (Roche Applied Science, Indianapolis, IN, USA). 
 
HMGB1 receptor inhibitors. The small molecular RAGE inhibitor, Azeliragon (DC 
Chemicals, cat.# DC8338) and LPS-RS ultrapure (InvivoGen, cat.# tlrl-prslps) were used 
at a concentration of 100ng/mL to inhibit RAGE and TLR4, respectively.  
 
In vitro HMGB1 neutralization. Following overnight culture, Cx43 or scramble 
control silenced MLO-Y4 osteocytic cells were exposed to 0.5μg/ml non-immune (ni) 
rabbit IgG or neutralizing rabbit anti-HMGB1 antibodies for 24h and CM was collected then 
concentrated 4x using centricon, as published.119 For cultures with immunoglobulins, CM 
was cultured with 10μl/ml Protein A agarose (Sigma-Aldrich, cat.#11134515001) overnight 
to remove the immunoglobulins. IgG-depleted CM was then collected, 1M HEPES was 
added and CM was stored at -20°C until used for the osteoclastogenesis assays.  
 
Ex vivo bone organ cultures. Long bones were isolated from young (4-month-
old) and old (21-month-old) female C57BL/6 mice obtained from National Institute on 
Aging (NIA). BMCs were flushed out with α-minimal essential medium (MEM). Osteocyte-
enriched marrow-flushed long bones were then cultured ex vivo in α-MEM containing 10% 
FBS and 1% penicillin/streptomycin (P/S) for 48h. Conditioned media was collected 1M 
HEPES was added and stored at -20°C until used for the osteoclastogenesis assays.  
 
Osteoclastogenesis assays: HMGB1 receptor inhibitor treatment. BMCs were 
collected from wildtype C57BL/6 mice and cultured for 48h with α-MEM supplemented 
with 10% FBS and 1% P/S.119 Next, non-adherent BMCs were collected and seeded at a 
density of 2x104 cells/cm2 on 96-well plates and cultured with sub-optimal levels of RANKL 
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(40 ng/ml) and M-CSF (20 ng/ml). Inhibitors of the HMGB1 receptors RAGE (Azeliragon) 
or TLR4 (LPS-RS) were added at 100ng/ml in BMMs (added during day 1-3) and pre-
osteoclasts (added during day 3-5).   
 
Osteoclastogenesis assays: in co-culture and with osteocytic conditioned 
medium. BMCs were collected from wildtype C57BL/6 mice and cultured for 48h with α-
MEM supplemented with 10% FBS and 1% P/S.119 Next, non-adherent BMCs, wildtype or 
RAGE-deficient, were collected and 2x104 cells/cm2 were plated on 96-well plates and 
exposed to conditioned media collected from scramble control and Cx43-deficient MLO-
Y4 osteocytic cells or ex vivo cultures of osteocyte-enriched marrow-flushed long bones 
isolated from 4- and 21-month old female C57BL/6 mice. RANKL (80 ng/ml) and M-CSF 
(20 ng/ml) were added to facilitate osteoclast differentiation and media was changed at 
day 3. For the co-culturing assays BMCs were isolated from C57BL/6 mice and cultured 
for 24–48 h. Non-adherent BMCs (2x105 cells/cm2) were seeded onto Cx43 and scramble 
control silenced MLO-Y4 osteocytic cells and treated with 10nM 1.25(OH)2 vitamin D3 
and 1M PGE2. Medium was changed every 2 days for 5 days, as previously published.97 
Cells were stained using a commercially available TRAPase kit (Sigma-Aldrich) and 
mature osteoclasts with ≥ 3 or more nuclei were quantified. A Zeiss Axiovert 35 
microscope with a digital camera was used to obtain images.   
 
Generation of RAGE knockout mice.  A CRISPR/Cas9 approach was employed 
to generate RAGE (Ager; MGI: 893592) knockout mice, using methods described by Low 
et al.221 A guide RNA protospacer sequence was selected using a combination of the MIT 
CRISPR Design tool developed by Hsu et. al.222 (crispr.mit.edu/; tool no longer available) 
and a second design tool develo.ped by Doench et. al.223 
(http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design).  The 19 nucleotide 
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(nt) guide sequence selected (shown in blue) was predicted to create a double-strand 
cleavage 3 bp downstream of the translational start site.  The biologically active sgRNA 
was generated as described,221 using forward and reverse RNA templates from Integrated 
DNA Technologies (IDT).  Homology-directed repair at the cleavage site utilized a 200-
base single-stranded oligodeoxynucleotide (ssODN) with homology to RAGE exon 1 and 
flanking regions (Fig. 6-5A). The ssODN contained a single-base insertion immediately 
following the start codon that induces a translational frame-shift, as well as six additional 
mutations that create an optimized Kozak sequence for efficient translational initiation, 
eliminate the Cas9 PAM sequence to prevent retargeting, and create a Bgl I site for 
screening purposes Fig. 6-5B KO shows a partial sequence of the ssODN).  A mix 
containing 50 ng/µl Cas9 protein (PNABio), 25 ng/µl sgRNA, and 20 ng/µl ssODN were 
microinjected into the pronuclei of fertilized C57BL/6J mouse eggs by the VCU 
Transgenic/Knockout Mouse Core using standard methods.  Microinjected eggs were 
implanted into the oviducts of ICR pseudopregnant females, and pups were screened for 
the desired knockout allele by two alternative PCR protocols. The first protocol employed 
KO and WT allele-specific reverse primers (KO: 5’-GACGCTGGCCATGGTGGCGG-3’), 
with mutations in red, and (WT: 5’-CCCCGCTGGCATGGTGCTTC-3’) in separate 
reactions with a common forward primer (5’-TTACAAAGCTCCAACAGGTTTGGG-3’), 
yielding allele-specific 408-bp PCR products (Fig. 6A). Cerk gene primers (5’-
GGTGGGAGAGAAATCTCCTAGTTC-3’) and (5’-AAAGCCACTTGCTGTCCCTCTGTG-
3’) were included in both reactions, generating a 630-bp internal control. The second PCR 
protocol primers flanked the targeted region, (5’-GAACTCGGTGGGTTGAAGGAAGTG-
3’) and (5’- AAGGGTAACTCCTGAGGTTGAGTG-3’), and yielded 676-bp (WT) or 677-bp 
(KO) products. Subsequent digestion of the KO product with Bgl I produced 405-bp and 
272-bp fragments (not shown). Three potential founders were selected for breeding and 
further characterization, including DNA sequencing. One line (line 7) carrying the desired 
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sequence changes was ultimately selected for study. Heterozygotes were bred to each 
other, yielding homozygous offspring with the expected frequency.  A 442-bp PCR product 
flanking the targeted region from a RAGE KO homozygote was sequenced to verify that 
the gene was correctly targeted (Fig. 6-5C). 
 
Western Blot Analysis. Lungs were collected, frozen immediately with liquid 
nitrogen, and stored at −80°C. Pulmonary tissue was homogenized in RIPA buffer with 
protease/phosphatase inhibitors and protein concentration was determined using the BCA 
protein assay (Thermoscientific). Samples (40μg/lane) were separated by 10% SDS-
PAGE and transferred to a nitrocellulose membrane. After incubation in 10% non-fat milk 
blocking solution overnight at 4°C, the membrane was incubated with rabbit anti-RAGE 
(1:1,000; Sigma–Aldrich) followed by incubation with horseradish peroxidase-conjugated 
secondary antibodies (Jackson ImmunoResearch). The membrane was probed again with 
a polyclonal anti-β actin antibody (1:5,000; Sigma– Aldrich, St. Louis, MO), followed by 
the corresponding secondary antibody. Immunopositive bands were detected by 
enhanced chemiluminescence (ECL). 
 
Statistical analysis. Data were analyzed with SigmaPlot (Systat Software Inc., 
San Jose, CA, USA). All results are presented as the mean ± standard deviation. 
Differences were assessed using two-way ANOVA, and Tukey Method for post-hoc 
analysis or Student’s t-test, as appropriate. Differences of p<0.05 were regarded as 
significant.  
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Results 
Inhibition of HMGB1 and its receptors alters osteoclast differentiation. 
Consistent with previous reports,54 direct inhibition of HMGB1 signaling during the process 
of osteoclast differentiation with anti-HMGB1 neutralizing antibodies reduced the number 
of mature osteoclasts generated in vitro from non-adherent BMCs compared to cells 
treated with control rabbit non-immune IgG antibodies (Fig. 6-1A). Therefore, we tested 
effects of the HMGB1 receptors, RAGE and TLR4, on different stages of the osteoclast 
differentiation process. For this, the inhibitors for the receptors were supplemented at early 
stages of differentiation (day 1-3), later in differentiation (day 3-5), or throughout the 
experiment (day 1-5) (Fig. 6-1B). We found that in osteoclasts precursors, inhibition of 
TLR4, but not RAGE, reduced osteoclast number; whereas, in later stages of 
differentiation, RAGE, but not TLR4 inhibition, decreased osteoclast formation (Fig. 6-1C). 
Further, when added throughout differentiation (day 1-5), osteoclast number was reduced 
by the individual inhibitors and additively suppressed with a combination of both 
Azeliragon and LPS-RS. Taken together, these data stress the critical function of HMGB1 
signaling at different stages of the osteoclast maturation process, and suggest that 
HGMB1 produced by osteoclasts has direct effects on differentiation via TLR4 activation 
in BMMs and RAGE activation in pre-osteoclasts. 
 
Apoptotic osteocyte induced increases in osteoclast differentiation are not 
mediated through RAGE-signaling in osteoclasts. Consistent with our previous 
findings that conditioned media from apoptotic Cx43def MLO-Y4 osteocytic cells induces 
osteoclastogenesis,119 more osteoclasts were produced when conditioned media from 
osteocyte-enriched long bone cultures of old (21-mo) compared to young (4-mo) mice was 
added to wildtype BMCs; an effect that was attenuated by pre-treatment with the apoptosis 
inhibitor, DEVD-CHO (Fig. 6-2A,B). 
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 Based on our previous findings that apoptotic osteocytes release elevated levels 
of HMGB1, we next evaluated whether RAGE signaling in osteoclasts facilitates the 
stimulatory effects of apoptotic osteocyte conditioned media on osteoclastogenesis. 
Similar to previous reports,184, 213 both genetic and pharmacological RAGE inhibition in 
BMCs decreased osteoclast number (Fig. 6-2C-E).  However, despite the inhibitory effects 
of RAGE inhibition in osteoclasts with control media, the addition of conditioned media 
from old bones to BMCs from wildtype or global RAGE-knockout mice enhanced 
osteoclast number by 1.3- and 1.7-fold, respectively, vs. conditioned media from young 
bones (Fig. 6-2C). Moreover, co-culturing Cx43def osteocytic cells with wildtype or RAGE-
knockout BMCs increased osteoclast number 2- and 4-fold, respectively compared to cells 
co-cultured with scramble control osteocytic cells (Fig. 6-2D). Additionally, Cx43def 
conditioned media induced 1.6-fold more osteoclasts than conditioned media from 
scramble control osteocytic cells, when cultured with or without the small-molecule RAGE 
inhibitor, Azeliragon (Fig. 6-2E). Taken together, our findings suggest that even though 
RAGE deficiency/inhibition reduces osteoclast differentiation, apoptotic osteocyte 
conditioned media-induced increases in osteoclastogenesis are not mediated through 
HMGB1/RAGE activation in osteoclasts. 
 
Autocrine actions of apoptotic osteocyte-derived HMGB1 in osteocytes, 
rather than direct signaling in osteoclasts promotes osteoclastogenesis. We next 
tested whether HMGB1 released by osteocytes has autocrine effects on the osteocytic 
cells and/or mediates the effect of the osteocytic cells on osteoclasts. We first cultured 
MLO-Y4 osteocytic cells silenced for Cx43 or scramble controls with an anti-HMGB1 
antibody to block the autocrine effects of secreted HMGB1 on osteocytes. The conditioned 
media was collected and then anti-HMGB1 antibody was removed by 
immunoprecipitation. Alternatively, conditioned media from MLO-Y4 cells was 
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immunodepleted with an anti-HMGB1 antibody after collection. Both conditioned media 
preparations were then used in osteoclastogenesis assays. We found that conditioned 
media prepared from MLO-Y4 cells that had been cultured in HMGB1-deficient conditions 
yielded fewer osteoclasts than control media (Fig. 6-3A). Conversely, and consistent with 
the results included in Fig. 6-2, immunodepletion of HMGB1 from Cx43def CM after 
collecting the media, did not prevent osteoclast formation (Fig. 6-3B).  Together, these 
data suggest that direct HMGB1 actions in osteocytes stimulates osteoclast differentiation.
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Discussion 
Numerous reports have shown that inflammatory cytokines function as local 
signals that influence bone cell function under both physiological and pathological 
conditions.160, 161  In particular, HMGB1 has been shown to be involved in mediating 
various cellular processes in bone. 191 In the current study, we demonstrate that HMGB1 
effects on both osteocytes and osteoclasts alter osteoclast differentiation (Fig. 6-4).  
  Our current findings provide additional evidence that HMGB1 receptor signaling 
regulates osteoclastogenesis. As predicted by Zhou et. at., our findings demonstrate that 
during osteoclast differentiation TLR4 is required for early HMGB1 signaling, whereas 
RAGE is required for later HMGB1 signaling.54 These studies showed that HMGB1-TLR4 
signaling is required for early osteoclast differentiation stages including ERK and NF-κB 
activation, whereas, HMGB1-RAGE signaling is required for integrin signaling and proper 
actin ring formation during later osteoclast differentiation signaling events.  
  Based on our previous findings that apoptotic osteocytes release elevated levels of 
extracellular HMGB1, we next tested whether RAGE signaling in osteoclasts mediates the 
stimulatory effects of apoptotic osteocyte conditioned media on osteoclastogenesis. 
However, while osteoclastogenesis was decreased with RAGE deficiency, neither genetic 
nor pharmacological RAGE inhibition blocked the apoptotic osteocyte-induced increases 
in osteoclastogenesis. Taken together, these pieces of evidence suggest that apoptotic 
osteocytes do not increase osteoclastogenesis by directly activating RAGE signaling in 
osteoclasts. 
In support of this notion, we also found that while HMGB1 immunodepletion from 
Cx43def conditioned media did not inhibit osteoclast formation, treatment of Cx43def 
osteocytes with HMGB1 neutralizing antibody followed by HMGB1 immunodepletion, 
prevented osteoclast differentiation stimulated by Cx43def conditioned media, suggesting 
direct HMGB1 actions in osteocytes, rather than indirect actions on osteoclasts, stimulates 
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osteoclast differentiation induced by apoptotic osteocytes. This idea is consistent with our 
previously published findings showing that HMGB1 neutralizing antibody treatment in 
Cx43def osteocytes attenuates the release of the pro-osteoclastogenic cytokine RANKL 
from Cx43def osteocytes.119 
Additionally, other inflammatory cytokines known to activate RAGE have also been 
shown to have similar effects on cell viability and cytokine production/release in 
osteoblasts and osteocytes.224, 225 For example, MLO-Y4 osteocytic cell apoptosis is 
stimulated by advanced glycation end products (AGEs)226 and promote pro-inflammatory 
cytokine release (IL-6, TNFα, RANKL, VEGFA) from both osteoblasts and osteocytes,50, 
139, 227 which may subsequently increase osteoclastogenesis. Further, high levels of AGEs 
in bone are associated with increased osteoclast activity in humans, despite a lack of 
effect of AGEs on osteoclast activity in vitro.228 In addition, S100A9, another ligand for 
RAGE, has similar effects on cell viability and cytokine secretion in osteoblasts and 
osteocytes.119, 224, 225 Specifically, S100A9 treatment in osteoblasts stimulates RAGE 
expression and promotes cytokine release; and S100A9-treated osteoblast CM increases 
osteoclast differentiation/activity, whereas when added directly to osteoclasts S100A9 
inhibits osteoclastogenesis.224 
Overall, these data suggest that in bone HMGB1 signaling in osteocytes stimulates 
pro-inflammatory cytokine release, which subsequently induces osteoclastogenesis. 
Future studies will be carried out aiming to elucidate the specific effects of HMGB1 
signaling in osteocytes and identify the receptor responsible for these effects.  
In summary, our findings demonstrate that HMGB1 directly promotes 
osteoclastogenesis through RAGE and TLR4 stimulation in osteoclasts, and increases 
pro-osteoclastogenic cytokine release from apoptotic osteocytes (Fig. 6-4). Thus, direct 
actions of HMGB1 signaling in osteoclasts and osteocytes, rather than indirect effects of 
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apoptotic osteocyte-derived extracellular HMGB1 appear to underlie the stimulatory 
effects of apoptotic osteocytes on osteoclasts.
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Figure 6-1. Inhibition of HMGB1 and its receptors alters osteoclast differentiation in a 
stage-dependent manner. (A) Non-adherent BMCs treated with rabbit IgG control or anti-
HMGB1 antibodies. Bars represent mean ± S.D. (n=6). *p<0.05 vs vehicle rabbit IgG 
control treated cells by t-test. Representative osteoclast images are shown. (B) Illustration 
of the experimental design testing the effects of inhibitor treatment at different stages of 
osteoclast differentiation and (C) osteoclast numbers reported as fold changes. Inhibitors 
or vehicle were added to BMMs (day 1-3) or pre-osteoclasts (day 3-5) HMGB1 receptor 
inhibitor- (Azeliragon and LPS-Rs) treated non-adherent BMCs at different stages of 
differentiation. *p<0.05 vs vehicle control treated non-adherent BMCs by one-way 
ANOVA. Bars represent mean ± S.D. (n=6).  
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Figure 6-2. Apoptotic osteocyte induced increases in osteoclast differentiation are not 
mediated through RAGE signaling in osteoclasts. (A) Scheme illustrating experimental 
design. (B) Non-adherent BMCs treated with conditioned media (CM) collected from ex 
vivo osteocyte-enriched bone cultures of young (4-month-old) and old (21-month-old) 
female mice treated with vehicle or DEVD-CHO. *p<0.05 vs young bone culture CM-
treated osteoclasts by two-way ANOVA, n=6. (C-E) Osteoclast differentiation was induced 
in non-adherent BMCs (C) Wildtype and RAGE-deficient BMCs treated with CM from ex 
vivo osteocyte-enriched bone cultures of young and old female mice. Bars represent mean 
± S.D. *p<0.05 versus young bone culture CM-treated osteoclasts by two-way ANOVA, 
n=6. (D) Wildtype and RAGE-deficient BMCs co-cultured with scramble or Cx43def MLO-
Y4 osteocytic cells. Bars represent mean ± S.D. *p<0.05 versus osteoclasts co-cultured 
with scramble MLO-Y4 cells by two-way ANOVA, n=6.  (n=6). (E) Wildtype BMCs treated 
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with CM from scramble or Cx43def MLO-Y4 osteocytic cells in the presence of vehicle or 
Azeliragon (100ng/mL). Bars represent mean ± S.D. *p<0.05 versus scramble CM treated 
osteoclasts precursors +/- Azeliragon by two-way ANOVA, n=6.  
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Figure 6-3.  Direct actions of apoptotic osteocyte-derived HMGB1 in osteocytes, rather 
than indirect signaling in osteoclasts promotes osteoclastogenesis. Mature osteoclasts 
generated in vitro from non-adherent BMCs treated with conditioned media from (A) 
scramble and Cx43-deficient MLO-Y4 osteocytic cells or (B) conditioned media from 
scramble and Cx43def MLO-Y4 osteocytic cells treated with rabbit IgG or anti-HMGB1 
neutralizing antibodies, then removed by immunoprecipitation. Bars represent mean ± 
S.D. *p<0.05 versus scramble cells, #<0.05 versus corresponding IgG-treated cells by two-
way ANOVA, n=4.  
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Figure 6-4. Schematic Summary. Dual effects exerted by HMGB1 on bone cells, resulting 
in increased osteoclastogenesis, directly by promoting osteoclast differentiation via 
activation of TLR4 and RAGE in osteoclasts and indirectly by increasing the release of 
pro-osteoclastogenic cytokine from osteocytes.  
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Figure 6-5. RAGE knockout mouse targeting strategy using CRISPR/Cas9. (A) Diagram 
of RAGE exon 1 and flanking sequences, indicating the locations of the translational start 
codon and 200-base ssODN repair template carrying seven mutations.  (B) Sequences of 
the WT and KO RAGE alleles. Indicated in the WT sequence is the translational start 
codon (green), and Cas9 cleavage site (arrow).  Indicated in the KO sequence is the 
translational start codon (green), and the 1-bp insertion (bold red) that creates both a 
translational frame-shift and an early translational termination site (orange). Six additional 
mutations (red) in the KO sequence create an optimized Kozak sequence (GCCGCCACC) 
for efficient translational initiation, eliminate the Cas9 PAM sequence to prevent 
retargeting, and create a Bgl I site (GCCACCATGGC) for screening purposes. Also shown 
are the Cas9 gRNA protospacer (blue) and PAM (pink) sequences. (C) Partial sequencing 
chromatogram from a homozygous RAGE KO mouse corresponding to the same region 
shown for the KO allele in (B). 
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Figure 6-6. Allele-specific PCR genotyping and western blot confirmation of RAGE KO 
mice generation. (A) Six pups from a RAGE KO heterozygote x heterozygote mating were 
genotyped using KO and WT allele-specific protocols.  Both protocols employed a 
common forward primer, but the reverse primers were specific for either the KO or WT 
allele.  Both KO and WT PCR products are 408 bp.  Cerk gene primers were included in 
both reactions, generating a 630-bp internal control. (B) RAGE protein levels measured in 
lung lysates from RAGE KO and WT littermate mice (n=3-4).
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Chapter 7 
Summary of Findings and Future Directions 
 
The current series of studies were conducted in order to better understand the 
mechanisms underlying the increases in osteocyte apoptosis seen in aging and to identify 
the apoptotic osteocyte-derived signaling factors responsible for the subsequent 
increases in osteoclastogenesis. Gaining a better understanding of these events is an 
important step towards the discovery of new therapeutic targets to treat bone fragility in 
aging. Overall, the findings from these studies provide further insights into the 
mechanisms underlying osteocyte apoptosis as well as the signaling molecules linking 
osteocyte apoptosis to osteoclast activation in aging. 
 
Figure 7-1. Cx43 expression in osteocytes ameliorates age-induced cortical bone changes 
by preserving osteocyte viability, decreasing bone resorption, and maintaining bone 
formation, leading to improved bone strength. 
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Previous work from our laboratory demonstrated that Cx43 is critical for osteocyte 
survival, and that removal of osteocytic Cx43 leads a skeletal phenotype similar to that 
observed in aging.38, 46 Based on this evidence, we first examined the contribution of 
osteocytic Cx43 to the skeletal phenotype of aged mice, using Cx43OT mice expressing a 
Cx43 transgene targeted to DMP1-8kb-expressing cells.90 As illustrated in Fig. 7-1, in 
these studies we showed overexpression of osteocytic Cx43 in aging attenuated the 
prevalence of apoptotic osteocytes in cortical bone, and to a lesser extent in the 
cancellous bone. In addition, we found that in aged Cx43OT mice these reductions in 
osteocyte apoptosis were accompanied by changes in bone remodeling with increased 
formation and decreased resorption along the endocortical bone surface. Further, 
consistent with the reductions in bone resorption, the RANKL/OPG gene expression ratio 
was lower in cortical bone lysates of 14-month-old Cx43OT compared to WT mice. Thus, 
these findings further demonstrate the critical role of Cx43 in maintaining osteocyte 
viability as well as the direct link between osteocyte apoptosis and osteoclastogenesis. 
Although, given the fact that we did not detect differences in cortical bone mass or 
geometry between the two genotypes at 14 months of age, it is reasonable to speculate 
that the increases in the structural and material properties in the 14-month-old Cx43OT 
mice were not due to changes in bone architecture, but are likely due to other factors at 
the level of the collagen/mineral. Thus, further studies are needed to better understand 
the mechanisms underlying the changes in the material properties of the bone of mice 
expressing DMP1-Cx43. In addition, whether the improved ability of the bone to resist 
damage is due to prevention of microdamage accumulation or direct preservation of the 
bone material by living osteocytes or a combination of both, remains to be determined.  
Interestingly, our findings that osteocyte-targeted Cx43 transgene expression was 
sufficient to reduce osteocyte apoptosis in both bone compartments, whereas changes in 
bone turnover and improvements in the bone mechanical properties were only observed 
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in cortical bone, further demonstrate the differential bone compartment-specific actions of 
Cx43. Additionally, these findings raise the possibility Cx43-dependent regulation of 
osteocyte viability is a critical regulator of bone turnover in cortical, but not trabecular bone.  
Therefore, future studies are also needed to better understand the mechanisms underlying 
these bone compartment specific effects of Cx43, and to identify whether Cx43 contributes 
to the divergent effects that aging has on bone remodeling in the trabecular and cortical 
bone compartments.  
 
Figure 7-2. Working model showing decreased osteocytic Cx43 leads to a reduction in 
miR21 levels which, in turn, leads to an increase in PTEN levels and consequently a 
reduction in Akt activation. Decreased Akt activity leads to increased expression of the 
apoptosis-related genes p27, FoxO3 and GADD153 resulting in caspase-3-mediated 
apoptosis. At the same time, apoptotic osteocytes release RANKL and HMGB1, which 
induce osteoclast differentiation and recruitment.119 
 
apoptosis molecular pathway
Akt
apoptosis
miR21
pAkt
PTEN
p27 FoxO3
GADD153
active
caspase-3
Aging
↓ Cx43
↑ osteocyte 
apoptosis 
↑ osteoclastogenesis
↑ RANKL
↑ HMGB1
192 
 
In the next series of studies we worked to dissect the molecular signaling pathway 
underlying osteocyte apoptosis triggered in the absence of osteocytic Cx43 and by aging, 
illustrated in Fig. 7-2.119 In addition, we sought to unveil the molecular link between 
osteocyte apoptosis and targeted osteoclastic bone resorption. Overall, our findings 
provide evidence that, at least in female mice, osteocyte apoptosis in old age and the 
absence of osteocytic Cx43 is a result of decreased miR21 levels, which subsequently 
lead to increased PTEN protein levels and decreased Akt activation. Further, we found 
that apoptotic osteocytes release more HMGB1, which in turn induces osteoclast 
precursor differentiation, highlighting osteocyte-derived HMGB1 as a possible factor 
linking osteocyte apoptosis and targeted osteoclastogenesis. 
 
Figure 7-3. In females osteocytic miR21 deletion led to high levels of osteocyte apoptosis 
that were accompanied by decreases in bone resorption. 
 
Given these findings regarding the role of osteocytic miR21 in vitro, we next 
investigated the role of osteocytic miR21 locus in vivo, using a mouse model in which 
miR21 was deleted from osteocytes. Surprisingly, in females, we found that osteocytic 
miR21 deletion led to high levels of osteocyte apoptosis that were accompanied by 
decreases in bone resorption (and formation) compared to miR21f/f littermates (Fig. 7-3). 
Taken together, these unexpected findings suggest that in addition to the role of osteocytic 
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miR21 in maintaining osteocyte viability, miR21 also appears to regulate osteocyte 
inflammatory-cytokine production/release. Consistently, recent studies in other tissues, 
have identified miR21 as a key switch in the control of inflammatory responses.230 In 
particular, miR21 has been shown to be involved in mediating both the initial pro-
inflammatory and later anti-inflammatory responses, and dysregulation of miR21 
expression contributes to the onset and progression of various inflammatory diseases.230 
Additionally, miR21 has been shown to be secreted in extracellular vesicles (EV), and 
increased exosomal-miR21 is a biomarker of several inflammatory diseases and has also 
been shown to mediate inflammatory responses.231, 232  
Following their release exosomes contribute to disease onset and progression by 
enhancing the release of pro-inflammatory proteins and miRs.232 Further, caspase3 
activation stimulates EV release233, 234 and coincides with extracellular HMGB1 release.50, 
160 Moreover, miR21 is increased in pancreatic βcell-derived EV in response to 
inflammatory cytokines.235 Additionally, miR21 regulates osteoclast survival and 
function,236 and promotes RANKL-induced osteoclastogenesis,237 and estrogen induces 
osteoclast apoptosis by repressing miR21.124 In osteoporotic patients, miR21 is elevated 
in serum and bone samples,147 and global miR21 deficiency inhibits osteoclast activity and 
prevents ovariectomy-induced bone loss.131 Taken together these pieces of evidence 
raise the possibility that in old age and Cx43 deficiency, low osteocytic miR21 and HMGB1 
levels result from enhanced EV release mediated by caspase3 activation in apoptotic 
osteocytes; with subsequent osteoclast activation facilitated through HMGB1 receptor 
activation and/or by osteoclast uptake of miR21-containing EV. Thus, future studies are 
needed to determine if EV, through cytokine and miR transfer, mediate osteoclast 
recruitment, which will provide insights into the mechanisms underlying the release of 
osteoclastogenic signals by apoptotic osteocytes in old age and Cx43 deficiency.   
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In addition to these findings, in this study we showed that the miR21 locus exerts 
a sex-divergent role in osteocytes controlling osteocyte viability and regulating bone 
mass/geometry through paracrine actions on osteoblasts and osteoclasts (Fig. 4-6B). 
Further, we revealed a potential mechanism by which miR21 removal from osteocytes 
differentially alters bone turnover by sex-specific regulation of key signaling pathways in 
osteocytes as well as cytokine production/secretion (Fig. 4-6A). However, additional 
studies are needed to clearly elucidate the specific mechanisms by which osteocytic 
miR21 exerts these sex-divergent effects. Further, future studies will be performed to 
determine whether the mild effect of miR21 deletion on bone mass and architecture is 
exacerbated with aging. Nevertheless, given the increasing interest of pharmaceutical 
companies in the development of miR-based drugs combined with the growing number of 
studies identifying gender-dependent adverse drug reactions,145 our findings highlight the 
importance of considering possible sex-dependent roles of miRs when developing 
therapeutics. 
Interestingly, despite these sex-specific effects of osteocytic miR21 deficiency in 
this study, both female and male miR21ΔOt mice exhibited markedly higher femoral cortical 
bone mechanical properties compared to the respective miR21f/f controls. While our 
findings highlight a possible mechanism by which osteocytic miR21 deficiency improves 
bone mechanical properties by stimulating collagen synthesis via downregulation of JNK 
signaling, extensive additional studies are required. Thus, in future studies we will also 
work to uncover the molecular and tissue-level mechanisms by which osteocytic miR21 
negatively influences bone mechanical integrity. Overall, our findings from this study 
provide novel insights into the sex-dependent and -independent mechanisms by which 
miR21 regulation in osteocytes alters bone, which offer a basis for future studies that could 
eventually lead to new therapeutic targets to treat bone fragility. 
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Based on our findings that apoptotic osteocytes release more HMGB1, and that 
inhibition of HMGB1-RAGE activation with HMGB1 BoxA treatment, blocks the increases 
in osteoclast differentiation induced by conditioned media from apoptotic osteocytes,119 
we next tested the skeletal effects of short-term systemic administration of the small-
molecule RAGE inhibitor, Azeliragon (AZ). Overall, our findings from this study showed 
that AZ did not prevent the aging-induced alterations in bone geometry or mechanics, 
likely due to its differential effects [direct vs. indirect] on bone cell viability/function, as 
illustrated in Fig. 7-4. Particularly, we found that AZ had differential effects on osteoclast 
differentiation and activity, which may have been due to the increases in cell death and 
inflammatory cytokine production in osteocytes we detected with AZ treatment both in vitro 
and in vivo. Hence, in addition to the direct inhibitory effects of AZ treatment on 
osteoclasts, the effects of RAGE inhibition in osteocytes may have indirectly stimulated 
bone resorption.  
Thus, given the cell type specific effects of AZ, future studies will be designed to 
examine whether administering a different dose or altering the treatment regimen 
[intermittent vs chronic], previously seen with other therapeutics, could optimize the 
beneficial effects of AZ on bone. However, since these pro-apoptotic effects of RAGE 
inhibition in osteocytes are consistent with previous studies in other cell types showing the 
HMGB1-RAGE signaling promotes autophagy and protects against apoptosis,238-240 it is 
also possible that an osteoclast targeted-RAGE inhibitor may be needed to obtain 
beneficial skeletal effects with aging. Additionally, given the previous findings showing that 
HMGB1-TLR4 signaling induces apoptosis and stimulates inflammatory responses,241, 242 
it is possible that treatment with the TLR4 inhibitor, Lps-Rs,243 rather than the RAGE 
inhibitor, AZ, may be more successful at attenuating the negative skeletal effects in aging 
mice. Thus, in order to better understand the skeletal effects of HMGB1 signaling in aging, 
future studies using the TLR4 inhibitor, Lps-Rs,243  in aged mice could also be performed.  
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 Interestingly, despite the lack of effect of AZ in bone, our findings suggest that 
short-term pharmacologic RAGE inhibition has distinct effects on skeletal muscle. In 
particular, our data validate the role of RAGE signaling in promoting musculoskeletal 
derangements associated with aging, thus making it an interesting therapeutic target. 
Altogether, our findings strongly support that idea that AZ may represent a novel 
therapeutic option for the treatment of aging-induced sarcopenia, which will be further 
tested in future studies.  
 
Figure 7-4. Model of the proposed effects of RAGE signaling in osteocytes and 
osteoclasts.  
We also tested whether RAGE signaling in osteoclasts mediates the stimulatory 
effects of apoptotic osteocyte conditioned media on osteoclastogenesis. However, 
consistent with the in vivo effects of AZ treatment on osteoclasts, while osteoclastogenesis 
was decreased with RAGE deficiency, neither genetic nor pharmacological RAGE 
inhibition blocked the apoptotic osteocyte-induced increases in osteoclastogenesis. Taken 
together these pieces of evidence suggest that apoptotic osteocytes do not increase 
osteoclastogenesis by directly activating RAGE signaling in osteoclasts. Conversely, our 
data suggest that, HMGB1 signaling in osteocytes stimulates pro-inflammatory cytokine 
release, which subsequently induces osteoclastogenesis. Thus, direct actions of HMGB1 
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derived extracellular HMGB1 appear to underlie the stimulatory effects of apoptotic 
osteocytes on osteoclasts (Fig. 7-5). Additionally, given our findings that RAGE inhibition 
with AZ treatment stimulated osteocyte cell death and inflammatory cytokine production, 
and the previous studies showing that HMGB1-RAGE signaling is anti-apoptotic while 
HMGB1-TLR4 signaling is pro-apoptotic,238, 241, 242, 244 one could speculate that HMGB1 
signaling through TLR4 rather than RAGE mediates these effects in osteocytes. Thus, 
future studies will be carried out in order to elucidate the specific effects of HMGB1 
signaling in osteocytes and clearly identify the receptor responsible for these effects.  
 
Figure 7-5. Autocrine actions of HMGB1 signaling in osteocytes, rather than paracrine 
effects of apoptotic osteocyte-derived extracellular HMGB1 signaling in osteoclasts 
appear to underlie the stimulatory effects of apoptotic osteocytes on osteoclasts. 
 
In summary, the findings from this current series of studies using a combination of 
several in vitro and in vivo models, summarized in Fig. 7-6, further highlight the critical role 
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in aging. We demonstrated the requirement of Cx43-mediated actions in osteocytes for 
the preservation of osteocyte viability and cortical bone quality in aging. Additionally, our 
findings support a model where reduced Cx43 levels in osteocytes in old animals leads to 
apoptosis and the release of RANKL and HMGB1, which signal osteoclasts to increase 
resorption along associated bone surfaces. However, our findings also suggest that 
HMGB1 exerts dual effects on osteoclasts, directly by inducing differentiation through 
TLR4 and RAGE activation and indirectly by increasing pro-osteoclastogenic cytokine 
secretion from osteocytes. Interestingly, our findings also provide evidence that the miR21 
locus in osteocytes exerts sex-dependent and -independent skeletal effects. Thus, while 
these studies answered many important questions, they also uncovered several key 
questions that need to be further investigated in future studies. Overall, these pieces of 
evidence provide a foundation for a variety of future studies to further examine the effects 
of preventing osteocyte viability and/or blocking apoptotic osteocyte-derived signaling 
molecules to prevent bone fragility in aging.   
 
Figure 7-6. Working model summarizing the findings of the current series of studies. 
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